<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Neurobiol</journal-id><journal-id journal-id-type="iso-abbrev">Mol. Neurobiol</journal-id><journal-title-group><journal-title>Molecular Neurobiology</journal-title></journal-title-group><issn pub-type="ppub">0893-7648</issn><issn pub-type="epub">1559-1182</issn><publisher><publisher-name>Springer US</publisher-name><publisher-loc>Boston</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4225054</article-id><article-id pub-id-type="publisher-id">8726</article-id><article-id pub-id-type="doi">10.1007/s12035-014-8726-5</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Genetic Addiction Risk Score (GARS): Molecular Neurogenetic Evidence for Predisposition to Reward Deficiency Syndrome (RDS)</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Blum</surname><given-names>Kenneth</given-names></name><address><phone>619-890-2167</phone><email>drd2gene@gmail.com</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff3"/><xref ref-type="aff" rid="Aff4"/><xref ref-type="aff" rid="Aff5"/><xref ref-type="aff" rid="Aff6"/><xref ref-type="aff" rid="Aff7"/><xref ref-type="aff" rid="Aff8"/><xref ref-type="aff" rid="Aff9"/></contrib><contrib contrib-type="author"><name><surname>Oscar-Berman</surname><given-names>Marlene</given-names></name><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Demetrovics</surname><given-names>Zsolt</given-names></name><xref ref-type="aff" rid="Aff10"/></contrib><contrib contrib-type="author"><name><surname>Barh</surname><given-names>Debmalya</given-names></name><xref ref-type="aff" rid="Aff8"/></contrib><contrib contrib-type="author"><name><surname>Gold</surname><given-names>Mark S.</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><label/>Department of Psychiatry &amp; McKnight Brain Institute, University of Florida College of Medicine, Gainesville, FL USA </aff><aff id="Aff2"><label/>Departments of Psychiatry, Neurology, and Anatomy &amp; Neurobiology, Boston University School of Medicine, and Boston VA Healthcare System, Boston, MA 02118 USA </aff><aff id="Aff3"><label/>Department of Holistic Medicine, National Institute for Holist Addiction Studies, North Miami Beach, FL USA </aff><aff id="Aff4"><label/>Human Integrated Services Unit University of Vermont Center for Clinical &amp; Translational Science, College of Medicine, Burlington, VT USA </aff><aff id="Aff5"><label/>Dominion Diagnostics, LLC, North Kingstown, RI USA </aff><aff id="Aff6"><label/>Department of Addiction Research &amp; Therapy, Malibu Beach Recovery Center, Malibu Beach, CA USA </aff><aff id="Aff7"><label/>Department of Clinical Neurology, PATH Foundation, New York, NY USA </aff><aff id="Aff8"><label/>Institute of Integrative Omics and Applied Biotechnology, Nonakuri, Purba Medinipur, West Bengal, India </aff><aff id="Aff9"><label/>IGENE, LLC, Austin, TX USA </aff><aff id="Aff10"><label/>Department of Clinical Psychology and Addiction, E&#246;tv&#246;s Lor&#225;nd University, Institute of Psychology, Budapest, Hungary </aff></contrib-group><pub-date pub-type="epub"><day>31</day><month>5</month><year>2014</year></pub-date><pub-date pub-type="pmc-release"><day>31</day><month>5</month><year>2014</year></pub-date><pub-date pub-type="ppub"><year>2014</year></pub-date><volume>50</volume><issue>3</issue><fpage>765</fpage><lpage>796</lpage><history><date date-type="received"><day>9</day><month>12</month><year>2013</year></date><date date-type="accepted"><day>29</day><month>4</month><year>2014</year></date></history><permissions><copyright-statement>&#169; The Author(s) 2014</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.</license-p></license></permissions><abstract id="Abs1"><p>We have published extensively on the neurogenetics of brain reward systems with reference to the genes related to dopaminergic function in particular. In 1996, we coined &#8220;Reward Deficiency Syndrome&#8221; (RDS), to portray behaviors found to have gene-based association with hypodopaminergic function. RDS as a useful concept has been embraced in many subsequent studies, to increase our understanding of Substance Use Disorder (SUD), addictions, and other obsessive, compulsive, and impulsive behaviors. Interestingly, albeit others, in one published study, we were able to describe lifetime RDS behaviors in a recovering addict (17&#160;years sober) blindly by assessing resultant Genetic Addiction Risk Score (GARS&#8482;) data only. We hypothesize that genetic testing at an early age may be an effective preventive strategy to reduce or eliminate pathological substance and behavioral seeking activity. Here, we consider a select number of genes, their polymorphisms, and associated risks for RDS whereby, utilizing GWAS, there is evidence for convergence to reward candidate genes. The evidence presented serves as a plausible brain-print providing relevant genetic information that will reinforce targeted therapies, to improve recovery and prevent relapse on an individualized basis. The primary driver of RDS is a hypodopaminergic trait (genes) as well as epigenetic states (methylation and deacetylation on chromatin structure). We now have entered a new era in addiction medicine that embraces the neuroscience of addiction and RDS as a pathological condition in brain reward circuitry that calls for appropriate evidence-based therapy and early genetic diagnosis and that requires further intensive investigation.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Genetic Addiction Risk Score (GARS)&#8482;</kwd><kwd>Polymorphisms</kwd><kwd>brain reward circuitry</kwd><kwd>Reward Deficiency Syndrome (RDS)</kwd><kwd>Neurogenetics</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Science+Business Media New York 2014</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>The Role of Dopaminergic Genetics in Reward Dependence</title><p>Neurotransmitter interactions regulate brain reward circuitry that result in the release of dopamine (DA) in the major loci for feelings of well-being and reward, the nucleus accumbens (NAc) part of the mesolimbic system of the brain. The inter-relationship of at least four important neurochemical pathways: serotonergic, endorphinergic, GABAergic, and dopaminergic constitute the &#8220;brain reward cascade&#8221; (see Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>) a natural sequence of events that produce feelings of well being. These activities including: the synthesis, vesicle storage, metabolism, release, and function of neurochemicals [<xref ref-type="bibr" rid="CR1">1</xref>] are regulated by genes, and their expression, in terms of messenger RNA-directed proteins. Thus, genetic testing is a potential window that can be used to identify the specific neurochemistry of individuals and formulate the best treatment options for them [<xref ref-type="bibr" rid="CR1">1</xref>&#8211;<xref ref-type="bibr" rid="CR13">13</xref>].<fig id="Fig1"><label>Fig. 1</label><caption><p>Brain Reward Cascade [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. In this cascade, stimulation of the serotonergic system in the hypothalamus leads to the stimulation of delta/mu receptors by serotonin to cause a release of enkephalin. Activation of the enkephalinergic system induces an inhibition of GABA transmission at the substania nigra by enkephalin stimulation of mu receptors at GABA neurons. This inhibitory effect allows for the fine-tuning of GABA activity. This provides the normal release of dopamine at the projected area of the NAc [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]</p></caption><graphic xlink:href="12035_2014_8726_Fig1_HTML" id="MO1"/></fig></p><p>DA is a neurotransmitter with multiple important functions including behavioral effects such as &#8220;pleasure&#8221; and &#8220;stress reduction.&#8221; Simply stated, without the normal function of this substance, an individual will suffer from cravings and have an inability to cope with stress. Thus, genetic hypodopaminergic brain function predisposes individuals to seek substances and or behaviors that can be used to overcome this craving state by activating the mesolimbic dopaminergic centers [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. Psychoactive substances like alcohol, psychostimulants and opiates, and risky behaviors like gambling, overeating and thrill seeking [<xref ref-type="bibr" rid="CR16">16</xref>] induce the release of neuronal DA into the synapse at the NAc, to overcome the hypodopaminergic state of that individual. Temporary relief from the discomfort and a pseudo sense of well-being is the product of this self-medication [<xref ref-type="bibr" rid="CR17">17</xref>]. Unfortunately, chronic abuse of psychoactive substances leads to inactivation, or a downregulation, like for example, inhibition of neurotransmitter synthesis, neurotransmitter depletion, formation of toxic pseudo neurotransmitters, and through structural receptor dysfunction. Therefore, substance-seeking and pathological behaviors are both used as a means of providing a feel-good response (a &#8220;fix&#8221;) to lessen uncontrollable cravings. Individuals who possess reward gene polymorphisms or variations, will, given environmental insult be at risk for impulsive, compulsive, and addictive behaviors. Reward Deficiency Syndrome (RDS) is a term used to embrace and characterize these genetically induced behaviors. Any and all of these pathological behaviors, as well as psychoactive drug-abuse, are candidates for addiction including tolerance and dependence. The behavior or drug of choice by the individual is a function of both genes and environmental factors like availability and peer pressure.</p></sec><sec id="Sec2"><title>Brain Reward Cascade Explanation</title><p>DA is crucial to the maintenance of natural rewards while the release of DA into NAc synaptic sites is a somewhat complex cascade of reactive activity that involves neurotransmitters and structures in the limbic system [<xref ref-type="bibr" rid="CR1">1</xref>]. Blum and Kozlowski first proposed the concept of a &#8220;brain reward cascade&#8221; in 1990 as a cascade of interactive events and mesolimbic function that produces the net release of DA [<xref ref-type="bibr" rid="CR1">1</xref>] (see Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). Simply, the interaction of activities in the separate subsystems of the brain&#8217;s reward circuitry combine into the much larger global system, and reveal the cascade of neurotransmission, which merges simultaneously and in a specific sequence. When these systems work normally, they result in a feeling of pleasure, well-being, and peace; an imbalance, or deficiency, on the other hand, will cause the system to function abnormally, displacing the sense of well-being with negative feelings like anxiety, anger, and low self-esteem. The need to mask these negative feelings leads to the use of substances such as alcohol and narcotics, meaning that excessive desires are spurred by the need for DA.</p><p>The DA pathway arises in the ventral tegmental area (VTA) and culminates in the DA D2 receptors on neurons located in the cell membranes of in the hippocampus and the NAc. Blum and Kozlowski [<xref ref-type="bibr" rid="CR1">1</xref>] describe a process that begins in the hypothalamus, where the excitatory activities of 5-HT-releasing-neurons cause the release of met-enkephalin, an opioid peptide. The opioid peptide regulates the activity of neurons responsible for the release of gamma-aminobutyric acid (GABA) the inhibitory neurotransmitter at the substantia nigra. When DA-containing neurons in the VTA, and in certain parts of the hippocampus via the amygdala, are disinhibited, DA is allowed to be released into the NAc, permitting the completion of the cascade. If the cascade is functioning correctly, the reward sensation, or the feeling of well-being, is experienced, provided certain basic genetic conditions are fulfilled (see Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>) [<xref ref-type="bibr" rid="CR1">1</xref>]. However, when the genes that govern the function of the brain reward cascade have polymorphic variations, these risk alleles provide the basis for therapeutic targets.</p></sec><sec id="Sec3"><title>RDS and Genetic Antecedents</title><p>The development of a blueprint for identifying certain candidate genes and polymorphisms that could negatively impact DA release is based on this understanding of the brain reward cascade [<xref ref-type="bibr" rid="CR2">2</xref>]. Many genes are involved, and it has been adequately established in association studies and animal research literature that, for example, polymorphisms of the serotonergic-2 A receptor (<italic>5-HTT2a</italic>), DA D2 receptor (<italic>DRD2</italic>), and the catechol-<italic>O</italic>-methyl-transferase (<italic>COMT</italic>) genes (see Genetic Addiction Risk Score (GARS) test), predispose individuals to aberrant RDS behaviors. These behaviors include craving not only for drugs and alcohol but eating and other addictive behaviors such as pathological gambling (see Table&#160;<xref rid="Tab1" ref-type="table">1</xref>) [<xref ref-type="bibr" rid="CR3">3</xref>]. Gene polymorphisms of both 5-HT and DA can result in significantly lower than normal receptor densities. A COMT gene polymorphism can result in increased catabolism of synaptic DA and subsequent reduction of DA function. These are three examples of how the identification of polymorphisms on these three genes can provide a window into an impaired brain reward cascade, and the identification of individuals at high risk can be accomplished. Based on a published [<xref ref-type="bibr" rid="CR11">11</xref>] mathematical Bayesian approach, it was found that individuals who carry the <italic>Taq</italic> A1 polymorphisms of the <italic>DRD2</italic> have a 74.4&#160;% chance of developing RDS behaviors, given an environmental insult and epigenetic effects (see Table&#160;<xref rid="Tab1" ref-type="table">1</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Reward deficiency syndrome behaviors (linked with DSM 5)</p></caption></table-wrap></p></sec><sec id="Sec4"><title>Genomics: Evidence-Based Studies</title><p>In general, inconsistencies in the literature involving association studies using single gene analysis prompted Conner [<xref ref-type="bibr" rid="CR4">4</xref>] and others to evaluate a number of dopaminergic gene polymorphisms as predictors of drug use in adolescents. We cannot ignore the importance of neurochemical mechanisms involved in drug-induced relapse behavior, as suggested by Bossert et al. [<xref ref-type="bibr" rid="CR5">5</xref>] for understanding the interaction of multiple genes and environmental elements. Using a drug relapse model previously shown to induce relapse by re-exposing rats to heroin-associated contexts, these investigators found that after extinction of drug-reinforced responding in different contexts, re-exposure reinstated heroin seeking. This effect was diminished by inhibition of GABA transmission in the VTA and medial accumbens shell and components of the mesolimbic DA system; this process enhances net DA release into the NAc. Indeed, this fits well with Li&#8217;s Knowledgebase for Addiction-Related Genes (KARG) addiction network map [<xref ref-type="bibr" rid="CR6">6</xref>] (see Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>). Li et al. [<xref ref-type="bibr" rid="CR6">6</xref>] also stressed the view that drug addiction is a serious problem worldwide with strong genetic and environmental influences. And that a variety of technologies were used to discover genes and pathways that underlie addiction however, each individual technology can be biased and incomplete. Li and his colleagues integrated evidence from peer-reviewed publications 2,343 items between 1976 and 2006 that inked genes and chromosomal regions to addiction by single-gene strategies, microarray, proteomics, or genetic studies. They identified 1,500 human addiction-related genes and developed the first molecular KARG (<ext-link ext-link-type="uri" xlink:href="http://karg.cbi.pku.edu.cn/">http://karg.cbi.pku.edu.cn</ext-link>), with a friendly web interface and extensive annotations. Their meta-analysis of 396 genes, each supported by two or more independent items of evidence, leads to the identification of 18 molecular pathways that were statistically significant and covered both upstream signaling events and downstream effects. For four different types of addictive drugs and five significant molecular pathways including two new ones; GnRH signaling pathway and gap junction were identified as common pathways that may underlie shared rewarding and addictive actions. In a hypothetical common molecular network for addiction, they connected the common pathways which linked all of these genes, to both the glutaminergic and dopaminergic pathways.<fig id="Fig2"><label>Fig. 2</label><caption><p>KARG an addiction network map [<xref ref-type="bibr" rid="CR6">6</xref>]</p></caption><graphic xlink:href="12035_2014_8726_Fig2_HTML" id="MO2"/></fig></p><p>Following the initial finding of Blum et al. in 1990 [<xref ref-type="bibr" rid="CR7">7</xref>] showing a positive association of the single gene DRD2 polymorphism in chromosome 11 and severe alcoholism, replication, although favorable has, to date, been fraught with inconsistent results. This has also been true for other complex behaviors [<xref ref-type="bibr" rid="CR9">9</xref>] when gene-gene and gene-environment interactions are tested the idea that complex gene-relationships may account for inconsistent findings across many different single gene studies is supported [<xref ref-type="bibr" rid="CR8">8</xref>]. The reasons for inconsistencies in trying to predict drug use are many and varied: they include single gene analysis, poorly screened controls, stratification of population, personality traits, co-morbidity of psychiatric disorders, gender-base differences, positive and negative life events, and neurocognitive dysfunctioning and epigenetic effects [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>].</p><p>In order to gain a more complex but stronger predictive set of genetic antecedents rather than continue to evaluate single gene associations, we embarked on a study to evaluate multiple candidate genes, especially those linked to the Brain Reward Cascade to predict future drug abuse [<xref ref-type="bibr" rid="CR1">1</xref>] and identify risk for hypodopaminergic functioning. Although exploratory, the goal is to develop an informative panel based on numerous known risk alleles to provide treatment facilities a means of stratifying patients entering treatment as having a high, moderate, or low, genetic risk prediction.</p><p>As noted above, an association between dopaminergic gene polymorphisms and addictive, compulsive, and impulsive behaviors classified as RDS has been revealed in numerous studies. We evaluated subjects derived from two families for a potential association with polymorphisms of the DA D2 receptor gene (<italic>DRD2</italic>), DA D1 receptor gene (<italic>DRD1</italic>), DA transporter gene (<italic>DAT1</italic>), and DA beta-hydroxylase gene (<italic>DBH</italic>). This association if found would demonstrate the relevance of a generalized RDS behavior set, as the phenotype.</p><p>An experimental group derived from up to five generations of two independent multiple-affected families <italic>n</italic>&#8201;=&#8201;55 were genotyped and compared to very rigorously screened controls. In addition to these subjects, data related to RDS behaviors was collected from 13 deceased family members. The genotyped family members carried the DRD2 <italic>Taq</italic>1 allele at 78&#160;% the DAT1 10/10 allele at 58&#160;%, the DBHB1 allele at 66&#160;%, and the DRD1 A1/A1 or the A2/A2 genotypes at 35&#160;%. Interestingly, all probands (<italic>n</italic>&#8201;=&#8201;32) from Family A genotyped for the DRD2 gene carried the <italic>Taq</italic>A1 allele (100&#160;%). The experimental positive rate for the DRD2 <italic>Taq</italic>1 allele with an odds ratio of 103.9 (12.8, 843.2) was significantly greater (<italic>X</italic><sup>2</sup>&#8201;=&#8201;43.6, <italic>P</italic>&#8201;&lt;&#8201;0.001). The experimental positive rate for the DAT1 10/10 allele with an odds ratio of 2.3 (1.2, 4.6) was also significantly greater (<italic>X</italic><sup>2</sup>&#8201;=&#8201;6.0, <italic>P</italic>&#8201;&lt;&#8201;0.015). Between the experimental and control positive rates of the DBH, DRD1 A1/A1, or A2/A2 genotypes no significant differences were observed [<xref ref-type="bibr" rid="CR18">18</xref>].</p><p>Patients genetic risk for drug-seeking behavior needs to be evaluated prior to, or upon entry to chemical dependency programs. The importance of genotyping to establish genetic severity for patients undergoing treatment and in danger of relapse is described below in the, as yet, unpublished results from a study of the data from Comprehensive Analysis of Reported Drugs (CARD). We have followed up by evaluating a panel of genes and associated polymorphisms termed GARS in patients with RDS behaviors attending two treatment centers. In this and other studies, we use the GARS for purposes of study identification and commercial testing [<xref ref-type="bibr" rid="CR9">9</xref>&#8211;<xref ref-type="bibr" rid="CR11">11</xref>].</p><p>To determine risk severity of 72 addicted patients, the percentage of prevalence of selected risk alleles was calculated to provide a severity score. We genotyped the patients using a nine reward genes and their polymorphisms (<italic>F</italic>&#8201;=&#8201;18 alleles; <italic>M</italic>&#8201;=&#8201;17 alleles). This panel included: <italic>DRD 2</italic>, <italic>3</italic>, <italic>4</italic>; <italic>MOA-A</italic>; <italic>COMT</italic>; <italic>DAT1</italic>; <italic>5HTTLLR</italic>; <italic>OPRM1</italic>; and <italic>GABRA3</italic> genes. The three severity ratings were: Low severity&#8201;=&#8201;1&#8211;36&#160;%; moderate severity&#8201;=&#8201;37&#8211;50&#160;%, and high severity&#8201;=&#8201;51&#8211;100&#160;%. We studied two distinct treatment populations: Group 1 consisted of 37 addicts from a holistic addiction treatment center in North Miami Beach, Florida, and Group 2 consisted of 35 addicts from Malibu Beach Recovery Center [<xref ref-type="bibr" rid="CR12">12</xref>]. We are in the process of analyzing 393 subjects using a multi-centered approach across the USA.</p><p>However, in the following unpublished experiment, we found risk stratification of the 72 genotyped patients to be as follows: 27&#160;% low risk; 74&#160;% moderate risk, and 4&#160;% severe risk. We are exploring potential risk correlation with the Addiction Severity Index (ASI). Preliminary statistical analysis reveals that with <italic>N</italic>&#8201;=&#8201;277, we found a significant trend whereby allelic risk above the means score associated with the ASI Alcohol Risk Severity Score at <italic>P</italic>&#8201;&lt;&#8201;0.07 (one sided P). Unlike CARD, the GARS could provide potential correlations to ASI to at least the alcohol risk composite score. If this finding is upheld through larger populations, it unequivocally demonstrates that objective genetic polymorphisms could predict clinical outcomes.</p><p>We are cognizant that, as the next steps in identifying candidate gene polymorphic associations with RDS as the overall phenotype, we must carefully dissect epigenetic effects such as miRNA and subsequent methylation and/or deacetylation of attached chromatin markers leading to altered gene expression in spite of DNA polymorphisms.</p></sec><sec id="Sec5"><title>CARD&#8482; Provides a Rationale for Genetic Testing</title><p>The primary reason to include some brief information regarding CARD is to provide a clear indication that genetic testing may provide valuable information about the risk that drives relapse. In an unpublished study but submitted article from our laboratory, a statistical analysis of unidentifiable data from a computer-based program called CARD was used to evaluate treatment adherence in a large clinical cohort from across a number of eastern states in America. This study consisted of 5,703 patients and 11,403 specimens, in various treatment settings across six eastern states. We found significant levels of both non-compliance and lack of abstinence (risk for relapse) during treatment. The CARD engine addresses issues of metabolism as well as contaminants in the production processes of some formulations. It addresses multi-faceted scenarios within and across drug classes, often involving the state of multiple analytes in order to reach a conclusion for each self-reported or prescribed drug. It evaluates thousands of rule sets to determine if the statement associated with each rule set is applicable to the specimen test results and reported drugs that are analyzed.</p><p>We are proposing a paradigm shift on the basis of these studies, whereby the predisposition to a risk for RDS (the true phenotype) can be accurately determined by utilizing GARS, and treatment outcome can be assessed by utilizing CARD. These results confirm the putative role of dopaminergic polymorphisms in RDS behaviors.</p></sec><sec id="Sec6"><title>The Addiction Phenotype and the Need for Super Controls</title><p>The family-based study [<xref ref-type="bibr" rid="CR18">18</xref>] demonstrates the importance of a nonspecific RDS phenotype and informed an understanding of how evaluating single subset of RDS behaviors, like for example, Tourette&#8217;s may lead to spurious results. Rather, the adoption of a nonspecific reward phenotype may be useful in future association and linkage studies involving neurotransmitter gene candidates as utilized in GARS. The putative role of dopaminergic polymorphisms in RDS behaviors is supported by the results [<xref ref-type="bibr" rid="CR18">18</xref>], although linkage analysis is necessary and the sample size was limited. We believe that using a nonspecific reward phenotype in future association and linkage studies that involve dopaminergic polymorphisms and other neurotransmitter gene candidates may be a necessary paradigm shift.</p><p>This underscores the problem concerning appropriate controls. While thousands of studies have associated the various reward gene risk polymorphisms for all types of addictive behaviors (including drugs, smoking, alcohol, gambling, sex, shopping) against putative controls, there remains a real need to develop super controls whereby the true phenotype is not just drug addiction per se but the absence of any RDS behavior. To suggest that researchers can provide accurate data by enlisting comparison individuals who are from an unscreened general population as controls, is fraught with an inappropriate and potentially inaccurate assessment. In one, example, assessing the DRD2 A1 allele, we found that while screened controls (eliminating drug and alcohol abuse) in over 3,000 subjects showed a prevalence of approximately 26&#160;%; when we eliminated all RDS behaviors in the probands and family surprisingly we found the DRD2 A1 allele prevalence to be only 3&#160;% [<xref ref-type="bibr" rid="CR19">19</xref>]. In the current GARS test being cognizant of this issue, we utilize the recognized method of counting risk alleles to provide addiction risk. Below, we provide a chart showing the remarkable Pub Med (3-16-14) list of articles published on each independent gene involving risk polymorphisms in RDS behavior and controls (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>).<fig id="Fig3"><label>Fig. 3</label><caption><p>This is a list of Pub Med articles that associate polymorphisms of reward genes with risk of RDS behaviors. For each gene, there are many polymorphisms, and there are multiple receptors for each listed transmitter. The DRD2 gene is the most widely studied as a single receptor type. Reward Gene Publications 3/16/2014</p></caption><graphic xlink:href="12035_2014_8726_Fig3_HTML" id="MO3"/></fig></p></sec><sec id="Sec7"><title>Theoretical Implications: Substance Abuse and Pain Medications</title><p>Understanding that there is a thread between opioid prescribed compounds for pain and addiction liability especially in subjects genetically predisposed to RDS risk provides the rationale to address this growing epidemic globally. The GARS test modified for pain clinics provides an analysis of about 14 genes and associated risk alleles. Thousands of studies in peer reviewed scientific journals have revealed significant associations between certain reward genes, with reward circuitry imbalances in the brain and risk for high substance seeking behavior. The predictive value for just one gene such as the DA D2 receptor gene is as high as 74.4&#160;% as described by Blum et al. [<xref ref-type="bibr" rid="CR12">12</xref>]. Simply, the occurrence or absence of these single nucleotide polymorphisms may determine a patient&#8217;s predisposition to potential treatment outcome and relapse. In addition to addiction risk, it may help guide the physician in determining the use of chronic opioid therapy, and a rationale for continuing urine monitoring consistent with the American College of Occupational and Environmental Medicine (ACOEM) guidelines. Most importantly, ACOEM suggests that genetics are an important factor in pain management, and according to the National Institute on Drug Abuse (NIDA), as well as the American Society of Addiction Medicine (ASAM), genes are responsible for a 60&#160;% contribution toward addictive behaviors. Not surprisingly, according to the American Pain Society, a physician&#8217;s ability to predict an opioid abuser is no better than chance (50&#160;%). In fact, Bornstein&#8217;s group [<xref ref-type="bibr" rid="CR20">20</xref>] found that when clinicians&#8217; only urine test patients suspected of medication misuse, they are missing a significant group; up to 72&#160;% and are quick to make wrong judgments. The ACOEM guidelines on Chronic Opioid Therapy suggest &#8220;screening for risk of addiction should be performed before starting a long-term opioid treatment in patients with chronic pain&#8221;, thus providing the physician with clues about the necessity for increased attention in susceptible patients. If opioid treatment results in pain control, better functioning, and improved health-related quality of life, the treatment should be continued, even in patients susceptible for addiction. However, these patients will need special attention with a focus on compliance, abstinence from other drugs of abuse and with discussion of the potential consequences of chronic treatment of pain with opioids.</p><p>Although the principal pain pathways ascend to the brain from the dorsal horn of the spinal cord the control of sensitivity to pain may reside in the mesolimbic system of the brain at the reward center, where gene polymorphisms may impact pain tolerance and/or sensitivity. These polymorphisms may associate with a predisposition to pain intolerance or tolerance to pain. It is hypothesized that the identification of certain gene polymorphisms may provide a unique therapeutic target to assist in pain treatment. Thus, testing for certain candidate genes like the mu receptors and PENK could assist in the design of pharmacogenomic solutions personalized to each patient and guided by their unique genetic makeup [<xref ref-type="bibr" rid="CR10">10</xref>], with potential for improvement in clinical outcomes [<xref ref-type="bibr" rid="CR11">11</xref>].</p><p>Understanding the role of neurogenetics in pain relief, including pharmacogenomics and nutrigenomic aspects, will pave the way to better treatment for the millions suffering from both acute and chronic pain. We now know that dopaminergic tone is involved in pain sensitivity mechanisms and even buprenorphine outcome response. The identification of certain gene polymorphisms as unique, therapeutic targets may assist in the treatment of pain. Pharmacogenetic testing for certain candidate genes, like mu receptors and PENK, is proposed, as a means to improve clinical outcomes by the provision of treatment. The use of GARS, as described above, to identify clients with high addiction risk by providing valuable information about genetic predisposition to opioid addiction, could become an important frontline approach, on admission to pain clinics.</p><p>One notable study evaluated the role of both mu-opioid receptors (MORs) and delta-opioid receptors (DORs) two genes expressed in the VTA that may be involved in the addictive properties of opiates. Researchers David et al. [<xref ref-type="bibr" rid="CR21">21</xref>] found that intra-VTA morphine self-administration was abolished in knockout MOR gene mice at all doses tested. While male and female WT and DOR&#8722;/&#8722; mice exhibited self-administration similarly, however, this behavior was disrupted without triggering physical signs of withdrawal by the administration of Naloxone (4&#160;mg/kg) to WT and DOR mutants. An increase in <italic>fos</italic> was associated with Morphine ICSA within the NAc, striatum, limbic cortices, amygdala, hippocampus, lateral mammillary nucleus, and the ventral posteromedial thalamus where high levels of <italic>fos</italic> were expressed exclusively in self-administering WT and DOR&#8722;/&#8722; mice. Abolition of morphine reward in MOR&#8722;/&#8722; mice was associated with a decrease in <italic>fos</italic> positive neurons in the mesocorticolimbic DA system, amygdala, hippocampus (CA1), lateral mammillary nucleus, and a complete absence within the ventral posteromedial thalamus. David et al. [<xref ref-type="bibr" rid="CR21">21</xref>] concluded that (a) ventral posteromedial thalamus MORs, but not DORs, are critical for morphine reward and (b) the role of VTA-thalamic projections in opiate reward warrants further exploration.</p><p>Moreover, clinical and laboratory studies have indicated that the MOR gene contributes to inheritable vulnerability to the development of opiate addiction. Polymorphisms that occur naturally have been identified in the MOR gene. Substitutions occur at high allelic frequencies (10.5 and 6.6&#160;%) in two coding regions single nucleotide polymorphisms (SNPs), the A118G and C17T respectively, of the MOR gene. These SNPs cause amino acid changes in the receptor that impact on an individual&#8217;s response to opioids and can influence increases or decreases in vulnerability to opiate addiction [<xref ref-type="bibr" rid="CR22">22</xref>]. Thus, in response to beta-endorphin in cellular assays, the A118G substitution encodes a variant receptor with differences in binding and signal transduction [<xref ref-type="bibr" rid="CR22">22</xref>]. Finally, to firmly establish the role of MOR in reward and response to buprenorphine, Ide et al. [<xref ref-type="bibr" rid="CR23">23</xref>] assessed buprenorphine anti-nociception by hot-plate and tail-flick tests, and found that it was significantly reduced in heterozygous mu-opioid receptor knockout (MOR-KO) mice and abolished in homozygous MOR-KO mice. Buprenorphine, on the other hand, was able to establish a conditioned place preference in homozygous MOR-KO, although as the number of copies of wild-type mu-opioid receptor genes was reduced, the magnitude of place preference was reduced. This study revealed that mu-opioid receptors mediate most of analgesic properties of buprenorphine [<xref ref-type="bibr" rid="CR23">23</xref>]. We are proposing that to determine patient addiction liability, genetic testing should be incorporated into the beginning of Occupational Medical Clinic programs to reduce iatrogenic opioid prescription addiction, and should include both opioid and dopaminergic risk alleles.</p></sec><sec id="Sec8"><title>Explanation of Single Nucleotide Polymorphisms</title><p>RDS-associated SNPs can be identified by any suitable method, including DNA sequencing of patients diagnosed with one or more RDS behaviors. After validation, newly identified RDS-associated SNPs can be used in the test. As will be appreciated, once identified and validated, the presence, if any, of one or more RDS-associated SNPs in the nucleic acids derived from a biological sample taken from a patient can be determined using any suitable now known or later-developed assay, including those that rely on site-specific hybridization, restriction enzyme analysis, or DNA sequencing. Table&#160;<xref rid="Tab2" ref-type="table">2</xref> lists a number of particularly preferred RDS-associated SNPs, whereby, the detection of which can be used for the GARS test.<table-wrap id="Tab2"><label>Table 2</label><caption><p>RDS-associated SNPs</p></caption></table-wrap></p></sec><sec id="Sec9"><title>Serotonin (5-Hydroxytriptamine5-HT) Genes (2AReceptor1438G/a)</title><p>Serotonin, also known as 5-hydroxytryptamine or 5-HT, is a neurotransmitter and peripheral NH2 signal mediator that was discovered in the late 1940s. By the early 1950s, neurotransmitter function was identified in the central nervous system of animals. In the late 1950s, there was evidence for 5-HT receptor peripheral heterogeneity, and by 1979, 5-HT binding sites were identified in the brain: 5-HT1 and 5-HT2. 5-HT 2A receptor (5-HT2A) is one of several proteins to which 5-HT binds when brain cells communicate. 5-HT receptors located on the membranes of nerve and other cell types mediate the effects of 5-HT as the endogenous ligand. 5-HT receptors are heptahelical; G protein coupled seven trans-membrane receptors, activated by an intracellular second messenger cascade except for the 5-HT3 receptor, a ligand gated ion channel. The 5-HT receptor contains 471 amino acids in rats, mice, and humans and is widely distributed in peripheral and central tissues. 5-HT receptors mediate contractile responses in a series of vascular smooth muscle preparations. In addition, platelet aggregation and increased capillary permeability following exposure to 5-HT have been linked to 5-HT receptor-mediated functions. Centrally, these receptors are located principally on cells in the cerebral cortex, claustrum, and basal ganglia. 5-HT receptors reduce cyclic adenosine monophosphate (cAMP) and modify the activity and release of other neurotransmitters like glutamate, enkephalin, DA, and GABA. 5-HT2A receptors increase glutamate activity of in many areas of the brain, some of the other 5-HT receptors have the effect of suppressing glutamate. The therapeutic actions that result from increased stimulation of 5-HT receptors in anti-depressant and anxiolytic treatments seems to be opposed by increased stimulation of the 5-HT2A receptors.</p></sec><sec id="Sec10"><title>Serotonin Receptors (2A) Genetics</title><p>Everyone inherits two copies of the 5-HT2A receptor gene, one from each parent. Small differences in the chemical sequence results, in some people having an adenine (A), switched at the same point for a guanine (G). So a subject can have gene types AA, AG, or GG. According to the US Department of Health and Human Services National Institutes of Health, &#8220;whether depressed patients will respond to an antidepressant depends in part, on which version of a gene they inherit.&#8221; The chance of a positive response to an antidepressant increase by up to 18&#160;% in those who have two copies of one version of a gene that codes for a component of brain mood-regulation. It is well known that polymorphisms at the 5-HT2A receptor gene vary in terms of frequency, for example, Whites have six times more of the minor allelic version compared to Blacks. These and other findings add to evidence that the component is a receptor for chemical antidepressant action. Serotonergic genes have been also associated with suicide ideation, trauma in children, and criminality [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>].</p><p>Specifically related to chemical dependencies, these particular genes have been associated with heroin dependence. The 5-HT2A-1438A allele was significantly more common in heroin dependent patients than controls [0.55 and 0.45, respectively; corrected <italic>P</italic>&#8201;=&#8201;0.042]. An interaction between A-1438G of 5-HT2A and 5-HTT polymorphisms was observed, in the presence of short 5-HTTLPR alleles and 12-repeat 5-HTT VNTR the association between heroin dependence and the &#8722;1438AA vs. AG/GG genotypes was enhanced [24.8&#160;% in heroin-dependent patients vs. 12.6&#160;% in controls; corrected <italic>P</italic>&#8201;=&#8201;0.045] [<xref ref-type="bibr" rid="CR26">26</xref>]. Moreover, genetic analyses showed that the frequency of 102C allele and C102C genotype in alcoholic subjects was significantly higher than in controls. In addition, alcoholic patients homozygous for C allele had alcoholic problems at significantly earlier age of onset than subjects having at least one T allele. These results point to the possibility of a role for the T102C HTR2A polymorphism in development of alcohol dependence and even relapse [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. Additionally, 5-HT2A, and 5-HT2C receptors that innervate the DA meso-accumbens pathway may play a prominent role in the behavioral effects of cocaine [<xref ref-type="bibr" rid="CR29">29</xref>]. Smoking behavior is influenced by genetic factors affecting the dopaminergic system, and dopaminergic polymorphisms have been linked to smoking habits [<xref ref-type="bibr" rid="CR30">30</xref>]. Since this T102C polymorphism of the 5-HT2A receptor gene modulates the mesolimbic DA system and is associated with reduced receptor gene expression, the purpose of one study [<xref ref-type="bibr" rid="CR31">31</xref>] was to investigate the relationship it has to tobacco use. The T102C polymorphism was found to be associated with maintenance, but not with the initiation of the smoking habit. The CC genotype was more frequent in current smokers than in never- or former-smokers (chi2&#8201;=&#8201;6.825, <italic>P</italic>&#8201;=&#8201;0.03) with an odds ratio of 1.63, 95&#160;% CI 1.06&#8211;2.51. Interestingly, Nichols et al. [<xref ref-type="bibr" rid="CR32">32</xref>] found that the gene response to LSD was quite dynamic. The expression of some genes increased rapidly and decreased rapidly while other genes changed more gradually. Dose-response studies showed two classes: (1) gene expression maximally stimulated at lower doses, and (2) gene expression that continued to rise at the higher doses. In a series of experiments that used receptor specific antagonists, the role of the 5-HT1A and 5-HT2A receptors in mediating the increases in gene expression, was examined and found that the 5-HT2A receptor activation was responsible for the majority of expression increases.</p></sec><sec id="Sec11"><title>5-HTTLPR (Serotonin Transporter-Linked Polymorphic Region)</title><p>The human 5-HT transporter is encoded by the SLC6A4 gene on chromosome 17q11.1-q12. This is the site for cellular reuptake of 5-HT and a site where many drugs with central nervous system effects are activated. They include therapeutic agents like antidepressants and psychoactive drugs of abuse like cocaine. The 5-HT transporter has a prominent role in the metabolic cycle of many antidepressants, antipsychotics, anxiolytics, anti-emetics, and anti-migraine drugs. Higher expression of brain 5-HTT is associated with the (long allele) insertion variant compared to the (short allele) deletion variant. The results of some studies show that long allele is responsible for increased 5HT transporter mRNA transcription in human cell lines. Further, this may be due to the A-allele of rs25531, so that subjects with the long-rs25531 (A) allelic combination (LA) have higher levels, with the long-rs25531(G) earners have levels more similar to short-allele carriers. Saiz et al. [<xref ref-type="bibr" rid="CR26">26</xref>] found an excess of -1438G and 5-HTTLPR L carriers in alcoholic patients in comparison to the heroin dependent group, the polymorphisms A-1438G and 5-HTTLPR also distinguished, alcohol from heroin dependent patients. The association of -1438A/G was especially pronounced with alcohol dependence when 5-HTTLPR S/S was present, less evident with 5-HTTLPR L/S, and not present with 5-HTTLPR.</p><p>The 5-HT transporter, encoded by the SLC6A4 gene, influences the synaptic actions of 5-HT and is responsive to stress hormones. In fact, the risk for suicidal behavior in CT exposed individuals is independently affected by the 5&#8242; and 3&#8242;SLC6A4 functional variants [<xref ref-type="bibr" rid="CR25">25</xref>]. National Longitudinal Study of Adolescent Health data shows that there is a significant gene-environment correlation between 5-HTTLPR and neglect for females only. Findings also reveal that 5-HTTLPR is associated with an increased risk of neglect for females and neglected females&#8217; risk of abusing marijuana [<xref ref-type="bibr" rid="CR33">33</xref>]. Socialization scores were significantly lower in males (greater sociopathy), with the L&#8242;L&#8242; genotype (i.e., those homozygous for the L (A) allele) than males who carried the S&#8242; allele (<italic>P</italic>&#8201;=&#8201;0.03). In contrast, women with the S&#8242;S&#8242; genotype tended to have a lower Socialization Index on the California Psychological Inventory than women with one copy of the L&#8242; allele (<italic>P</italic>&#8201;=&#8201;0.07) and lower socialization scores than women with two L&#8242; alleles (<italic>P</italic>&#8201;=&#8201;0.002). The tri-allelic 5-HTTLPR polymorphism had opposite effects on socialization scores in men than women with alcohol use disorders [<xref ref-type="bibr" rid="CR34">34</xref>].</p><p>The genotype coding for low 5-HTT expression is associated with a better opioid analgesic effect, while the 5-HTTLPR s-allele has been associated with higher risk of developing chronic pain conditions. Downregulation of 5-HT1 receptors has been associated with the s-allele, and Kosek et al. [<xref ref-type="bibr" rid="CR35">35</xref>] have suggested that individuals have an increased analgesic response to opioids during acute pain stimuli with a desensitization of 5-HT1 receptors, but may still be at increased risk of developing chronic pain conditions. The risk of alcohol dependence and co-occurring clinical features is increased in the presence of the short (S) allele of the 5-HT transporter gene promoter polymorphism (5-HTTLPR). While no other factor that were measured played a significant role, the S allele was significantly associated with relapse (<italic>P</italic>&#8201;=&#8201;0.008). Thus, in abstinent alcohol-dependent patients the risk of relapse may be influenced by S allele of the 5-HTTLPR polymorphism, possibly through intermediate phenotypes [<xref ref-type="bibr" rid="CR36">36</xref>].</p></sec><sec id="Sec12"><title>Catecholamine-<italic>O</italic>-Methyltransferase (COMT) Val158Met Polymorphism</title><p>Catechol-<italic>O</italic>-methyltransferase (COMT) was discovered in 1957 by the Nobel Prize Winner biochemist Julius Axelrod. COMT is an extra cellular enzyme that breaks down DA, adrenaline, and noradrenaline in the synapse. COMT is involved in the metabolism of the catecholamine neurotransmitters (DA, epinephrine, and norepinephrine). The enzyme introduces a methyl group donated by <italic>SA</italic>-denosyl-methionine to the catecholamine. Any compound having a catechol structure, like catechol-estrogens and catechol-containing flavonoids, are substrates of COMT, for example, <sc>l</sc>-dopa, a precursor of catecholamines and an important substrate of COMT. Variability of the COMT activity has previously been associated with the Val158Met polymorphism of the COMT gene and alcoholism. Ser&#253; et al. [<xref ref-type="bibr" rid="CR37">37</xref>] found an association between alcoholism in male subjects and the Val158Met polymorphism of the COMT gene. Ser&#253; et al. also found the significant difference between allele and genotype frequencies of male alcoholics and male controls. In one of the subjects genotyped with heroin addiction, carries of the DRD2 A1 allele, also carried the low enzyme COMT activity genotype (A/A). This is in agreement with the work of Cao et al. [<xref ref-type="bibr" rid="CR38">38</xref>] in 2003 who found no association with the high G/G and heroin addiction. No significant differences in genotype and allele frequencies of 108&#160;val/met polymorphism of COMT gene were observed between heroin-dependent subjects and normal controls. No differences in genotype and allele frequencies of 900 Ins C/Del C polymorphism of COMT gene were observed between heroin-dependent subjects and normal controls. While there is still some controversy regarding the COMT association with heroin addiction, it was also interesting that the A allele of the val/met polymorphisms (&#8722;287 A/G) found by Cao et al. [<xref ref-type="bibr" rid="CR38">38</xref>] was found to be much higher in heroin addicts than controls. Faster metabolism results in reduced DA availability at the synapse, which reduces postsynaptic activation, inducing hypodopaminergic functioning. Generally, Vandenbergh et al. [<xref ref-type="bibr" rid="CR39">39</xref>] in 1997, and others [<xref ref-type="bibr" rid="CR40">40</xref>] supported an association with the Val allele and Substance Use Disorder, but others did not [<xref ref-type="bibr" rid="CR41">41</xref>]. Li et al. [<xref ref-type="bibr" rid="CR42">42</xref>] found the COMT rs737866 gene variants were independently associated with both novelty seeking (NS) and age of onset of drug use. Those subjects with the TT genotype had higher NS subscale scores and an earlier onset age of heroin use than individuals with CT or CC genotypes. In a multivariate analysis, the inclusion of the NS sub score variable weakened the relationship between the COMT rs737866 TT genotype and an earlier age of onset of drug use. Li&#8217;s findings that COMT is associated with both NS personality traits and with the age of onset of heroin use helps to clarify the complex relationship between genetic and psychological factors in the development of substance abuse. Case-control analyses did not show any significant difference in allele or genotype distributions. However, a dimensional approach revealed a significant association between the COMT-Val (158) Met and NS. Both controls and opiate users with Met/Met genotypes showed higher NS scores compared to those with the Val allele. Demetrovics et al. [<xref ref-type="bibr" rid="CR43">43</xref>] reported the NS scores also were significantly higher among opiate users; however, no interaction was found between group status and COMT genotype. A functional single nucleotide polymorphism (a common normal variant) of the gene for COMT has been shown to affect cognitive tasks broadly related to executive function, such asset shifting, response inhibition, abstract thought, and the acquisition of rule sorting structure. This polymorphism in the COMT gene results in the substitution of the amino acid valine for methionine. It has been shown that this valine variant catabolizes DA at up to four times the rate of its methionine counterpart resulting in a significant reduction of synaptic DA following neurotransmitter release, ultimately reducing dopaminergic stimulation of the post-synaptic neuron [<xref ref-type="bibr" rid="CR44">44</xref>] another driver in the GARS.</p></sec><sec id="Sec13"><title>Monoamine Oxidase-A</title><p>Monoamine oxidase-A (MAOA) is an enzyme that degrades the neurotransmitters 5-HT, norepinephrine, and DA in the mitochondria. MAOA is involved with both physical and psychological functioning and classified as a flavoprotein since it contains the covalently bonded cofactor FAD. MAOA is an oxidative catalyst that uses oxygen to deaminate-remove an amine group from molecules, resulting in the corresponding aldehyde and ammonia.</p><p>Both forms of MOA (A and B) enzymes are substrates for the activity of a number of monoamine oxidase inhibitor drugs and are, therefore, well known in pharmacology. They are particularly important in the catabolism of monoamines ingested in food and vital to the inactivation of monoaminergic neurotransmitters. They display different specificities MAO-A primarily breaks down serotonin, melatonin, norepinephrine, and epinephrine while phenylalanine and benzyl amine are mainly broken down by MAO-B. Both forms break down DA, tyramine and tryptamine equally.</p><p>The gene that encodes MAOA is found on the X chromosome is located 1.2&#160;kb upstream of the MAOA coding sequences and contains a polymorphism (MAOA-uVNTR) [<xref ref-type="bibr" rid="CR45">45</xref>]. The MAOA-uVNTR consists of a 30-base pair repeated sequence, six allele variants containing either 2-, 3-, 3.5-, 4-, 5-, or 6-repeat copies [<xref ref-type="bibr" rid="CR46">46</xref>]. Functional studies have indicated the alleles confer variations in transcriptional efficiency, for example, the 3.5- and 4-repeat alleles result in higher efficiency, whereas, the 3-repeat variant conveys lower efficiency [<xref ref-type="bibr" rid="CR47">47</xref>]. To date, there are fewer consensuses regarding the transcriptional efficiency of the other less commonly occurring alleles, for example, 2-, 5-, and 6-repeat. The MAOA gene is a highly plausible candidate for effecting differences in the manifestation of psychological traits and psychiatric disorders based on its primary role in regulating monoamine turnover, and thereby influencing levels of norepinephrine, DA, and 5-HT [<xref ref-type="bibr" rid="CR48">48</xref>]. Levels of MAO-A in the brain of patients with major depressive disorder, measured using positron emission tomography (PET), are elevated by an average of 34&#160;%. Recently, evidence has indicated that the MAOA gene may associate with depression [<xref ref-type="bibr" rid="CR49">49</xref>] and stress [<xref ref-type="bibr" rid="CR50">50</xref>]. Evidence regarding whether lower or higher transcriptional efficiency of the MAOA gene, is positively associated with psychological pathology, has however, been mixed. The MAOA-uVNTR polymorphism low-activity 3-repeat allele has been positively related to symptoms of cluster B personality disorders and antisocial personality [<xref ref-type="bibr" rid="CR51">51</xref>]. Other studies suggest that unhealthy psychological characteristics such as trait aggressiveness and impulsivity are related to alleles associated with higher transcriptional efficiency. Low MAO activity and the neurotransmitter DA are both important factors in the development of alcohol dependence. Huang et al. [<xref ref-type="bibr" rid="CR52">52</xref>] investigated whether the association between the <italic>DRD2</italic> gene and alcoholism is affected by different polymorphisms of the MAO type A (<italic>MAOA</italic>) gene since MAO is an important enzyme associated with the metabolism of biogenic amines. They found that the genetic variant of the <italic>DRD2</italic> gene associated with the anxiety, depression (ANX/DEP) alcoholic phenotype, and the genetic variant of the MAOA gene was associated with alcoholism. Specifically, subjects carrying the MAOA 3-repeat allele and genotype A1/A1 of the DRD2 were 3.48 times more likely to be ANX/DEP alcoholics than the subjects carrying the MAOA 3-repeat allele and DRD2 A2/A2 genotype. Thus, the MAOA gene may modify the association between the DRD2 gene and ANX/DEP alcoholic phenotype. Overall, Vanyukov et al. [<xref ref-type="bibr" rid="CR53">53</xref>] suggested that, although not definitive, variants in MAOA account for a small portion of the variance of risk for Substance Use Disorder, possibly mediated by liability to early onset behavioral problems.</p></sec><sec id="Sec14"><title>Dopamine D1 Receptor Gene</title><p>The DA receptor D1, also known as DRD1 a subtype of the DA receptor is a protein encoded by the DRD1 gene and the most abundant DA receptor in the human central nervous system where it expresses primarily in the caudate putamen. This G-protein-coupled receptor activates cyclic AMP-dependent protein kinases and stimulates adenylyl cyclase. D1 receptors regulate neuronal growth and development, modulate DA D2 receptor-mediated events and mediate some behavioral responses. There are two transcript variants of the DRD1 gene that are initiated at alternate transcription sites.</p><p>The DA D1 receptor has been associated with many brain functions that include, motor control, inattentive symptoms, and reward and reinforcement mechanisms. Betel et al. [<xref ref-type="bibr" rid="CR54">54</xref>] found that the DRD1 gene polymorphism T allele of the rs686 was significantly (<italic>P</italic>&#8201;=&#8201;0.0008) more frequent in patients with alcohol dependence. Frequency increased with severe dependence and was even higher for patients with severe complications like withdrawal seizures. Alcohol dependence was significantly, more precisely associated with a specific haplotype rs686*T-rs4532*G within the DRD1 gene. In another study, Kim et al. [<xref ref-type="bibr" rid="CR55">55</xref>] found that the severity of the alcohol-related problem as measured by the Alcohol Use Disorders Identification Test in a gene dose-dependent manner, was significantly associated with one 5&#8242; UTR polymorphism in the DRD1 (DRD1-48A&gt;G) gene; 24.37 (&#177;8.19) among patients with &#8722;48A/A genotype, 22.37 (&#177;9.49) among those with &#8722;48A/G genotype, and 17.38 (&#177;8.28) among those with &#8722;48G/G genotype (<italic>P</italic>&#8201;=&#8201;0.002). Novelty seeking, harm avoidance and persistence were also found to be associated with the DRD1-48A&gt;A genotype. Most recently, Peng et al. [<xref ref-type="bibr" rid="CR56">56</xref>] indicated that DRD1 gene polymorphism may be associated with the rapid acquisition of heroin dependence, from first drug use but may not play an important role in the susceptibility to heroin dependence in the Chinese Han population. Others have also found significant associations with opiate abuse relative to controls [<xref ref-type="bibr" rid="CR57">57</xref>]. DRD1 antagonists may indeed reduce the acquisition of cocaine-cue associations and cocaine-seeking behavior. Genetic association studies revealed that polymorphisms of the DRD1 gene significantly associated with nicotine dependence [<xref ref-type="bibr" rid="CR58">58</xref>]. Ni et al. [<xref ref-type="bibr" rid="CR59">59</xref>] found a significant association between DRD1 and bipolar disorder for haplotype TDT analysis. Thus, these results suggest DRD1 may play a role in the etiology of bipolar disorder.</p></sec><sec id="Sec15"><title>Dopamine D2 Receptor Gene (DRD2)</title><p>DA receptor D<sub>2</sub>, also known as DRD2, is a protein that is encoded by the <italic>DRD2</italic> gene which encodes the D<sub>2</sub> subtype of the DA receptor in humans. This G protein-coupled receptor inhibits adenyl cyclase activity. Two transcript variants encode different isoforms and a third variant that has been described are the result of alternative splicing of the gene. In mice, of D2R surface expression is regulated in the dentate gyrus by the calcium sensor NCS-1 and controls exploration, synaptic plasticity, and memory formation.</p><p>DA has the chemical formula (C<sub>6</sub>H<sub>3</sub> (OH)<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-NH<sub>2</sub>) is a member of the catecholamine family. DA is a precursor to the chemical messengers&#8217; epinephrine (adrenaline) and norepinephrine (noradrenaline). Arvid Carlsson won a share of the 2000 Nobel Prize in Physiology and Medicine for showing that DA is not just a precursor to these substances, but is also a neurotransmitter.</p><p>Older antipsychotic drugs, like haloperidol and chlorpromazine are DRD2 antagonists, however they are exceedingly nonselective, being selective for the &#8220;D2-like family&#8221; receptors; binding to D2, D3, and D4 and many other receptors, such as, those for 5-HT and histamine. This lack of selectivity makes them difficult to research and results in a range of side effects. Similarly, older DA agonists like bromocriptine and cabergoline used to treat Parkinson&#8217;s disease are also poorly selective. However, the number of selective D2 ligands available for scientific research is likely to increase.</p><p>Almost a decade before Carlsson and others were awarded the Nobel Prize the DA D2 receptor gene (DRD2) was first associated with severe alcoholism and is today the most widely studied gene in psychiatric genetics [<xref ref-type="bibr" rid="CR7">7</xref>]. The <italic>Taq</italic>1 A is a SNP (rs: 1800497) originally thought to be located in the 3&#8242;-untranslated region of the DRD2 but has since been shown to be located within exon 8 of an adjacent gene, the ankyrin repeat and kinase domain containing 1 (ANKK1). Importantly, while there may be distinct differences in function, the miss-location of the <italic>Taq</italic>1A allele may be attributable to the ANKKI and the DRD2 being on the same haplotype or the ANKKI being involved in reward processing through a signal transduction pathway [<xref ref-type="bibr" rid="CR60">60</xref>]. The ANKKI and the DRD2 gene polymorphisms may have distinct and different actions with regard to brain function [<xref ref-type="bibr" rid="CR61">61</xref>]. Presence of the A1<sup>+</sup> genotype (A1/A1, A1/A2) compared to the A<sup>&#8722;</sup> genotype (A2/A2) is associated with reduced receptor density [<xref ref-type="bibr" rid="CR62">62</xref>&#8211;<xref ref-type="bibr" rid="CR64">64</xref>]. This reduction causes hypodopaminergic functioning in the DA reward pathway. Other DRD2 polymorphisms such as the C (57T, A SNP (rs: 6277)) at exon 7 also associates with a number of RDS behaviors including drug use [<xref ref-type="bibr" rid="CR65">65</xref>]. Compared to the T<sup>&#8722;</sup> genotype (C/C), the T<sup>+</sup> genotype (T/T, T/C) is associated with reduced translation of DRD2 mRNA and diminished DRD2 mRNA, leading to reduced DRD2 density and a predisposition to alcohol dependence [<xref ref-type="bibr" rid="CR66">66</xref>]. The <italic>Taq</italic>1 A allele is a predictive risk allele in families [<xref ref-type="bibr" rid="CR67">67</xref>].</p><p>More recently, Kraschewski and colleagues [<xref ref-type="bibr" rid="CR68">68</xref>] found the DRD2 haplotypes I-C-G-A2 and I-C-A-A1 to occur with a higher frequency in alcoholics. The rare haplotype I-C-A-A2 occurred less often in alcoholics and was less often transmitted from parents to their affected children (1 vs. 7). Among the subgroups, I-C-G-A2 and I-C-A-A1 had a higher frequency in Cloninger 1 alcoholics and alcoholics with a positive family history. Cloninger 2 alcoholics had a higher frequency of the rare haplotype D-T-A-A2 as compared with controls. In patients with a positive family history, haplotype I-C-A-A2 and Cloninger 1 alcoholics, haplotype I-T-A-A1 was less often present, confirming that haplotypes, which are supposed to induce a low DRD2 expression, were associated with alcohol dependence. Furthermore, supposedly high-expressing haplotypes weakened or neutralized the action of low-expressing haplotypes [<xref ref-type="bibr" rid="CR68">68</xref>]. Moreover, Kazantseva et al. [<xref ref-type="bibr" rid="CR69">69</xref>] found, significant effects of the ANKK1/DRD2 <italic>Taq1</italic>A on &#8220;Neuroticism&#8221; and of SLC6A3 rs27072 on &#8220;Persistence&#8221; in both genders. The association between ANKK1/DRD2 <italic>Taq</italic>1A A2/A2-genotype and higher Novelty Seeking and lower Reward Dependence was shown in men but not in women.</p></sec><sec id="Sec16"><title>Dopamine D3 Receptor Gene</title><p>The DA D3 receptor is a protein that is encoded by the DRD3 gene in humans and is a subtype of the DA receptor which inhibits adenylyl cyclase through inhibitory G-proteins. This receptor is expressed in older regions of the brain phylogenetically. This suggests that it is important in emotional functions. It is a target for drugs that treat Parkinson&#8217;s disease, schizophrenia, and drug addiction. Differently encoded isoforms from alternative gene splicing result in transcription of multiple variants. Some of these variants may be subject to nonsense-mediated decay, however, in rodent models of depression D3 agonists like pramipexole, rotigotine, and 7-OH DPAT, among others, display antidepressant effects.</p><p>Data from Vengeliene et al. [<xref ref-type="bibr" rid="CR70">70</xref>] revealed an up-regulation of the DA D3 receptor (D3R) in the striatum after 1&#160;year of voluntary alcohol consumption of alcohol preferring rats that was confirmed by qRT-polymerase chain reaction. This finding was further supported by up-regulation of striatal D3R mRNA found in non-selected Wistar rats, after long-term alcohol consumption when compared with age-matched control animals. Moreover, they examined the role of the D3R in mediating alcohol relapse behavior. They used the alcohol-deprivation-effect model, in long-term alcohol drinking Wistar rats and the model of cue-induced reinstatement of alcohol-seeking behavior, using the selective D3R antagonist SB-277011-A (0, 1, 3, and 10&#160;mg/kg) and the partial agonist BP 897 (0, 0.1, 1, and 3&#160;mg/kg). Both treatments caused a dose-dependent reduction of relapse-like drinking in the alcohol-deprivation-effect model, as well as a decrease in cue-induced ethanol-seeking behavior. They concluded that long-term alcohol consumption led to an up-regulation of the DA D3R that might have contributed to alcohol-seeking and relapse. Moreover, the Gly9, Gly9 genotype of the DRD3 Ser9Gly polymorphism was associated with increased rates of obsessive personality disorder symptomatology [<xref ref-type="bibr" rid="CR71">71</xref>].</p><p>Furthermore, several lines of evidence indicate that dopaminergic neurotransmission is involved in the regulation of impulsive aggression and violence and that genetically determined variability in dopaminergic gene expression modifies complex traits including that of impulsivity and aggression. In one study, Retz et al. [<xref ref-type="bibr" rid="CR72">72</xref>] reported an association of the DRD3 polymorphism with impulsiveness according to Eysenck&#8217;s EIQ and scores on the German short version of the Wender Utah Rating Scale (WURS-k), which they used for the assessment of a history of attention deficit hyperactivity disorder (ADHD) symptoms. This association was detected in a group of violent offenders, but not in non-violent individuals. Highest scores of EIQ impulsiveness and the WURS-k were found in heterozygous violent individuals while homozygotes showed significant lower rating scores, suggesting a heterosis effect. The results of their study suggest that variations of the DRD3 gene are likely involved in the regulation of impulsivity and some psychopathological aspects of ADHD related to violent behavior.</p><p>Finally, as opiates increase DA transmission, Spangler et al. [<xref ref-type="bibr" rid="CR73">73</xref>] measured the effects of morphine on DA-related genes using a real-time optic PCR assay that reliably detects small differences in mRNA in discrete brain regions. As reported previously by others, there was no alteration in D1R mRNA and a 25&#160;% decrease in D2R mRNA in the caudate-putamen, 2&#160;h after the final morphine injection. Importantly, in the same RNA extracts, D3R mRNA showed significant increases of 85&#160;% in the caudate-putamen and 165&#160;% in the ventral midbrain, including the substantia nigra and VTA. There were no other significant morphine effects. The understanding of the ability of D3R agonists to reduce the effects of morphine was extended by the finding that chronic intermittent injections of morphine caused an increase in D3R mRNA extends.</p></sec><sec id="Sec17"><title>Dopamine D4 Receptor Gene</title><p>The DA receptor D4 is encoded by the DRD4 gene on chromosome 11 located in 11p15.5 in humans. Like the DRD2 the D4 receptor is a G protein-coupled receptor, activated by the neurotransmitter DA. It also inhibits the adenylate cyclase enzyme which reduces the intracellular second messenger cyclic AMP concentration. The DRD4 has been associated with numerous psychiatric and neurological conditions including addictive behaviors, and eating disorders (like binge-eating anorexia and bulimia nervosa, bipolar disorder) schizophrenia and Parkinson&#8217;s disease. Slight variations (mutations/polymorphisms) in the human DRD4 gene include: A 48-base pair VNTR in exon 3; 13-base pair deletion of bases 235 to 247 in exon 1; C-521T in the promoter; Val194gLY; 12 base pair repeat in exon I; A polymorphic tandem duplication of 120&#160;bp. These mutations have been associated with a number of behavioral phenotypes, including autonomic nervous system dysfunction, ADHD, schizophrenia, and the personality trait of novelty seeking. Specifically, the 48-base pair VNTR in exon 3 ranges from 2 to 11 repeats. Polymorphisms with 6 to 10 repeats are the &#8220;Long&#8221; versions of the alleles. The frequency of the alleles varies considerably between populations, for example, the incidence of the 7-repeat version is high in America and low in Asia. The DRD4 long variant, or more specifically the 7 repeat (7R), has been loosely linked to psychological traits and disorders like susceptibility for developing ADHD appears to react less strongly to DA molecules. The 7R allele appears to have been selected about 40,000&#160;years ago then in 1999, Chen et al. [<xref ref-type="bibr" rid="CR74">74</xref>, <xref ref-type="bibr" rid="CR75">75</xref>] showed that nomadic populations had higher frequencies of 7R alleles than sedentary ones. They also observed that higher frequency of 7R/long alleles in populations who migrated further from 1,000 to 30,000&#160;years ago. Recently, it was found that Ariaals with the 7R alleles, who are newly sedentary (non-nomadic), are not as healthy as nomadic Ariaal men with 7R alleles [<xref ref-type="bibr" rid="CR76">76</xref>].</p><p>Despite early findings of an association between the DRD4 48&#160;bp VNTR and novelty seeking (characteristic of exploratory and excitable people), a 2008 meta-analysis compared 36 published studies of novelty seeking and the polymorphism and found no effect. The meta-analysis of 11 studies did find that another polymorphism in the gene, the &#8722;521C/T, showed an association with novelty seeking [<xref ref-type="bibr" rid="CR77">77</xref>]. In any case, novelty-seeking behavior probably is mediated by several genes, and the variance attributable to DRD4 by itself is not particularly large.</p><p>Several studies have suggested that parenting may affect the cognitive development of children with the 7-repeat allele of DRD4 [<xref ref-type="bibr" rid="CR78">78</xref>]. Parenting that has maternal sensitivity, mindfulness, and autonomy-support at 15&#160;months was found to alter children&#8217;s executive functions at 18 to 20&#160;months [<xref ref-type="bibr" rid="CR78">78</xref>]. Children with poorer quality parenting were more impulsive and sensation seeking than those with higher quality parenting [<xref ref-type="bibr" rid="CR78">78</xref>]. Higher quality parenting was associated with better effortful control in 4-year-olds [<xref ref-type="bibr" rid="CR78">78</xref>] and these effects are impacted by epigenetic markers on chromatin structures.</p><p>There is evidence that the length of the D4 DA receptor (DRD4) exon 3 variable number of tandem repeats (VNTR) affects DRD4 functioning by modulating the expression and efficiency of maturation of the receptor [<xref ref-type="bibr" rid="CR79">79</xref>]. The 7R VNTR requires significantly higher amounts of DA to produce a response of the same magnitude as other size VNTRs [<xref ref-type="bibr" rid="CR80">80</xref>], and this reduced sensitivity or DA resistance leads to hypodopaminergic functioning. Thus, 7R VNTR has been associated with substance-seeking behaviors [<xref ref-type="bibr" rid="CR81">81</xref>, <xref ref-type="bibr" rid="CR82">82</xref>]. However, not all reports support this association. Biederman et al. [<xref ref-type="bibr" rid="CR83">83</xref>] evaluating a number of putative risk alleles using survival analysis, revealed that by 25&#160;years of age, 76&#160;% of subjects with a DRD4 7R allele were estimated to have significantly more persistent ADHD compared with 66&#160;% of subjects without the risk allele. In contrast, there were no significant associations between the course of ADHD and the DAT1 10-repeat allele and 5HTTLPR long allele. These findings suggested that the DRD4 7R allele, is associated with increased persistence in the course of ADHD. Moreover, Grzywacz et al. [<xref ref-type="bibr" rid="CR84">84</xref>] evaluated the role of DRD4 exon 3 polymorphisms (48&#160;bp VNTR) in the pathogenesis of alcoholism and found significant differences in the short alleles (2&#8211;5 VNTR) frequencies, between controls and patients with a history of delirium tremens and/or alcohol seizures. A trend also was observed in the higher frequency of short alleles amongst individuals with an early age of onset of alcoholism. The results of this study suggest that inherited short variants of DRD4 alleles (3R) may play a role in the pathogenesis of alcohol dependence and carriers of the 4R may have a protective effect for alcoholism risk behaviors. It is of further interest that work from Kotler et al. [<xref ref-type="bibr" rid="CR85">85</xref>] in heroin addicts illustrated that central dopaminergic pathways figure prominently in drug-mediated reinforcement including novelty seeking, suggesting that DA receptors are likely candidates for association with substance abuse. These researchers showed that the 7R allele was significantly over-represented in the opioid-dependent cohort and conferred a relative risk of 2.46.</p></sec><sec id="Sec18"><title>Dopamine Transporter Gene (DAT1)</title><p>The DA transporter, also known as DA active transporter (DAT, SLC6A3), moves DA the neurotransmitter out of the synapse back into the cytosol via a membrane-spanning protein pump. From there, DA and norepinephrine are sequestered by other transporters into vesicles for later storage and release. DA reuptake through which DA is cleared from synapses primary by the mechanism of the DAT gene, although in the prefrontal cortex, there may be an exception, where evidence points to a larger role for the norepinephrine transporter [<xref ref-type="bibr" rid="CR86">86</xref>, <xref ref-type="bibr" rid="CR87">87</xref>].</p><p>DAT is thought to be implicated in a number of DA-related disorders, including ADHD, bipolar disorder, clinical depression, and RDS. The gene that encodes the DAT protein is located on human chromosome 5, consists of 15 coding exons and is roughly 64&#160;kbp long. Evidence for the associations between DAT- and DA-related disorders has come from a type of genetic polymorphism, known as a VNTR, in the DAT gene (DAT1), which influences the amount of protein expressed. DAT is an integral membrane protein that removes DA from the synaptic cleft and deposits it into surrounding cells, thus terminating the signal of the neurotransmitter. DA underlies several aspects of cognition, including reward, and DAT facilitates regulation of that signal [<xref ref-type="bibr" rid="CR88">88</xref>, <xref ref-type="bibr" rid="CR89">89</xref>].</p><p>In the model for monoamine transporter function that is most widely accepted, before DA can bind sodium ions must bind to the DAT extracellular domain. Once DA binds to sodium ions change in the conformation of the protein allows both the DA and the sodium to unbind intracellularly [<xref ref-type="bibr" rid="CR90">90</xref>]. Studies using electrophysiology and radioactive-labeled DA have confirmed that DA is transported across the neuronal membrane with sodium ions. The chlorine ions are required to prevent a buildup of positive charge. These studies have demonstrated that the direction and rate of transport, depends on the sodium gradient [<xref ref-type="bibr" rid="CR77">77</xref>]. It is known that any resultant activity changes in membrane polarity will profoundly affect transport rates and depolarization will induce DA release [<xref ref-type="bibr" rid="CR91">91</xref>].</p><p>Like the GABA transporter, the brain distribution of DAT is highest in the nigrostriatal, mesocortical, and mesolimbic pathways [<xref ref-type="bibr" rid="CR92">92</xref>] and gene expression patterns in adult mouse show that expression is high in the substantia nigra pars compacta [<xref ref-type="bibr" rid="CR93">93</xref>]. It has been confirmed that DAT in the mesocortical pathway was also found in the VTA. DAT is localized in the axon terminals of the striatum and shown experimentally to be co-localized with nigrostriatal terminals, tyrosine, and DA D2 receptors. These results suggest that striatal DA reuptake may occur and DA diffuses into the substantia nigra from the synaptic cleft. It appears that DAT is transported into the dendrites, where it can be found in pre- and postsynaptic active zones, smooth endoplasmic reticulum, and plasma membrane. These localizations suggest that intracellular and extracellular DA levels of nigral dendrites are modulated by DAT.</p></sec><sec id="Sec19"><title>Genetics and Regulation</title><p>The gene for DAT is located on chromosome 5p15, it is confirmed that the protein encoding for the gene is over 64&#160;kb long and comprises 15 coding segments or exons [<xref ref-type="bibr" rid="CR94">94</xref>]. The DAT gene has a VNTR at the intron 8 region and another at the 3&#8242; end (rs28363170) [<xref ref-type="bibr" rid="CR95">95</xref>]. VNTR differences have been shown to influence the basal level of expression of the transporter and associate with RDS behaviors, such as various addictions and other DA-related disorders [<xref ref-type="bibr" rid="CR96">96</xref>]. Interestingly, Nurri, a nuclear receptor that regulates many DA-related genes, can bind the promoter region of this gene and subsequently induce expression [<xref ref-type="bibr" rid="CR97">97</xref>]. In addition, the DAT promoter also may be the target of the transcription factor Sp-1. Kinases are essential for functional regulation of this protein. The rate at which DAT removes DA from the synapse affecting the quantitative amount of DA in the cell depends upon kinases. Understanding the molecular neurobiology of the DAT gene provides the basis for studies showing hyperactivity, severe cognitive deficits, and motor abnormalities of mice with no DA transporters [<xref ref-type="bibr" rid="CR98">98</xref>]. Similarities of these effects to the symptoms of ADHD characteristics are striking. Differences in the functional differences, in VNTR, have been identified as risk factors for bipolar disorder [<xref ref-type="bibr" rid="CR99">99</xref>] and ADHD [<xref ref-type="bibr" rid="CR100">100</xref>]. Although controversial, data have emerged that suggest there also is an association with stronger alcohol withdrawal symptoms [<xref ref-type="bibr" rid="CR101">101</xref>, <xref ref-type="bibr" rid="CR102">102</xref>]. On the other hand, non-smoking behavior and ease of quitting is associated with an allele of the DAT gene of the with normal protein levels [<xref ref-type="bibr" rid="CR103">103</xref>]. Additionally, male adolescents in high-risk families, with an absence of maternal affection and a disengaged mother, who carry the 10-allele VNTR repeat, associate with a statistically significant affinity for antisocial peers [<xref ref-type="bibr" rid="CR104">104</xref>]. Increased DAT activity is associated with clinical depression [<xref ref-type="bibr" rid="CR105">105</xref>]. Decreased DAT levels of expression are associated with aging, and may underlie a mechanism that compensates for decreases in DA release as a person ages [<xref ref-type="bibr" rid="CR106">106</xref>].</p><p>Cocaine reduces the rate of transport, blocking DAT by binding directly to the transporter [<xref ref-type="bibr" rid="CR107">107</xref>]. In contrast, amphetamines trigger a signal cascade thought to involve PKC or MAPK that leads to the internalization of DAT molecules, which are normally expressed on the neuron&#8217;s surface [<xref ref-type="bibr" rid="CR108">108</xref>]. Amphetamine on DAT also has a direct effect in the increased levels of secreted DA [<xref ref-type="bibr" rid="CR109">109</xref>]. Lipophilic AMPH diffuses into the cytoplasm and the DA secretory vesicles disrupting the proton gradient established across the vesicle wall. This induces a leaky channel, and DA diffuses out into the cytoplasm. Additionally, AMPH causes a reversal of normal DA flow at the DAT. Instead of DA reuptake, in the presence of AMPH, a reversal in the mechanism of DAT occurs causing an outflow of DA released into the cytoplasm into the synaptic space changing it from a symporter to an antiporter-like functionality [<xref ref-type="bibr" rid="CR110">110</xref>&#8211;<xref ref-type="bibr" rid="CR112">112</xref>]. These mechanisms both result in less removal of DA from the synapse, increased signaling, which may underlie the pleasurable feelings elicited by these substances [<xref ref-type="bibr" rid="CR113">113</xref>].</p><p>The DA transporter protein regulates DA-mediated neurotransmission by rapidly accumulating DA that has been released into the synapse [<xref ref-type="bibr" rid="CR113">113</xref>]. Moreover, within 3 noncoding region of DAT1 lies a VNTR polymorphism [<xref ref-type="bibr" rid="CR113">113</xref>]. There are two important alleles that may independently increase risk for RDS behaviors. The 9 repeat (9R) VNTR has been shown to influence gene expression and to augment transcription of the DA transporter protein [<xref ref-type="bibr" rid="CR114">114</xref>]. Therefore, this results in an enhanced clearance of synaptic DA, yielding reduced levels of DA to activate postsynaptic neurons. Presence of the 9R VNTR has been linked to Substance Use Disorder [<xref ref-type="bibr" rid="CR115">115</xref>], but not consistently [<xref ref-type="bibr" rid="CR116">116</xref>]. Moreover, in terms of RDS behaviors, Cook et al. [<xref ref-type="bibr" rid="CR117">117</xref>] was the first group that associated tandem repeats of the DAT gene in the literature. While there have been some inconsistencies associated with the earlier results, the evidence is mounting in favor of the view that the 10R allele of DAT is associated with high risk for ADHD in children and adults alike. Specifically, it was the non-additive association for the 10-repeat allele to be significant for hyperactivity-impulsivity symptoms, but exploratory analyses of the non-additive association of the 9-repeat allele of DAT1 with HI and oppositional defiant disorder symptoms also was significant. However, Volkow&#8217;s [<xref ref-type="bibr" rid="CR118">118</xref>] group found that 12&#160;months of methylphenidate treatment significantly increased striatal DA transporter availability in ADHD (caudate, putamen, and ventral striatum) by 24&#160;%, whereas there were no changes in control subjects retested at the 12-month interval.</p></sec><sec id="Sec20"><title>Gamma Aminobutyric Acid (GABA) 1519T&gt;CGABA(A)alpha6Gene</title><p>The role of GABA as the primary inhibitory neurotransmitter is the regulation of neuronal excitability throughout human central nervous system. First synthesized in 1883, as a plant and microbe metabolic product, it was not until 1950 that GABA was found to be an integral to brain functioning and directly responsible for muscle tone regulation [<xref ref-type="bibr" rid="CR119">119</xref>].</p><p>GABA acts at the brains inhibitory synapses where it binds to specific transmembrane receptors. This binding in the plasma membrane of both pre- and postsynaptic neuronal processes opens the ion channels, discovered by Nobel Prize winner Erwin Neher in 1991. Ion channels allow chloride ions which are negatively charged into the cell or potassium ions which are positively charged to flow out of the cell. These actions change the transmembrane potential, causing hypo- or hyperpolarization. Polarization depends on the direction chloride flow. GABA is depolarizing (excitatory) when net chloride flows out of the cell and hyperpolarizing (inhibitory) when the net chloride flows into the cell. It is known that as the brain develops into adulthood the role of GABA changes from excitatory to inhibitory [<xref ref-type="bibr" rid="CR120">120</xref>].</p><p>There are two known classes of GABA receptor: GABA<sub>A</sub> receptor, which is part, of a ligand-gated ion complex, and GABA<sub>B</sub> (G protein-coupled) metabotropic receptors that use intermediaries to open or close ion channels. GABAergic neurons that produce GABA have a mostly inhibitory action at receptors, although some GABAergic neurons, such as chandelier cells are able to excite their glutamatergic receptors or neurons counterparts [<xref ref-type="bibr" rid="CR120">120</xref>&#8211;<xref ref-type="bibr" rid="CR123">123</xref>].</p><p>In the metabolic pathway, called the GABA shunt, the enzyme <sc>l</sc>-glutamic acid decarboxylase and pyridoxal phosphate, the active form of vitamin B6, is used, as a cofactor, to synthesize GABA in the brain from glutamate, the principal excitatory neurotransmitter. In this process that converts glutamate into GABA [<xref ref-type="bibr" rid="CR124">124</xref>, <xref ref-type="bibr" rid="CR125">125</xref>], the GABA transaminase enzyme catalyzes the conversion of 2-oxoglutarate and 4-aminobutanoic acid into glutamate and succinic semialdehyde. Then the enzyme succinic semialdehyde dehydrogenase oxidizes succinic semialdehyde into succinic acid which enters the citric acid cycle as a usable source of energy [<xref ref-type="bibr" rid="CR126">126</xref>].</p><p>Drugs, known as GABA analogues or GABAergic drugs act as allosteric modulators of GABA receptors, to increase the amount of available GABA and usually have, anti-anxiety, anti-convulsive, and relaxing effects [<xref ref-type="bibr" rid="CR127">127</xref>, <xref ref-type="bibr" rid="CR128">128</xref>]. In general, GABA does not cross the blood-brain barrier [<xref ref-type="bibr" rid="CR129">129</xref>]. At least one study suggests that blocking GABA increases the amount of DA released [<xref ref-type="bibr" rid="CR130">130</xref>].</p></sec><sec id="Sec21"><title>Genetics of GABA Receptor Gene Polymorphisms</title><p>GABA receptor genes have received some attention as candidates for drug use disorders. One reason for this is that the DA and GABA systems are functionally interrelated [<xref ref-type="bibr" rid="CR112">112</xref>]. Research suggests that DA neurons projecting from the anterior VTA to the NAc are tonically inhibited by GABA through its actions at the GABAA receptor [<xref ref-type="bibr" rid="CR131">131</xref>]. Moreover, it has been shown that alcohol [<xref ref-type="bibr" rid="CR132">132</xref>] or opioids [<xref ref-type="bibr" rid="CR133">133</xref>] enhancement of GABAergic (through GABAA receptor) transmission inhibits the release of DA in the mesocorticolimbic system. Thus, a hyperactive GABA system, by inhibiting DA release, could also lead to hypodopaminergic functioning. Because of this, GABA genes are of interest in the search for causes of drug use disorders. A dinucleotide repeat polymorphism of the GABA receptor &#946;3 subunit gene (GABRB3) results in either the presence of the 181-bp&#160;G1 or 11 other repeats designated as non-G1 (NG1) [<xref ref-type="bibr" rid="CR134">134</xref>]. Research indicates that the NG1 has an increased prevalence in children of alcoholics [<xref ref-type="bibr" rid="CR134">134</xref>]. Presence of the NG1 has been associated with alcohol dependence [<xref ref-type="bibr" rid="CR135">135</xref>, <xref ref-type="bibr" rid="CR136">136</xref>]. In addition, other GABA receptor genes have been associated with this disorder [<xref ref-type="bibr" rid="CR137">137</xref>]. In fact, craving for alcohol and food has been studied in association with alcohol dependence and eating disorders, respectively. Thus, one subclass of the GABA receptor, 1519T&gt;C GABA (A) alpha 6 has been associated with both ethanol dependence and weight gain. This gene polymorphism has been associated with hypo-cortisolism and perhaps abdominal obesity. Interestingly, the pathophysiology may involve various epigenetic factors, such as stress that destabilize the GABA-hypothalamic-pituitary adrenal systems in those with genetic vulnerability. In T-allele carriers, the change in craving for alcohol during treatment for alcohol dependence is negatively associated with changes in craving for food as well [<xref ref-type="bibr" rid="CR137">137</xref>].</p><p>Expression patterns of GABAergic genes in rodent brains have been elucidated but not in humans. There are many GABAergic pathways and factor analysis involving global expression on 21 of these pathways has been performed. Specifically, postmortem data from hippocampus of eight alcoholics, eight cocaine addicts, and eight controls was evaluated to determine factor specificity for response to chronic alcohol/cocaine exposure. While RNA-Seq six gene expression factors were identified and loaded onto two factors, most genes loaded (&#8805;0.5) onto one factor. These analyses led to the understanding that the chromosome 5 gene cluster was the largest factor (0.30 variance) and as such encodes the most common GABAA receptor, &#945;1&#946;2&#947;2, and genes encoding the &#945;3&#946;3&#947;2 receptor. Interestingly, within this factor, these genes were unresponsive to chronic alcohol/cocaine exposure. However, chronic alcohol/cocaine exposure affected chromosome 4 gene-cluster factor (0.14 variance) that encoded the &#945;2&#946;1&#947;1 receptor. Moreover, in both alcoholics and cocaine-dependent humans, two other factors (0.17 and 0.06 variance) included genes specifically involved in GABA synthesis and synaptic transport showed expression changes. It has been suggested that there is specificity of GABAergic gene groups, for response to chronic alcohol/cocaine exposure. Thus, understanding the nature of GABAergic gene group specificity could have therapeutic implications for combating stress-related craving and relapse [<xref ref-type="bibr" rid="CR138">138</xref>].</p></sec><sec id="Sec22"><title>Mu-Opioid Receptor Genes</title><p>Opioid receptors are a group of G-protein coupled receptors with opioids as ligands [<xref ref-type="bibr" rid="CR139">139</xref>&#8211;<xref ref-type="bibr" rid="CR141">141</xref>]. The original work on these receptors occurred in the late 1960s, with the first group being that of Avram Goldstein at Stanford [<xref ref-type="bibr" rid="CR142">142</xref>]. The endogenous opioids are dynorphins, enkephalin, endorphins, endomophins, and nociception. In 1973, Pert and Snyder were first to publish a detailed binding study of what turned out to be the mu-opioid receptor using 3H-naloxone [<xref ref-type="bibr" rid="CR143">143</xref>], although two other studies followed shortly after [<xref ref-type="bibr" rid="CR144">144</xref>, <xref ref-type="bibr" rid="CR145">145</xref>]. The opioid receptors are ~40&#160;% identical to somatostatin receptors (SSTRs). Opiate receptors are found in the spinal cord digestive tract and are distributed widely in the brain. The mu opiate receptor (OPRM) has high affinity for enkephalin, beta endorphins, and morphine.</p><p>An International Union of Basic and Clinical Pharmacology (IUPHAR) subcommittee has recommended that appropriate terminology for the four principal subtypes of opioid receptors the three classical (&#956;, &#948;, &#954;) receptors, and the non-classical (nociception) receptor, should be MOP, DOP, KOP, and NOP, respectively [<xref ref-type="bibr" rid="CR146">146</xref>&#8211;<xref ref-type="bibr" rid="CR148">148</xref>] (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>).<table-wrap id="Tab3"><label>Table 3</label><caption><p>Four major subtypes of opiate receptors</p></caption><table-wrap-foot><p>
<sup>a</sup>The name is based on order of discovery (from Wikipedia)</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec23"><title>Genetics of the Mu Opiate Receptor Gene</title><p>The activity at the micro-opioid receptor is central to both pain responses and opioid addiction. The opioidergic hypothesis suggests variations at the opioid receptor mu 1 (OPRM1) gene locus associate with opiate addiction. Several SNPs in exon I contained in the OPRM1 gene, which encodes for mu-opioid receptor. The polymerase chain reaction-restriction fragment length polymorphism method was used to genotype SNPs, A118G (rs 1799971) and C17T (rs 1799972) that have been associated with substance abuse. For the 118G allele, the opioid dependents (<italic>n</italic>&#8201;=&#8201;126) had an approximately 2.5-fold higher frequency of 0.31 (odds ratio 3.501; CI(95&#160;%) 2.212&#8211;5.555; <italic>P</italic>&#8201;&lt;&#8201;0.0001) while the control subjects (<italic>n</italic>&#8201;=&#8201;156) showed a frequency of 0.12. For the C17T polymorphism, 0.83 seen in opioid dependents (<italic>n</italic>&#8201;=&#8201;123; odds ratio of 0.555; CI(95&#160;%) 0.264&#8211;1.147; <italic>P</italic>&#8201;=&#8201;0.121) versus the controls (<italic>n</italic>&#8201;=&#8201;57) showed a frequency of 0.89 for C allele. Thus, a significant association was observed between the 118G allele, and opioid dependence but no association was found with C17T polymorphism [<xref ref-type="bibr" rid="CR149">149</xref>].</p><p>The effects of opiate drugs on pain experiences differ in humans. Recent twin studies documented individual differences, in several types of pain that are likely to be substantially determined by genetics. Genetic components to migraine pain susceptibility are documented in large twin studies, although in family studies have found substantial genetic heterogeneity in migraine. Humans &#956;OR densities also differ. Both in vivo PET radioligand analyses and binding studies to postmortem brain samples suggest ranges of 30&#8211;50&#160;%, or even larger, in individual differences in human &#956;OR densities. Elucidation of the genetic basis for these differences based on receptor expression would advance substantially understanding of individual differences in and drug responses and nociceptive behaviors. The likelihood of high or low levels of expression in an individual can be predicted by information about &#956;OR gene polymorphisms and may allow drug treatments to be individualized. These data could aid in optimization of dose ranges and selection of analgesic agents. Pain management for individuals with acute or long-term pain problems could be improved. These data could also add new therapeutic specificities and efficacies to this well-established opiate drug class, still a major weapon for amelioration of pain states [<xref ref-type="bibr" rid="CR150">150</xref>].</p><p>Decreased analgesic effects of opioids are associated with the SNP 118A&gt;G in the micro-1 opioid receptor gene (OPRM1) [<xref ref-type="bibr" rid="CR151">151</xref>]. One recent study shows that postoperative pain response in heterozygous patients is affected by the OPRM1 118A&gt;G polymorphism. The efficacy of the analgesic therapy for postoperative pain may be impaired compared to patients with wild-type genes [<xref ref-type="bibr" rid="CR151">151</xref>]. In another study, Liu and Wang [<xref ref-type="bibr" rid="CR152">152</xref>] reported that the allelic frequency of variant (118G) allele was 39.6&#160;%, and the prevalence of OPRM1-118 AA, AG, and GG genotypes was 31.3&#160;% (<italic>n</italic>&#8201;=&#8201;30), 58.3&#160;% (<italic>n</italic>&#8201;=&#8201;56), and 10.4&#160;% (<italic>n</italic>&#8201;=&#8201;10), respectively. For all patients, pre-treatment to post-treatment pain judgments were reduced significantly. Patients with AA genotype had a better analgesic effect than those with G allele variants (AG or GG genotypes). Pre- and post-treatment pain judgments for patients with G allele variants were also reduced significantly. However, for patients with AA genotype, pre-treatment and post-treatment pain judgments were especially dramatic. The requirement for rescue analgesia also was highest for patients with G allele variants. Interestingly, Setiawan et al. [<xref ref-type="bibr" rid="CR153">153</xref>] found that one etiological pathway to alcoholism may be influenced by the A118G substitution, for which naltrexone pharmacotherapy is effective. Moreover, studies by Kranzler et al. [<xref ref-type="bibr" rid="CR154">154</xref>] showed a modest association between OPRM1 alleles and substance (alcohol, cocaine, or opioid) dependence.</p><p>Finally, we provide a selective sample of the relationship of certain reward genes and their respective risk alleles (see Tables&#160;<xref rid="Tab4" ref-type="table">4</xref>, <xref rid="Tab5" ref-type="table">5</xref>, <xref rid="Tab6" ref-type="table">6</xref>, <xref rid="Tab7" ref-type="table">7</xref>, <xref rid="Tab8" ref-type="table">8</xref>, <xref rid="Tab9" ref-type="table">9</xref>, <xref rid="Tab10" ref-type="table">10</xref>, <xref rid="Tab11" ref-type="table">11</xref>, and <xref rid="Tab12" ref-type="table">12</xref>).<table-wrap id="Tab4"><label>Table 4</label><caption><p>Dopamine D2 receptor gene (a sampling)</p></caption></table-wrap><table-wrap id="Tab5"><label>Table 5</label><caption><p>Dopamine D4 receptor gene (a sampling)</p></caption></table-wrap><table-wrap id="Tab6"><label>Table 6</label><caption><p>Dopamine transporter gene (DAT1)</p></caption></table-wrap><table-wrap id="Tab7"><label>Table 7</label><caption><p>Catechol-O-methyl-transferase (COMT) [a sampling]</p></caption></table-wrap><table-wrap id="Tab8"><label>Table 8</label><caption><p>Serotonin transporter gene (a sampling)</p></caption></table-wrap><table-wrap id="Tab9"><label>Table 9</label><caption><p>Mu opiate receptor (MOR) [a sampling]</p></caption></table-wrap><table-wrap id="Tab10"><label>Table 10</label><caption><p>GABA beta subunit 3 (a sampling)</p></caption></table-wrap><table-wrap id="Tab11"><label>Table 11</label><caption><p>MOA-A (a sampling)</p></caption></table-wrap><table-wrap id="Tab12"><label>Table 12</label><caption><p>Dopamine D3 (a sampling)</p></caption></table-wrap></p></sec><sec id="Sec24"><title>Genetic Addiction Risk Score Panel</title><p>We are proposing a number of well- known risk alleles based on a plethora of literature based studies. Table&#160;<xref rid="Tab13" ref-type="table">13</xref> represents a list of each top gene (s) that should drive the risk stratification of the individual.<table-wrap id="Tab13"><label>Table 13</label><caption><p>GARS panel</p></caption></table-wrap></p><p>Understanding that RDS is a very complex polygenic disorder, we have carefully considered and chosen the primary risk alleles based on thousands of support articles in the literature. We feel confident that GARS will provide a snapshot into RDS risk. We are cognizant that this panel may change over time as new and other gene polymorphisms are discovered. Moreover, until we can develop a weighted algorithm based on utilization of &#8220;super controls&#8221; for RDS, we cannot provide a perfect test.</p></sec><sec id="Sec25"><title>GWAS vs Candidate Gene Approach Issues</title><p>The need for genetic testing as a way of understanding or pinpointing therapeutic targets is certainly the wave of the future. Since the earliest study of the DRD2 gene, a remarkable list of associations with gene polymorphisms has been elucidated and eventually morphed into in the field, known today as Psychiatric Genetics. The DSM criteria are not the only method of diagnosis of psychiatric disorders. We are proposing that coupling verified standard pencil and paper tests, like the Addiction Severity Index among others, with DSM and GARS should enhance the understanding of each patient presenting for addiction treatment. In fact, it will remove guessing by providing objective risk stratification, as well as opportunities for DNA-targeted therapies (personalized addiction medicine). We are beginning to understand the power of Genome Wide Association (GWAS) [<xref ref-type="bibr" rid="CR155">155</xref>] and EWAS studies, especially the epigenetics of gene expression via mRNA transcription. This knowledge could pave the way for either nutraceutical nutrigenomic solutions or highly specific pharmaceuticals, that by targeting select neuronal sites can reduce toxic side effects. In either case, we strongly recommend additional studies to provide the recovering addict with an epigenetic [<xref ref-type="bibr" rid="CR156">156</xref>&#8211;<xref ref-type="bibr" rid="CR158">158</xref>] tool to activate DA D2 receptors while attenuating the anti-reward effects of DA D1 and possibly D3 receptors, respectively. Finally, we as neuroscientists should begin to perform studies that control for possible comorbid medical and psychiatric conditions in the research (dual diagnosis). This work supports earlier non-genetic concepts of addiction in psychiatric medicine [<xref ref-type="bibr" rid="CR159">159</xref>&#8211;<xref ref-type="bibr" rid="CR163">163</xref>].</p><p>We are cognizant that there is controversy related to the importance of both GWAS and Whole-Exome Sequencing (WES) and analytical approaches relative to candidate association and linkage studies, used to unravel the contribution of specific genes and associated polymorphisms to addiction liability. In the late 1980s realizing the complexity of the problem of both vulnerability and resilience for risk of drug abuse and other behavioral addictions, we decided to analyze candidate genes based on a theoretical model developed and subsequently published, identified as the &#8220;Brain Reward Cascade&#8221; [<xref ref-type="bibr" rid="CR1">1</xref>]. Initially our approach utilizing this &#8220;blue print of reward&#8221; involved association rather than linkage analysis because Lander et al. argued against linkage analysis for complex disorders like drug addiction [<xref ref-type="bibr" rid="CR8">8</xref>] instead of linkage analysis as previously accomplished with one gene one disease (OGOD).</p><p>Important advances have been made over the last two decades concerning &#8220;Psychiatric Genetics&#8221;. Certainly, substantial genetic contributions to addiction liability are now supported by earlier twin studies and more recently linkage, candidate association and GWAS studies. Animal studies initially focusing upon genes that targeted mechanism of action of major drugs of abuse. Many of these studies were successful in the identification of quantitative trait loci including association of chromosomal 9 (DRD2 gene) and ethanol behavioral responses [<xref ref-type="bibr" rid="CR164">164</xref>, <xref ref-type="bibr" rid="CR165">165</xref>] as well as other reward genes including serotonin, opioids and GABA [<xref ref-type="bibr" rid="CR166">166</xref>]. Most of these and many other studies have identified gene/proteins that affect responses to drugs of abuse. Parallel to these animal studies, human genetic research has evolved over the last 5&#160;years. Now, it is possible to detect genetic variation in the human genome inexpensively. The era of genome sequencing began with the detection of SNPs on gene chips. Very recently, we are also utilizing WES, which is a high-throughput sequencing, to identify the molecular arrangement of DNA base pairs specifying the coding regions of a person&#8217;s genome also referred to as the exome. While this is exciting, it may not have clinical utility because the exome only comprises about 1&#160;% of the entire genome [<xref ref-type="bibr" rid="CR167">167</xref>].</p><p>When compared to the enormous literature on candidate gene analysis (6120 studies) currently there is a paucity of GWAS/WES studies relevant to addiction liability (239 studies). A commentary by Hall et al. [<xref ref-type="bibr" rid="CR168">168</xref>] from NIDA and others have argued that candidate gene analysis may be wrong. However, they do suggest the following from many GWAS studies: (1) addiction is highly polygenic, each allelic variant contributing in a small, additive (counting) amount to addiction liability; (2) classes of genes (such as reward circuitry based genes) are most important in explaining both risk and resilience to all addictions and (3) substantial genetic heterogeneity exists, and there is a convergence of GWAS signals on particular candidate-genes.</p><p>It is well-known that the action of psychoactive drugs primarily affects synaptic neurotransmission. Reynolds et al. [<xref ref-type="bibr" rid="CR169">169</xref>] correctly suggest that specific genes for neurotransmitter receptors and transporters have provided strong candidates in pharmacogenetic research in psychiatry. Moreover, there are many inconsistencies between candidate gene and GWAS studies. Reynolds further suggests that consistencies have accumulated through candidate gene studies involving the dopamine D2 receptor; serotonin transporter; and GABA dysfunction in mental illness. Moreover, Han et al. [<xref ref-type="bibr" rid="CR170">170</xref>] reported that following GWAS, functional enrichment analysis revealed specific genes to underlie alcohol risk such as cation transport, synaptic transmission, and transmission of nerve impulses representing meaningful biological processes. In agreement, Uhl et al. [<xref ref-type="bibr" rid="CR171">171</xref>] suggest that following GWAS, clusters of SNPs within selected genes display 10(&#8722;2)&#8201;&gt;&#8201;<italic>P</italic>&#8201;&gt;&#8201;10 (&#8722;8) associations with dependence in many independent studies. Importantly, along these lines, specific candidate genes associated with substance dependence phenotypes, for example, in Native Americans, these include <italic>OPRM1</italic>, <italic>CRN1</italic>, <italic>COMT</italic>, <italic>GABA2</italic>, <italic>MAOA</italic>, and <italic>HTR3-B</italic> [<xref ref-type="bibr" rid="CR172">172</xref>]. In a cross-species GWAS study to access risk genes, in alcoholism, it was found that 47 genes associated including GABA, signaling pathway and cell communication [<xref ref-type="bibr" rid="CR173">173</xref>]. In one study using GWAS and factor analysis, Agrawal et al. [<xref ref-type="bibr" rid="CR174">174</xref>] found a high loading (0.89) for alcohol craving and convergence resulted in an association of SNPs in DRD3 and craving.</p><p>While there are many more examples showing promising convergence between GWAS and candidate gene analyses, albeit others showing no convergence, Li et al. [<xref ref-type="bibr" rid="CR175">175</xref>] performed a meta-analysis of addiction candidate gene association studies and GWAS to investigate functional mechanisms linked to addiction risk. When they compared the lists of genes identified by molecular biological studies of drug-related genes and those by association studies, they observed significantly higher participation in the same gene interaction networks than expected by chance. This work is underscored by Li&#8217;s earlier work, the KARG analysis that evaluated 1,500 human genes regulating addictive behaviors and found that these genes significantly impact glutaminergic and dopaminergic pathways [<xref ref-type="bibr" rid="CR176">176</xref>].</p><p>GWAS studies in psychiatry frequently fail to explain a large proportion of variance and non-replication of individual SNPs. Derringer et al. [<xref ref-type="bibr" rid="CR177">177</xref>] utilizing a &#8220;selective scoring&#8221; whereby variants (273 SNPs) from eight dopamine-related genes for association with cocaine dependence were considered. They identified a four SNP score significantly associated with the variance. They suggested that (1) limiting SNPs to genes of theoretical importance improves the chances of identifying replicable effects (2) utilizing this scoring approach which considers top-associated SNPs in the aggregate can reveal replicable effects that are too small to be identified at the level of individual SNPs. Along with these precautions we also propose the utilization of &#8220;super controls&#8221; to eliminate cross contamination of having a control phenotype that also carries the associated disorder especially when considering the complex nature of RDS. Also in developing GARS we are cognizant that the proposed test only provides risk stratification and not actual diagnosis of any disorder including RDS. Most importantly, full comprehension of &#8220;psychiatric pharmacogenomics&#8221; will undoubtedly involve epigenetic factors, such as DNA histone modifications, for example, methylation and or acetylation that can affect responses to drugs and polymorphic antecedents for either vulnerability or resilience to reward behaviors like RDS, as well as, GWAS convergence to candidate genes [<xref ref-type="bibr" rid="CR178">178</xref>&#8211;<xref ref-type="bibr" rid="CR185">185</xref>].</p><p>Moreover, the utilization of GARS in the clinic has benefits other than just risk stratification, such as, potential therapeutic targets, reduced denial, medical monitoring, for example, in terms of pharmacogenomic tagging [<xref ref-type="bibr" rid="CR186">186</xref>]. Moreover, we are cognizant that certain ethnic groups will have different rates of polymorphic genes as well different rates of gene polymorphic frequencies [<xref ref-type="bibr" rid="CR187">187</xref>], and we are developing an algorithm to address this issue involving weighting. In addition, we are analyzing additional data including a total of 393 subjects derived from 9 treatment centers of which 320 have taken the Addiction Severity Index (ASI).</p><p>The problem of GWAS is that a general conclusion from GWAS is that most polymorphisms confer little risk increments and explain a small portion of heritability. One example is that 40 loci have been associated with human height, with a known heritability of about 80&#160;%, but those total variants explain only 5&#160;% of the phenotypic variance. It has been suggested that a main problem with GWAS is the need for a level of multiple statistical comparisons that are unprecedented in biology, with stringent analyses to achieve genome-wide significance [<xref ref-type="bibr" rid="CR186">186</xref>]. In fact, Belcher et al. [<xref ref-type="bibr" rid="CR188">188</xref>] suggest there is clear evidence to support a genetic basis for SUD. While these authors consider personality as an appropriate endophenotype, we argue that the real endophenotype is RDS as we suggested in the generational study [<xref ref-type="bibr" rid="CR18">18</xref>]. Certainly, there are a number of studies showing enhanced relapse with specific polymorphisms such as carriers of the DRD2 A1 allele as only one example [<xref ref-type="bibr" rid="CR189">189</xref>]. Finally, as we pointed out herein, there are fairly recent studies showing GWAS convergence to candidate genes suggesting the continued importance of the candidate approach to identify genetic risk [<xref ref-type="bibr" rid="CR166">166</xref>&#8211;<xref ref-type="bibr" rid="CR177">177</xref>].</p></sec><sec id="Sec26" sec-type="conclusion"><title>Conclusion</title><p>We encourage further work in the area of psychiatric genetics like GARS and new technology like CARD to track patients during recovery more intensively. While GARS may not be perfect as yet and more research is necessary in the near future, we should not at this point &#8220;throw out the baby with the bath water.&#8221; Utilization of these suggested new technologies should impact the &#8220;revolving door&#8221; and secure significant reduction in relapse.</p></sec></body><back><ack><p>The writing of this paper was supported in part by funds from the National Institutes of Health, NIAAA (RO1-AA07112 and K05-AA00219) and the Medical Research Service of the US Department of Veterans Affairs (MOB). The authors appreciate the editorial assistance of Margaret A. Madigan and Paula J. Edge. Kenneth Blum is the recipient of a grant to PATH FOUNDATION NY, by Life Extension Foundation, Ft/Lauderdale, Florida.</p><sec id="d30e3230"><title>Conflicts of Interest</title><p>Kenneth Blum, PhD holds certain US and foreign patents related to genetic testing which has been licensed to Dominion Diagnostics. Dr. Blum is also an officer and stock holder of IGENE, LLC and is a paid consultant of Dominion Diagnostics, LLC., IGENE, and Malibu Recovery Center. Dr. Blum is a member of the scientific advisory board of Dominion Diagnostics, LLC and Chief Scientific Adviser.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Blum</surname><given-names>K</given-names></name><name><surname>Kozlowski</surname><given-names>GP</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Ollat</surname><given-names>H</given-names></name><name><surname>Parvez</surname><given-names>S</given-names></name><name><surname>Parvez</surname><given-names>H</given-names></name></person-group><article-title>Ethanol and neuromodulator interactions: a cascade model of reward</article-title><source>Alcohol and behavior</source><year>1990</year><publisher-loc>Utrecht</publisher-loc><publisher-name>VSP</publisher-name><fpage>131</fpage><lpage>149</lpage></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noble</surname><given-names>EP</given-names></name></person-group><article-title>D2 dopamine receptor gene in psychiatric and neurologic disorders and its phenotypes</article-title><source>Am J Med Genet Part B Neuropsychiatr Genet Off Publ Int Soc Psychiatr Genet</source><year>2003</year><volume>116B</volume><issue>1</issue><fpage>103</fpage><lpage>125</lpage></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thanos</surname><given-names>PK</given-names></name><name><surname>Volkow</surname><given-names>ND</given-names></name><name><surname>Freimuth</surname><given-names>P</given-names></name><name><surname>Umegaki</surname><given-names>H</given-names></name><name><surname>Ikari</surname><given-names>H</given-names></name><name><surname>Roth</surname><given-names>G</given-names></name><name><surname>Ingram</surname><given-names>DK</given-names></name><name><surname>Hitzemann</surname><given-names>R</given-names></name></person-group><article-title>Overexpression of dopamine D2 receptors reduces alcohol self-administration</article-title><source>J Neurochem</source><year>2001</year><volume>78</volume><issue>5</issue><fpage>1094</fpage><lpage>1103</lpage><?supplied-pmid 11553683?><pub-id pub-id-type="pmid">11553683</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conner</surname><given-names>BT</given-names></name><name><surname>Hellemann</surname><given-names>GS</given-names></name><name><surname>Ritchie</surname><given-names>TL</given-names></name><name><surname>Noble</surname><given-names>EP</given-names></name></person-group><article-title>Genetic, personality, and environmental predictors of drug use in adolescents</article-title><source>J Subst Abus Treat</source><year>2010</year><volume>38</volume><issue>2</issue><fpage>178</fpage><lpage>190</lpage></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bossert</surname><given-names>JM</given-names></name><name><surname>Liu</surname><given-names>SY</given-names></name><name><surname>Lu</surname><given-names>L</given-names></name><name><surname>Shaham</surname><given-names>Y</given-names></name></person-group><article-title>A role of ventral tegmental area glutamate in contextual cue-induced relapse to heroin seeking</article-title><source>J Neurosci Off J Soc Neurosci</source><year>2004</year><volume>24</volume><issue>47</issue><fpage>10726</fpage><lpage>10730</lpage></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>CY</given-names></name><name><surname>Mao</surname><given-names>X</given-names></name><name><surname>Wei</surname><given-names>L</given-names></name></person-group><article-title>Genes and (common) pathways underlying drug addiction</article-title><source>PLoS Comput Biol</source><year>2008</year><volume>4</volume><issue>1</issue><fpage>e2</fpage><?supplied-pmid 18179280?><pub-id pub-id-type="pmid">18179280</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blum</surname><given-names>K</given-names></name><name><surname>Noble</surname><given-names>EP</given-names></name><name><surname>Sheridan</surname><given-names>PJ</given-names></name><name><surname>Montgomery</surname><given-names>A</given-names></name><name><surname>Ritchie</surname><given-names>T</given-names></name><name><surname>Jagadeeswaran</surname><given-names>P</given-names></name><name><surname>Nogami</surname><given-names>H</given-names></name><name><surname>Briggs</surname><given-names>AH</given-names></name><name><surname>Cohn</surname><given-names>JB</given-names></name></person-group><article-title>Allelic association of human dopamine D2 receptor gene in alcoholism</article-title><source>JAMA J Am Med Assoc</source><year>1990</year><volume>263</volume><issue>15</issue><fpage>2055</fpage><lpage>2060</lpage></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Schork</surname><given-names>NJ</given-names></name></person-group><article-title>Genetic dissection of complex traits</article-title><source>Science (New York, NY)</source><year>1994</year><volume>265</volume><issue>5181</issue><fpage>2037</fpage><lpage>2048</lpage></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chanock</surname><given-names>SJ</given-names></name><name><surname>Manolio</surname><given-names>T</given-names></name><name><surname>Boehnke</surname><given-names>M</given-names></name><name><surname>Boerwinkle</surname><given-names>E</given-names></name><name><surname>Hunter</surname><given-names>DJ</given-names></name><name><surname>Thomas</surname><given-names>G</given-names></name><name><surname>Hirschhorn</surname><given-names>JN</given-names></name><name><surname>Abecasis</surname><given-names>G</given-names></name><name><surname>Altshuler</surname><given-names>D</given-names></name><name><surname>Bailey-Wilson</surname><given-names>JE</given-names></name><name><surname>Brooks</surname><given-names>LD</given-names></name><name><surname>Cardon</surname><given-names>LR</given-names></name><name><surname>Daly</surname><given-names>M</given-names></name><name><surname>Donnelly</surname><given-names>P</given-names></name><name><surname>Fraumeni</surname><given-names>JF</given-names><suffix>Jr</suffix></name><name><surname>Freimer</surname><given-names>NB</given-names></name><name><surname>Gerhard</surname><given-names>DS</given-names></name><name><surname>Gunter</surname><given-names>C</given-names></name><name><surname>Guttmacher</surname><given-names>AE</given-names></name><name><surname>Guyer</surname><given-names>MS</given-names></name><name><surname>Harris</surname><given-names>EL</given-names></name><name><surname>Hoh</surname><given-names>J</given-names></name><name><surname>Hoover</surname><given-names>R</given-names></name><name><surname>Kong</surname><given-names>CA</given-names></name><name><surname>Merikangas</surname><given-names>KR</given-names></name><name><surname>Morton</surname><given-names>CC</given-names></name><name><surname>Palmer</surname><given-names>LJ</given-names></name><name><surname>Phimister</surname><given-names>EG</given-names></name><name><surname>Rice</surname><given-names>JP</given-names></name><name><surname>Roberts</surname><given-names>J</given-names></name><name><surname>Rotimi</surname><given-names>C</given-names></name><name><surname>Tucker</surname><given-names>MA</given-names></name><name><surname>Vogan</surname><given-names>KJ</given-names></name><name><surname>Wacholder</surname><given-names>S</given-names></name><name><surname>Wijsman</surname><given-names>EM</given-names></name><name><surname>Winn</surname><given-names>DM</given-names></name><name><surname>Collins</surname><given-names>FS</given-names></name></person-group><article-title>Replicating genotype-phenotype associations</article-title><source>Nature</source><year>2007</year><volume>447</volume><issue>7145</issue><fpage>655</fpage><lpage>660</lpage><?supplied-pmid 17554299?><pub-id pub-id-type="pmid">17554299</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>AL</given-names></name><name><surname>Chen</surname><given-names>TJ</given-names></name><name><surname>Waite</surname><given-names>RL</given-names></name><name><surname>Reinking</surname><given-names>J</given-names></name><name><surname>Tung</surname><given-names>HL</given-names></name><name><surname>Rhoades</surname><given-names>P</given-names></name><name><surname>Downs</surname><given-names>BW</given-names></name><name><surname>Braverman</surname><given-names>E</given-names></name><name><surname>Braverman</surname><given-names>D</given-names></name><name><surname>Kerner</surname><given-names>M</given-names></name><name><surname>Blum</surname><given-names>SH</given-names></name><name><surname>DiNubile</surname><given-names>N</given-names></name><name><surname>Smith</surname><given-names>D</given-names></name><name><surname>Oscar-Berman</surname><given-names>M</given-names></name><name><surname>Prihoda</surname><given-names>TJ</given-names></name><name><surname>Floyd</surname><given-names>JB</given-names></name><name><surname>O&#8217;Brien</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>HH</given-names></name><name><surname>Blum</surname><given-names>K</given-names></name></person-group><article-title>Hypothesizing that brain reward circuitry genes are genetic antecedents of pain sensitivity and critical diagnostic and pharmacogenomic treatment targets for chronic pain conditions</article-title><source>Med Hypotheses</source><year>2009</year><volume>72</volume><issue>1</issue><fpage>14</fpage><lpage>22</lpage><?supplied-pmid 18951726?><pub-id pub-id-type="pmid">18951726</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blum</surname><given-names>K</given-names></name><name><surname>Sheridan</surname><given-names>PJ</given-names></name><name><surname>Wood</surname><given-names>RC</given-names></name><name><surname>Braverman</surname><given-names>ER</given-names></name><name><surname>Chen</surname><given-names>TJ</given-names></name><name><surname>Cull</surname><given-names>JG</given-names></name><name><surname>Comings</surname><given-names>DE</given-names></name></person-group><article-title>The D2 dopamine receptor gene as a determinant of reward deficiency syndrome</article-title><source>J R Soc Med</source><year>1996</year><volume>89</volume><issue>7</issue><fpage>396</fpage><lpage>400</lpage><?supplied-pmid 8774539?><pub-id pub-id-type="pmid">8774539</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blum</surname><given-names>K</given-names></name><name><surname>Braverman</surname><given-names>ER</given-names></name><name><surname>Holder</surname><given-names>JM</given-names></name><name><surname>Lubar</surname><given-names>JF</given-names></name><name><surname>Monastra</surname><given-names>VJ</given-names></name><name><surname>Miller</surname><given-names>D</given-names></name><name><surname>Lubar</surname><given-names>JO</given-names></name><name><surname>Chen</surname><given-names>TJ</given-names></name><name><surname>Comings</surname><given-names>DE</given-names></name></person-group><article-title>Reward deficiency syndrome: a biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviors</article-title><source>J Psychoactive Drugs</source><year>2000</year><volume>32</volume><issue>Suppl:i-iv</issue><fpage>1</fpage><lpage>112</lpage></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Comings</surname><given-names>DE</given-names></name><name><surname>Blum</surname><given-names>K</given-names></name></person-group><article-title>Reward deficiency syndrome: genetic aspects of behavioral disorders</article-title><source>Prog Brain Res</source><year>2000</year><volume>126</volume><fpage>325</fpage><lpage>341</lpage><?supplied-pmid 11105655?><pub-id pub-id-type="pmid">11105655</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Blum</surname><given-names>K</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Barth</surname><given-names>RJ</given-names></name><name><surname>Blum</surname><given-names>K</given-names></name><name><surname>Madigan</surname><given-names>M</given-names></name></person-group><article-title>Chapter 26, neurogenetics and nutrigenomics of reward deficiency syndrome</article-title><source>Omics&#8212;biomedical perspectives and applications</source><year>2012</year><publisher-loc>Boca Raton</publisher-loc><publisher-name>CRC (Taylor &amp; Francis)</publisher-name><fpage>535</fpage><lpage>576</lpage></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blum</surname><given-names>K</given-names></name><name><surname>Oscar-Berman</surname><given-names>M</given-names></name><name><surname>Stuller</surname><given-names>E</given-names></name><name><surname>Miller</surname><given-names>D</given-names></name><name><surname>Giordano</surname><given-names>J</given-names></name><name><surname>Morse</surname><given-names>S</given-names></name><name><surname>McCormick</surname><given-names>L</given-names></name><name><surname>Downs</surname><given-names>WB</given-names></name><name><surname>Waite</surname><given-names>RL</given-names></name><name><surname>Barh</surname><given-names>D</given-names></name><name><surname>Neal</surname><given-names>D</given-names></name><name><surname>Braverman</surname><given-names>ER</given-names></name><name><surname>Lohmann</surname><given-names>R</given-names></name><name><surname>Borsten</surname><given-names>J</given-names></name><name><surname>Hauser</surname><given-names>M</given-names></name><name><surname>Han</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Helman</surname><given-names>M</given-names></name><name><surname>Simpatico</surname><given-names>T</given-names></name></person-group><article-title>Neurogenetics and nutrigenomics of neuro-nutrient therapy for reward deficiency syndrome (RDS): clinical ramifications as a function of molecular neurobiological mechanisms</article-title><source>J Addict Res Ther</source><year>2012</year><volume>3</volume><issue>5</issue><fpage>139</fpage><?supplied-pmid 23926462?><pub-id pub-id-type="pmid">23926462</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dackis</surname><given-names>CA</given-names></name><name><surname>Gold</surname><given-names>MS</given-names></name></person-group><article-title>New concepts in cocaine addiction: the dopamine depletion hypothesis</article-title><source>Neurosci Bio Rev</source><year>1985</year><volume>9</volume><fpage>469</fpage><lpage>477</lpage></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gold</surname><given-names>MS</given-names></name><name><surname>Redmond</surname><given-names>DE</given-names><suffix>Jr</suffix></name><name><surname>Kleber</surname><given-names>HD</given-names></name></person-group><article-title>Clonidine blocks acute opiate-withdrawal symptoms</article-title><source>Lancet</source><year>1978</year><volume>2</volume><issue>8090</issue><fpage>599</fpage><lpage>602</lpage><?supplied-pmid 80526?><pub-id pub-id-type="pmid">80526</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blum</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>AL</given-names></name><name><surname>Oscar-Berman</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>TJ</given-names></name><name><surname>Lubar</surname><given-names>J</given-names></name><name><surname>White</surname><given-names>N</given-names></name><name><surname>Bowirrat</surname><given-names>A</given-names></name><name><surname>Braverman</surname><given-names>E</given-names></name><name><surname>Schoolfield</surname><given-names>J</given-names></name><name><surname>Waite</surname><given-names>RL</given-names></name><name><surname>Downs</surname><given-names>BW</given-names></name><name><surname>Madigan</surname><given-names>M</given-names></name><name><surname>Comings</surname><given-names>DE</given-names></name><name><surname>Davis</surname><given-names>C</given-names></name><name><surname>Kerner</surname><given-names>MM</given-names></name><name><surname>Knopf</surname><given-names>J</given-names></name><name><surname>Palomo</surname><given-names>T</given-names></name><name><surname>Giordano</surname><given-names>JJ</given-names></name><name><surname>Morse</surname><given-names>SA</given-names></name><name><surname>Fornari</surname><given-names>F</given-names></name><name><surname>Barh</surname><given-names>D</given-names></name><name><surname>Femino</surname><given-names>J</given-names></name><name><surname>Bailey</surname><given-names>JA</given-names></name></person-group><article-title>Generational association studies of dopaminergic genes in reward deficiency syndrome (RDS) subjects: selecting appropriate phenotypes for reward dependence behaviors</article-title><source>Int J Environ Res Public Health</source><year>2011</year><volume>8</volume><issue>12</issue><fpage>4425</fpage><lpage>4459</lpage><?supplied-pmid 22408582?><pub-id pub-id-type="pmid">22408582</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>TJ</given-names></name><name><surname>Blum</surname><given-names>K</given-names></name><name><surname>Mathews</surname><given-names>D</given-names></name><name><surname>Fisher</surname><given-names>L</given-names></name><name><surname>Schnautz</surname><given-names>N</given-names></name><name><surname>Braverman</surname><given-names>ER</given-names></name><name><surname>Schoolfield</surname><given-names>J</given-names></name><name><surname>Downs</surname><given-names>BW</given-names></name><name><surname>Comings</surname><given-names>DE</given-names></name></person-group><article-title>Are dopaminergic genes involved in a predisposition to pathological aggression? hypothesizing the importance of &#8220;super normal controls&#8221; in psychiatricgenetic research of complex behavioral disorders</article-title><source>Med Hypotheses</source><year>2005</year><volume>65</volume><issue>4</issue><fpage>703</fpage><lpage>707</lpage><?supplied-pmid 15964153?><pub-id pub-id-type="pmid">15964153</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayes</surname><given-names>LC</given-names></name><name><surname>Granger</surname><given-names>RH</given-names></name><name><surname>Bornstein</surname><given-names>MH</given-names></name><name><surname>Zuckerman</surname><given-names>B</given-names></name></person-group><article-title>The problem of prenatal cocaine exposure. A rush to judgment</article-title><source>JAMA J Am Med Assoc</source><year>1992</year><volume>267</volume><issue>3</issue><fpage>406</fpage><lpage>408</lpage></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>David</surname><given-names>V</given-names></name><name><surname>Matifas</surname><given-names>A</given-names></name><name><surname>Gavello-Baudy</surname><given-names>S</given-names></name><name><surname>Decorte</surname><given-names>L</given-names></name><name><surname>Kieffer</surname><given-names>BL</given-names></name><name><surname>Cazala</surname><given-names>P</given-names></name></person-group><article-title>Brain regional Fos expression elicited by the activation of mu- but not delta-opioid receptors of the ventral tegmental area: evidence for an implication of the ventral thalamus in opiate reward</article-title><source>Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol</source><year>2008</year><volume>33</volume><issue>7</issue><fpage>1746</fpage><lpage>1759</lpage></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bond</surname><given-names>C</given-names></name><name><surname>LaForge</surname><given-names>KS</given-names></name><name><surname>Tian</surname><given-names>M</given-names></name><name><surname>Melia</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Borg</surname><given-names>L</given-names></name><name><surname>Gong</surname><given-names>J</given-names></name><name><surname>Schluger</surname><given-names>J</given-names></name><name><surname>Strong</surname><given-names>JA</given-names></name><name><surname>Leal</surname><given-names>SM</given-names></name><name><surname>Tischfield</surname><given-names>JA</given-names></name><name><surname>Kreek</surname><given-names>MJ</given-names></name><name><surname>Yu</surname><given-names>L</given-names></name></person-group><article-title>Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction</article-title><source>Proc Natl Acad Sci U S A</source><year>1998</year><volume>95</volume><issue>16</issue><fpage>9608</fpage><lpage>9613</lpage><?supplied-pmid 9689128?><pub-id pub-id-type="pmid">9689128</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ide</surname><given-names>S</given-names></name><name><surname>Minami</surname><given-names>M</given-names></name><name><surname>Satoh</surname><given-names>M</given-names></name><name><surname>Uhl</surname><given-names>GR</given-names></name><name><surname>Sora</surname><given-names>I</given-names></name><name><surname>Ikeda</surname><given-names>K</given-names></name></person-group><article-title>Buprenorphine antinociception is abolished, but naloxone-sensitive reward is retained, in mu-opioid receptor knockout mice</article-title><source>Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol</source><year>2004</year><volume>29</volume><issue>9</issue><fpage>1656</fpage><lpage>1663</lpage></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Enoch</surname><given-names>MA</given-names></name><name><surname>Hodgkinson</surname><given-names>CA</given-names></name><name><surname>Gorodetsky</surname><given-names>E</given-names></name><name><surname>Goldman</surname><given-names>D</given-names></name><name><surname>Roy</surname><given-names>A</given-names></name></person-group><article-title>Independent effects of 5&#8242; and 3&#8242; functional variants in the serotonin transporter gene on suicidal behavior in the context of childhood trauma</article-title><source>J Psychiatr Res</source><year>2013</year><volume>47</volume><issue>7</issue><fpage>900</fpage><lpage>907</lpage><?supplied-pmid 23558235?><pub-id pub-id-type="pmid">23558235</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaske</surname><given-names>J</given-names></name><name><surname>Newsome</surname><given-names>J</given-names></name><name><surname>Wright</surname><given-names>JP</given-names></name></person-group><article-title>Interaction of serotonin transporter linked polymorphic region and childhood neglect on criminal behavior and substance use for males and females</article-title><source>Dev Psychopathol</source><year>2012</year><volume>24</volume><issue>1</issue><fpage>181</fpage><lpage>193</lpage><?supplied-pmid 22293003?><pub-id pub-id-type="pmid">22293003</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saiz</surname><given-names>PA</given-names></name><name><surname>Garcia-Portilla</surname><given-names>MP</given-names></name><name><surname>Arango</surname><given-names>C</given-names></name><name><surname>Morales</surname><given-names>B</given-names></name><name><surname>Martinez-Barrondo</surname><given-names>S</given-names></name><name><surname>Alvarez</surname><given-names>C</given-names></name><name><surname>San Narciso</surname><given-names>G</given-names></name><name><surname>Carreno</surname><given-names>E</given-names></name><name><surname>Alvarez</surname><given-names>V</given-names></name><name><surname>Coto</surname><given-names>E</given-names></name><name><surname>Bobes</surname><given-names>J</given-names></name></person-group><article-title>Association between heroin dependence and 5-HT2A receptor gene polymorphisms</article-title><source>Eur Addict Res</source><year>2008</year><volume>14</volume><issue>1</issue><fpage>47</fpage><lpage>52</lpage><?supplied-pmid 18182772?><pub-id pub-id-type="pmid">18182772</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herman</surname><given-names>AI</given-names></name><name><surname>Conner</surname><given-names>TS</given-names></name><name><surname>Anton</surname><given-names>RF</given-names></name><name><surname>Gelernter</surname><given-names>J</given-names></name><name><surname>Kranzler</surname><given-names>HR</given-names></name><name><surname>Covault</surname><given-names>J</given-names></name></person-group><article-title>Variation in the gene encoding the serotonin transporter is associated with a measure of sociopathy in alcoholics</article-title><source>Addict Biol</source><year>2011</year><volume>16</volume><issue>1</issue><fpage>124</fpage><lpage>132</lpage><?supplied-pmid 20192950?><pub-id pub-id-type="pmid">20192950</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jakubczyk</surname><given-names>A</given-names></name><name><surname>Klimkiewicz</surname><given-names>A</given-names></name><name><surname>Kopera</surname><given-names>M</given-names></name><name><surname>Krasowska</surname><given-names>A</given-names></name><name><surname>Wrzosek</surname><given-names>M</given-names></name><name><surname>Matsumoto</surname><given-names>H</given-names></name><name><surname>Burmeister</surname><given-names>M</given-names></name><name><surname>Brower</surname><given-names>KJ</given-names></name><name><surname>Wojnar</surname><given-names>M</given-names></name></person-group><article-title>The CC genotype in the T102C HTR2A polymorphism predicts relapse in individuals after alcohol treatment</article-title><source>J Psychiatr Res</source><year>2013</year><volume>47</volume><issue>4</issue><fpage>527</fpage><lpage>533</lpage><?supplied-pmid 23321485?><pub-id pub-id-type="pmid">23321485</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herin</surname><given-names>DV</given-names></name><name><surname>Bubar</surname><given-names>MJ</given-names></name><name><surname>Seitz</surname><given-names>PK</given-names></name><name><surname>Thomas</surname><given-names>ML</given-names></name><name><surname>Hillman</surname><given-names>GR</given-names></name><name><surname>Tarasenko</surname><given-names>YI</given-names></name><name><surname>Wu</surname><given-names>P</given-names></name><name><surname>Cunningham</surname><given-names>KA</given-names></name></person-group><article-title>Elevated expression of serotonin 5-HT(2A) receptors in the rat ventral tegmental area enhances vulnerability to the behavioral effects of cocaine</article-title><source>Front Psychiatry</source><year>2013</year><volume>4</volume><fpage>2</fpage><?supplied-pmid 23390419?><pub-id pub-id-type="pmid">23390419</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>AH</given-names></name><name><surname>Wilson</surname><given-names>JF</given-names></name><name><surname>Burns</surname><given-names>A</given-names></name><name><surname>Blum-Kemelor</surname><given-names>D</given-names></name><name><surname>Singh</surname><given-names>A</given-names></name><name><surname>Race</surname><given-names>PO</given-names></name><name><surname>Soto</surname><given-names>V</given-names></name><name><surname>Lockett</surname><given-names>AF</given-names></name></person-group><article-title>Use of qualitative research to inform development of nutrition messages for low-income mothers of preschool children</article-title><source>J Nutr Educ Behav</source><year>2011</year><volume>43</volume><issue>1</issue><fpage>19</fpage><lpage>27</lpage><?supplied-pmid 20797907?><pub-id pub-id-type="pmid">20797907</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>do Prado-Lima</surname><given-names>PA</given-names></name><name><surname>Chatkin</surname><given-names>JM</given-names></name><name><surname>Taufer</surname><given-names>M</given-names></name><name><surname>Oliveira</surname><given-names>G</given-names></name><name><surname>Silveira</surname><given-names>E</given-names></name><name><surname>Neto</surname><given-names>CA</given-names></name><name><surname>Haggstram</surname><given-names>F</given-names></name><name><surname>Bodanese</surname><given-names>LC</given-names></name><name><surname>da Cruz</surname><given-names>IB</given-names></name></person-group><article-title>Polymorphism of 5HT2A serotonin receptor gene is implicated in smoking addiction</article-title><source>Am J Med Genetics Part B Neuropsychiatric genet Off Publ Int Soc Psychiatr Genet</source><year>2004</year><volume>128B</volume><issue>1</issue><fpage>90</fpage><lpage>93</lpage></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nichols</surname><given-names>CD</given-names></name><name><surname>Garcia</surname><given-names>EE</given-names></name><name><surname>Sanders-Bush</surname><given-names>E</given-names></name></person-group><article-title>Dynamic changes in prefrontal cortex gene expression following lysergic acid diethylamide administration</article-title><source>Brain Res Mol Brain Res</source><year>2003</year><volume>111</volume><issue>1&#8211;2</issue><fpage>182</fpage><lpage>188</lpage><?supplied-pmid 12654518?><pub-id pub-id-type="pmid">12654518</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Otten</surname><given-names>R</given-names></name><name><surname>Engels</surname><given-names>RC</given-names></name></person-group><article-title>Testing bidirectional effects between cannabis use and depressive symptoms: moderation by the serotonin transporter gene</article-title><source>Addict Biol</source><year>2013</year><volume>18</volume><issue>5</issue><fpage>826</fpage><lpage>835</lpage><?supplied-pmid 21967091?><pub-id pub-id-type="pmid">21967091</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Treister</surname><given-names>R</given-names></name><name><surname>Pud</surname><given-names>D</given-names></name><name><surname>Ebstein</surname><given-names>RP</given-names></name><name><surname>Laiba</surname><given-names>E</given-names></name><name><surname>Raz</surname><given-names>Y</given-names></name><name><surname>Gershon</surname><given-names>E</given-names></name><name><surname>Haddad</surname><given-names>M</given-names></name><name><surname>Eisenberg</surname><given-names>E</given-names></name></person-group><article-title>Association between polymorphisms in serotonin and dopamine-related genes and endogenous pain modulation</article-title><source>J Pain Off J Am Pain Soc</source><year>2011</year><volume>12</volume><issue>8</issue><fpage>875</fpage><lpage>883</lpage></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kosek</surname><given-names>E</given-names></name><name><surname>Jensen</surname><given-names>KB</given-names></name><name><surname>Lonsdorf</surname><given-names>TB</given-names></name><name><surname>Schalling</surname><given-names>M</given-names></name><name><surname>Ingvar</surname><given-names>M</given-names></name></person-group><article-title>Genetic variation in the serotonin transporter gene (5-HTTLPR, rs25531) influences the analgesic response to the short acting opioid Remifentanil in humans</article-title><source>Mol Pain</source><year>2009</year><volume>5</volume><fpage>37</fpage><?supplied-pmid 19570226?><pub-id pub-id-type="pmid">19570226</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinto</surname><given-names>E</given-names></name><name><surname>Reggers</surname><given-names>J</given-names></name><name><surname>Gorwood</surname><given-names>P</given-names></name><name><surname>Boni</surname><given-names>C</given-names></name><name><surname>Scantamburlo</surname><given-names>G</given-names></name><name><surname>Pitchot</surname><given-names>W</given-names></name><name><surname>Ansseau</surname><given-names>M</given-names></name></person-group><article-title>The short allele of the serotonin transporter promoter polymorphism influences relapse in alcohol dependence</article-title><source>Alcohol Alcohol</source><year>2008</year><volume>43</volume><issue>4</issue><fpage>398</fpage><lpage>400</lpage><?supplied-pmid 18364363?><pub-id pub-id-type="pmid">18364363</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sery</surname><given-names>O</given-names></name><name><surname>Didden</surname><given-names>W</given-names></name><name><surname>Mikes</surname><given-names>V</given-names></name><name><surname>Pitelova</surname><given-names>R</given-names></name><name><surname>Znojil</surname><given-names>V</given-names></name><name><surname>Zvolsky</surname><given-names>P</given-names></name></person-group><article-title>The association between high-activity COMT allele and alcoholism</article-title><source>Neuro Endocrinol Lett</source><year>2006</year><volume>27</volume><issue>1&#8211;2</issue><fpage>231</fpage><lpage>235</lpage><?supplied-pmid 16648777?><pub-id pub-id-type="pmid">16648777</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name></person-group><article-title>Association study of heroin dependence and catechol-O-methyltransferase gene</article-title><source>Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi Chin J Med Genet</source><year>2003</year><volume>20</volume><issue>2</issue><fpage>127</fpage><lpage>130</lpage></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vandenbergh</surname><given-names>DJ</given-names></name><name><surname>Rodriguez</surname><given-names>LA</given-names></name><name><surname>Hivert</surname><given-names>E</given-names></name><name><surname>Schiller</surname><given-names>JH</given-names></name><name><surname>Villareal</surname><given-names>G</given-names></name><name><surname>Pugh</surname><given-names>EW</given-names></name><name><surname>Lachman</surname><given-names>H</given-names></name><name><surname>Uhl</surname><given-names>GR</given-names></name></person-group><article-title>Long forms of the dopamine receptor (DRD4) gene VNTR are more prevalent in substance abusers: no interaction with functional alleles of the catechol-o-methyltransferase (COMT) gene</article-title><source>Am J Med Genet</source><year>2000</year><volume>96</volume><issue>5</issue><fpage>678</fpage><lpage>683</lpage><?supplied-pmid 11054777?><pub-id pub-id-type="pmid">11054777</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pelayo-Teran</surname><given-names>JM</given-names></name><name><surname>Suarez-Pinilla</surname><given-names>P</given-names></name><name><surname>Chadi</surname><given-names>N</given-names></name><name><surname>Crespo-Facorro</surname><given-names>B</given-names></name></person-group><article-title>Gene-environment interactions underlying the effect of cannabis in first episode psychosis</article-title><source>Curr Pharm Des</source><year>2012</year><volume>18</volume><issue>32</issue><fpage>5024</fpage><lpage>5035</lpage><?supplied-pmid 22716151?><pub-id pub-id-type="pmid">22716151</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Eitan</surname><given-names>LN</given-names></name><name><surname>Jaradat</surname><given-names>SA</given-names></name><name><surname>Hulse</surname><given-names>GK</given-names></name><name><surname>Tay</surname><given-names>GK</given-names></name></person-group><article-title>Custom genotyping for substance addiction susceptibility genes in Jordanians of Arab descent</article-title><source>BMC Res Notes</source><year>2012</year><volume>5</volume><fpage>497</fpage><?supplied-pmid 22963930?><pub-id pub-id-type="pmid">22963930</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Yu</surname><given-names>S</given-names></name><name><surname>Du</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Xu</surname><given-names>K</given-names></name><name><surname>Fu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Zhao</surname><given-names>M</given-names></name></person-group><article-title>Role of novelty seeking personality traits as mediator of the association between COMT and onset age of drug use in Chinese heroin dependent patients</article-title><source>PLoS One</source><year>2011</year><volume>6</volume><issue>8</issue><fpage>e22923</fpage><?supplied-pmid 21857968?><pub-id pub-id-type="pmid">21857968</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Demetrovics</surname><given-names>Z</given-names></name><name><surname>Varga</surname><given-names>G</given-names></name><name><surname>Szekely</surname><given-names>A</given-names></name><name><surname>Vereczkei</surname><given-names>A</given-names></name><name><surname>Csorba</surname><given-names>J</given-names></name><name><surname>Balazs</surname><given-names>H</given-names></name><name><surname>Hoffman</surname><given-names>K</given-names></name><name><surname>Sasvari-Szekely</surname><given-names>M</given-names></name><name><surname>Barta</surname><given-names>C</given-names></name></person-group><article-title>Association between Novelty Seeking of opiate-dependent patients and the catechol-O-methyltransferase Val(158)Met polymorphism</article-title><source>Compr Psychiatry</source><year>2010</year><volume>51</volume><issue>5</issue><fpage>510</fpage><lpage>515</lpage><?supplied-pmid 20728009?><pub-id pub-id-type="pmid">20728009</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiy</surname><given-names>A</given-names></name><name><surname>Wilhelm</surname><given-names>O</given-names></name><name><surname>Hildebrandt</surname><given-names>A</given-names></name><name><surname>Reuter</surname><given-names>M</given-names></name><name><surname>Sommer</surname><given-names>W</given-names></name></person-group><article-title>On the genetic basis of face cognition and its relation to fluid cognitive abilities</article-title><source>Genes Brain Behav</source><year>2013</year><volume>12</volume><issue>4</issue><fpage>438</fpage><lpage>445</lpage><?supplied-pmid 23489762?><pub-id pub-id-type="pmid">23489762</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shih</surname><given-names>JC</given-names></name></person-group><article-title>Molecular basis of human MAO A and B</article-title><source>Neuropsychopharmacol Offi Publ Am Coll Neuropsychopharmacol</source><year>1991</year><volume>4</volume><issue>1</issue><fpage>1</fpage><lpage>7</lpage></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Q</given-names></name><name><surname>Shih</surname><given-names>JC</given-names></name></person-group><article-title>An extensive repeat structure down-regulates human monoamine oxidase a promoter activity independent of an initiator-like sequence</article-title><source>J Neurochem</source><year>1997</year><volume>69</volume><issue>4</issue><fpage>1368</fpage><lpage>1373</lpage><?supplied-pmid 9326264?><pub-id pub-id-type="pmid">9326264</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brummett</surname><given-names>BH</given-names></name><name><surname>Krystal</surname><given-names>AD</given-names></name><name><surname>Siegler</surname><given-names>IC</given-names></name><name><surname>Kuhn</surname><given-names>C</given-names></name><name><surname>Surwit</surname><given-names>RS</given-names></name><name><surname>Zuchner</surname><given-names>S</given-names></name><name><surname>Ashley-Koch</surname><given-names>A</given-names></name><name><surname>Barefoot</surname><given-names>JC</given-names></name><name><surname>Williams</surname><given-names>RB</given-names></name></person-group><article-title>Associations of a regulatory polymorphism of monoamine oxidase-A gene promoter (MAOA-uVNTR) with symptoms of depression and sleep quality</article-title><source>Psychosom Med</source><year>2007</year><volume>69</volume><issue>5</issue><fpage>396</fpage><lpage>401</lpage><?supplied-pmid 17585061?><pub-id pub-id-type="pmid">17585061</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shih</surname><given-names>JC</given-names></name><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Ridd</surname><given-names>MJ</given-names></name></person-group><article-title>Role of MAO A and B in neurotransmitter metabolism and behavior</article-title><source>Pol J Pharmacol</source><year>1999</year><volume>51</volume><issue>1</issue><fpage>25</fpage><lpage>29</lpage><?supplied-pmid 10389141?><pub-id pub-id-type="pmid">10389141</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brummett</surname><given-names>BH</given-names></name><name><surname>Boyle</surname><given-names>SH</given-names></name><name><surname>Siegler</surname><given-names>IC</given-names></name><name><surname>Kuhn</surname><given-names>CM</given-names></name><name><surname>Surwit</surname><given-names>RS</given-names></name><name><surname>Garrett</surname><given-names>ME</given-names></name><name><surname>Collins</surname><given-names>A</given-names></name><name><surname>Ashley-Koch</surname><given-names>A</given-names></name><name><surname>Williams</surname><given-names>RB</given-names></name></person-group><article-title>HPA axis function in male caregivers: effect of the monoamine oxidase-A gene promoter (MAOA-uVNTR)</article-title><source>Biol Psychol</source><year>2008</year><volume>79</volume><issue>2</issue><fpage>250</fpage><lpage>255</lpage><?supplied-pmid 18639608?><pub-id pub-id-type="pmid">18639608</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lavigne</surname><given-names>JV</given-names></name><name><surname>Herzing</surname><given-names>LB</given-names></name><name><surname>Cook</surname><given-names>EH</given-names></name><name><surname>Lebailly</surname><given-names>SA</given-names></name><name><surname>Gouze</surname><given-names>KR</given-names></name><name><surname>Hopkins</surname><given-names>J</given-names></name><name><surname>Bryant</surname><given-names>FB</given-names></name></person-group><article-title>Gene x environment effects of serotonin transporter, dopamine receptor D4, and monoamine oxidase A genes with contextual and parenting risk factors on symptoms of oppositional defiant disorder, anxiety, and depression in a community sample of 4-year-old children</article-title><source>Dev Psychopathol</source><year>2013</year><volume>25</volume><issue>2</issue><fpage>555</fpage><lpage>575</lpage><?supplied-pmid 23627963?><pub-id pub-id-type="pmid">23627963</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cicchetti</surname><given-names>D</given-names></name><name><surname>Rogosch</surname><given-names>FA</given-names></name><name><surname>Thibodeau</surname><given-names>EL</given-names></name></person-group><article-title>The effects of child maltreatment on early signs of antisocial behavior: genetic moderation by tryptophan hydroxylase, serotonin transporter, and monoamine oxidase A genes</article-title><source>Dev Psychopathol</source><year>2012</year><volume>24</volume><issue>3</issue><fpage>907</fpage><lpage>928</lpage><?supplied-pmid 22781862?><pub-id pub-id-type="pmid">22781862</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>SY</given-names></name><name><surname>Lin</surname><given-names>WW</given-names></name><name><surname>Wan</surname><given-names>FJ</given-names></name><name><surname>Chang</surname><given-names>AJ</given-names></name><name><surname>Ko</surname><given-names>HC</given-names></name><name><surname>Wang</surname><given-names>TJ</given-names></name><name><surname>Wu</surname><given-names>PL</given-names></name><name><surname>Lu</surname><given-names>RB</given-names></name></person-group><article-title>Monoamine oxidase-A polymorphisms might modify the association between the dopamine D2 receptor gene and alcohol dependence</article-title><source>J Psychiatry Neurosci JPN</source><year>2007</year><volume>32</volume><issue>3</issue><fpage>185</fpage><lpage>192</lpage></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vanyukov</surname><given-names>MM</given-names></name><name><surname>Maher</surname><given-names>BS</given-names></name><name><surname>Devlin</surname><given-names>B</given-names></name><name><surname>Tarter</surname><given-names>RE</given-names></name><name><surname>Kirillova</surname><given-names>GP</given-names></name><name><surname>Yu</surname><given-names>LM</given-names></name><name><surname>Ferrell</surname><given-names>RE</given-names></name></person-group><article-title>Haplotypes of the monoamine oxidase genes and the risk for substance use disorders</article-title><source>Am J Med Genet Part B Neuropsychiatric Genet Off Publ Int Soc Psychiatr Genet</source><year>2004</year><volume>125B</volume><issue>1</issue><fpage>120</fpage><lpage>125</lpage></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Batel</surname><given-names>P</given-names></name><name><surname>Houchi</surname><given-names>H</given-names></name><name><surname>Daoust</surname><given-names>M</given-names></name><name><surname>Ramoz</surname><given-names>N</given-names></name><name><surname>Naassila</surname><given-names>M</given-names></name><name><surname>Gorwood</surname><given-names>P</given-names></name></person-group><article-title>A haplotype of the DRD1 gene is associated with alcohol dependence</article-title><source>Alcohol Clin Exp Res</source><year>2008</year><volume>32</volume><issue>4</issue><fpage>567</fpage><lpage>572</lpage><?supplied-pmid 18341651?><pub-id pub-id-type="pmid">18341651</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>DJ</given-names></name><name><surname>Park</surname><given-names>BL</given-names></name><name><surname>Yoon</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>HK</given-names></name><name><surname>Joe</surname><given-names>KH</given-names></name><name><surname>Cheon</surname><given-names>YH</given-names></name><name><surname>Gwon</surname><given-names>DH</given-names></name><name><surname>Cho</surname><given-names>SN</given-names></name><name><surname>Lee</surname><given-names>HW</given-names></name><name><surname>NamGung</surname><given-names>S</given-names></name><name><surname>Shin</surname><given-names>HD</given-names></name></person-group><article-title>5&#8242; UTR polymorphism of dopamine receptor D1 (DRD1) associated with severity and temperament of alcoholism</article-title><source>Biochem Biophys Res Commun</source><year>2007</year><volume>357</volume><issue>4</issue><fpage>1135</fpage><lpage>1141</lpage><?supplied-pmid 17466946?><pub-id pub-id-type="pmid">17466946</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>S</given-names></name><name><surname>Du</surname><given-names>J</given-names></name><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Fu</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Sun</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Yu</surname><given-names>S</given-names></name><name><surname>Zhao</surname><given-names>M</given-names></name></person-group><article-title>The dopamine receptor D1 gene is associated with the length of interval between first heroin use and onset of dependence in Chinese Han heroin addicts</article-title><source>J Neural Transm</source><year>2013</year><volume>120</volume><issue>11</issue><fpage>1591</fpage><lpage>1598</lpage><?supplied-pmid 23661099?><pub-id pub-id-type="pmid">23661099</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacobs</surname><given-names>MM</given-names></name><name><surname>Okvist</surname><given-names>A</given-names></name><name><surname>Horvath</surname><given-names>M</given-names></name><name><surname>Keller</surname><given-names>E</given-names></name><name><surname>Bannon</surname><given-names>MJ</given-names></name><name><surname>Morgello</surname><given-names>S</given-names></name><name><surname>Hurd</surname><given-names>YL</given-names></name></person-group><article-title>Dopamine receptor D1 and postsynaptic density gene variants associate with opiate abuse and striatal expression levels</article-title><source>Mol Psychiatry</source><year>2013</year><volume>18</volume><issue>11</issue><fpage>1205</fpage><lpage>1210</lpage><?supplied-pmid 23044706?><pub-id pub-id-type="pmid">23044706</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>W</given-names></name><name><surname>Ma</surname><given-names>JZ</given-names></name><name><surname>Payne</surname><given-names>TJ</given-names></name><name><surname>Beuten</surname><given-names>J</given-names></name><name><surname>Dupont</surname><given-names>RT</given-names></name><name><surname>Li</surname><given-names>MD</given-names></name></person-group><article-title>Significant association of DRD1 with nicotine dependence</article-title><source>Hum Genet</source><year>2008</year><volume>123</volume><issue>2</issue><fpage>133</fpage><lpage>140</lpage><?supplied-pmid 18092181?><pub-id pub-id-type="pmid">18092181</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ni</surname><given-names>X</given-names></name><name><surname>Trakalo</surname><given-names>JM</given-names></name><name><surname>Mundo</surname><given-names>E</given-names></name><name><surname>Macciardi</surname><given-names>FM</given-names></name><name><surname>Parikh</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>L</given-names></name><name><surname>Kennedy</surname><given-names>JL</given-names></name></person-group><article-title>Linkage disequilibrium between dopamine D1 receptor gene (DRD1) and bipolar disorder</article-title><source>Biol Psychiatry</source><year>2002</year><volume>52</volume><issue>12</issue><fpage>1144</fpage><lpage>1150</lpage><?supplied-pmid 12488059?><pub-id pub-id-type="pmid">12488059</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neville</surname><given-names>MJ</given-names></name><name><surname>Johnstone</surname><given-names>EC</given-names></name><name><surname>Walton</surname><given-names>RT</given-names></name></person-group><article-title>Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1</article-title><source>Hum Mutat</source><year>2004</year><volume>23</volume><issue>6</issue><fpage>540</fpage><lpage>545</lpage><?supplied-pmid 15146457?><pub-id pub-id-type="pmid">15146457</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>W</given-names></name><name><surname>Payne</surname><given-names>TJ</given-names></name><name><surname>Ma</surname><given-names>JZ</given-names></name><name><surname>Beuten</surname><given-names>J</given-names></name><name><surname>Dupont</surname><given-names>RT</given-names></name><name><surname>Inohara</surname><given-names>N</given-names></name><name><surname>Li</surname><given-names>MD</given-names></name></person-group><article-title>Significant association of ANKK1 and detection of a functional polymorphism with nicotine dependence in an African-American sample</article-title><source>Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol</source><year>2009</year><volume>34</volume><issue>2</issue><fpage>319</fpage><lpage>330</lpage></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noble</surname><given-names>EP</given-names></name><name><surname>Blum</surname><given-names>K</given-names></name><name><surname>Ritchie</surname><given-names>T</given-names></name><name><surname>Montgomery</surname><given-names>A</given-names></name><name><surname>Sheridan</surname><given-names>PJ</given-names></name></person-group><article-title>Allelic association of the D2 dopamine receptor gene with receptor-binding characteristics in alcoholism</article-title><source>Arch Gen Psychiatry</source><year>1991</year><volume>48</volume><issue>7</issue><fpage>648</fpage><lpage>654</lpage><?supplied-pmid 2069496?><pub-id pub-id-type="pmid">2069496</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montag</surname><given-names>C</given-names></name><name><surname>Markett</surname><given-names>S</given-names></name><name><surname>Basten</surname><given-names>U</given-names></name><name><surname>Stelzel</surname><given-names>C</given-names></name><name><surname>Fiebach</surname><given-names>C</given-names></name><name><surname>Canli</surname><given-names>T</given-names></name><name><surname>Reuter</surname><given-names>M</given-names></name></person-group><article-title>Epistasis of the DRD2/ANKK1 Taq Ia and the BDNF Val66Met polymorphism impacts novelty seeking and harm avoidance</article-title><source>Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol</source><year>2010</year><volume>35</volume><issue>9</issue><fpage>1860</fpage><lpage>1867</lpage></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jonsson</surname><given-names>EG</given-names></name><name><surname>Nothen</surname><given-names>MM</given-names></name><name><surname>Grunhage</surname><given-names>F</given-names></name><name><surname>Farde</surname><given-names>L</given-names></name><name><surname>Nakashima</surname><given-names>Y</given-names></name><name><surname>Propping</surname><given-names>P</given-names></name><name><surname>Sedvall</surname><given-names>GC</given-names></name></person-group><article-title>Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers</article-title><source>Mol Psychiatry</source><year>1999</year><volume>4</volume><issue>3</issue><fpage>290</fpage><lpage>296</lpage><?supplied-pmid 10395223?><pub-id pub-id-type="pmid">10395223</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duan</surname><given-names>J</given-names></name><name><surname>Wainwright</surname><given-names>MS</given-names></name><name><surname>Comeron</surname><given-names>JM</given-names></name><name><surname>Saitou</surname><given-names>N</given-names></name><name><surname>Sanders</surname><given-names>AR</given-names></name><name><surname>Gelernter</surname><given-names>J</given-names></name><name><surname>Gejman</surname><given-names>PV</given-names></name></person-group><article-title>Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor</article-title><source>Hum Mol Genet</source><year>2003</year><volume>12</volume><issue>3</issue><fpage>205</fpage><lpage>216</lpage><?supplied-pmid 12554675?><pub-id pub-id-type="pmid">12554675</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirvonen</surname><given-names>M</given-names></name><name><surname>Laakso</surname><given-names>A</given-names></name><name><surname>Nagren</surname><given-names>K</given-names></name><name><surname>Rinne</surname><given-names>JO</given-names></name><name><surname>Pohjalainen</surname><given-names>T</given-names></name><name><surname>Hietala</surname><given-names>J</given-names></name></person-group><article-title>C957T polymorphism of the dopamine D2 receptor (DRD2) gene affects striatal DRD2 availability in vivo</article-title><source>Mol Psychiatry</source><year>2004</year><volume>9</volume><issue>12</issue><fpage>1060</fpage><lpage>1061</lpage><?supplied-pmid 15278099?><pub-id pub-id-type="pmid">15278099</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hill</surname><given-names>SY</given-names></name><name><surname>Hoffman</surname><given-names>EK</given-names></name><name><surname>Zezza</surname><given-names>N</given-names></name><name><surname>Thalamuthu</surname><given-names>A</given-names></name><name><surname>Weeks</surname><given-names>DE</given-names></name><name><surname>Matthews</surname><given-names>AG</given-names></name><name><surname>Mukhopadhyay</surname><given-names>I</given-names></name></person-group><article-title>Dopaminergic mutations: within-family association and linkage in multiplex alcohol dependence families</article-title><source>Am J Med Genet Part B Neuropsychiatr Genet Off Publ Int Soc Psychiatr Genet</source><year>2008</year><volume>147B</volume><issue>4</issue><fpage>517</fpage><lpage>526</lpage></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kraschewski</surname><given-names>A</given-names></name><name><surname>Reese</surname><given-names>J</given-names></name><name><surname>Anghelescu</surname><given-names>I</given-names></name><name><surname>Winterer</surname><given-names>G</given-names></name><name><surname>Schmidt</surname><given-names>LG</given-names></name><name><surname>Gallinat</surname><given-names>J</given-names></name><name><surname>Finckh</surname><given-names>U</given-names></name><name><surname>Rommelspacher</surname><given-names>H</given-names></name><name><surname>Wernicke</surname><given-names>C</given-names></name></person-group><article-title>Association of the dopamine D2 receptor gene with alcohol dependence: haplotypes and subgroups of alcoholics as key factors for understanding receptor function</article-title><source>Pharmacogenet Genomics</source><year>2009</year><volume>19</volume><issue>7</issue><fpage>513</fpage><lpage>527</lpage><?supplied-pmid 19603545?><pub-id pub-id-type="pmid">19603545</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kazantseva</surname><given-names>A</given-names></name><name><surname>Gaysina</surname><given-names>D</given-names></name><name><surname>Malykh</surname><given-names>S</given-names></name><name><surname>Khusnutdinova</surname><given-names>E</given-names></name></person-group><article-title>The role of dopamine transporter (SLC6A3) and dopamine D2 receptor/ankyrin repeat and kinase domain containing 1 (DRD2/ANKK1) gene polymorphisms in personality traits</article-title><source>Prog Neuro-Psychopharmacol Biol Psychiatry</source><year>2011</year><volume>35</volume><issue>4</issue><fpage>1033</fpage><lpage>1040</lpage></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vengeliene</surname><given-names>V</given-names></name><name><surname>Leonardi-Essmann</surname><given-names>F</given-names></name><name><surname>Perreau-Lenz</surname><given-names>S</given-names></name><name><surname>Gebicke-Haerter</surname><given-names>P</given-names></name><name><surname>Drescher</surname><given-names>K</given-names></name><name><surname>Gross</surname><given-names>G</given-names></name><name><surname>Spanagel</surname><given-names>R</given-names></name></person-group><article-title>The dopamine D3 receptor plays an essential role in alcohol-seeking and relapse</article-title><source>FASEB J Off Publ Fed Am Soc Exp Biol</source><year>2006</year><volume>20</volume><issue>13</issue><fpage>2223</fpage><lpage>2233</lpage></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joyce</surname><given-names>PR</given-names></name><name><surname>Rogers</surname><given-names>GR</given-names></name><name><surname>Miller</surname><given-names>AL</given-names></name><name><surname>Mulder</surname><given-names>RT</given-names></name><name><surname>Luty</surname><given-names>SE</given-names></name><name><surname>Kennedy</surname><given-names>MA</given-names></name></person-group><article-title>Polymorphisms of DRD4 and DRD3 and risk of avoidant and obsessive personality traits and disorders</article-title><source>Psychiatry Res</source><year>2003</year><volume>119</volume><issue>1&#8211;2</issue><fpage>1</fpage><lpage>10</lpage><?supplied-pmid 12860355?><pub-id pub-id-type="pmid">12860355</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Retz</surname><given-names>W</given-names></name><name><surname>Rosler</surname><given-names>M</given-names></name><name><surname>Supprian</surname><given-names>T</given-names></name><name><surname>Retz-Junginger</surname><given-names>P</given-names></name><name><surname>Thome</surname><given-names>J</given-names></name></person-group><article-title>Dopamine D3 receptor gene polymorphism and violent behavior: relation to impulsiveness and ADHD-related psychopathology</article-title><source>J Neural Transm</source><year>2003</year><volume>110</volume><issue>5</issue><fpage>561</fpage><lpage>572</lpage><?supplied-pmid 12721816?><pub-id pub-id-type="pmid">12721816</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spangler</surname><given-names>R</given-names></name><name><surname>Goddard</surname><given-names>NL</given-names></name><name><surname>Avena</surname><given-names>NM</given-names></name><name><surname>Hoebel</surname><given-names>BG</given-names></name><name><surname>Leibowitz</surname><given-names>SF</given-names></name></person-group><article-title>Elevated D3 dopamine receptor mRNA in dopaminergic and dopaminoceptive regions of the rat brain in response to morphine</article-title><source>Brain Res Mol Brain Res</source><year>2003</year><volume>111</volume><issue>1&#8211;2</issue><fpage>74</fpage><lpage>83</lpage><?supplied-pmid 12654507?><pub-id pub-id-type="pmid">12654507</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>E</given-names></name><name><surname>Ding</surname><given-names>YC</given-names></name><name><surname>Flodman</surname><given-names>P</given-names></name><name><surname>Kidd</surname><given-names>JR</given-names></name><name><surname>Kidd</surname><given-names>KK</given-names></name><name><surname>Grady</surname><given-names>DL</given-names></name><name><surname>Ryder</surname><given-names>OA</given-names></name><name><surname>Spence</surname><given-names>MA</given-names></name><name><surname>Swanson</surname><given-names>JM</given-names></name><name><surname>Moyzis</surname><given-names>RK</given-names></name></person-group><article-title>The genetic architecture of selection at the human dopamine receptor D4 (DRD4) gene locus</article-title><source>Am J Hum Genet</source><year>2004</year><volume>74</volume><issue>5</issue><fpage>931</fpage><lpage>944</lpage><?supplied-pmid 15077199?><pub-id pub-id-type="pmid">15077199</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>CS</given-names></name><name><surname>Burton</surname><given-names>M</given-names></name><name><surname>Greenberger</surname><given-names>E</given-names></name><name><surname>Dmitrieva</surname><given-names>J</given-names></name></person-group><article-title>Population migration and the variation of dopamine D4 receptor (DRD4) allele frequencies around the globe</article-title><source>Evol Hum Behav</source><year>1999</year><volume>20</volume><issue>5</issue><fpage>309</fpage><lpage>324</lpage></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eisenberg</surname><given-names>DT</given-names></name><name><surname>Campbell</surname><given-names>B</given-names></name><name><surname>Gray</surname><given-names>PB</given-names></name><name><surname>Sorenson</surname><given-names>MD</given-names></name></person-group><article-title>Dopamine receptor genetic polymorphisms and body composition in undernourished pastoralists: an exploration of nutrition indices among nomadic and recently settled Ariaal men of northern Kenya</article-title><source>BMC Evol Biol</source><year>2008</year><volume>8</volume><fpage>173</fpage><?supplied-pmid 18544160?><pub-id pub-id-type="pmid">18544160</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Munafo</surname><given-names>MR</given-names></name><name><surname>Yalcin</surname><given-names>B</given-names></name><name><surname>Willis-Owen</surname><given-names>SA</given-names></name><name><surname>Flint</surname><given-names>J</given-names></name></person-group><article-title>Association of the dopamine D4 receptor (DRD4) gene and approach-related personality traits: meta-analysis and new data</article-title><source>Biol Psychiatry</source><year>2008</year><volume>63</volume><issue>2</issue><fpage>197</fpage><lpage>206</lpage><?supplied-pmid 17574217?><pub-id pub-id-type="pmid">17574217</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Posner</surname><given-names>MI</given-names></name><name><surname>Rothbart</surname><given-names>MK</given-names></name><name><surname>Sheese</surname><given-names>BE</given-names></name><name><surname>Voelker</surname><given-names>P</given-names></name></person-group><article-title>Control networks and neuromodulators of early development</article-title><source>Dev Psychol</source><year>2012</year><volume>48</volume><issue>3</issue><fpage>827</fpage><lpage>835</lpage><?supplied-pmid 21942663?><pub-id pub-id-type="pmid">21942663</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schoots</surname><given-names>O</given-names></name><name><surname>Van Tol</surname><given-names>HH</given-names></name></person-group><article-title>The human dopamine D4 receptor repeat sequences modulate expression</article-title><source>Pharmacogenomics J</source><year>2003</year><volume>3</volume><issue>6</issue><fpage>343</fpage><lpage>348</lpage><?supplied-pmid 14581929?><pub-id pub-id-type="pmid">14581929</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oak</surname><given-names>JN</given-names></name><name><surname>Oldenhof</surname><given-names>J</given-names></name><name><surname>Van Tol</surname><given-names>HH</given-names></name></person-group><article-title>The dopamine D(4) receptor: one decade of research</article-title><source>Eur J Pharmacol</source><year>2000</year><volume>405</volume><issue>1&#8211;3</issue><fpage>303</fpage><lpage>327</lpage><?supplied-pmid 11033337?><pub-id pub-id-type="pmid">11033337</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mackillop</surname><given-names>J</given-names></name><name><surname>Menges</surname><given-names>DP</given-names></name><name><surname>McGeary</surname><given-names>JE</given-names></name><name><surname>Lisman</surname><given-names>SA</given-names></name></person-group><article-title>Effects of craving and DRD4 VNTR genotype on the relative value of alcohol: an initial human laboratory study</article-title><source>Behav Brain Funct</source><year>2007</year><volume>3</volume><fpage>11</fpage><?supplied-pmid 17309802?><pub-id pub-id-type="pmid">17309802</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lusher</surname><given-names>JM</given-names></name><name><surname>Chandler</surname><given-names>C</given-names></name><name><surname>Ball</surname><given-names>D</given-names></name></person-group><article-title>Dopamine D4 receptor gene (DRD4) is associated with Novelty Seeking (NS) and substance abuse: the saga continues</article-title><source>Mol Psychiatry</source><year>2001</year><volume>6</volume><issue>5</issue><fpage>497</fpage><lpage>499</lpage><?supplied-pmid 11526461?><pub-id pub-id-type="pmid">11526461</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biederman</surname><given-names>J</given-names></name><name><surname>Petty</surname><given-names>CR</given-names></name><name><surname>Ten Haagen</surname><given-names>KS</given-names></name><name><surname>Small</surname><given-names>J</given-names></name><name><surname>Doyle</surname><given-names>AE</given-names></name><name><surname>Spencer</surname><given-names>T</given-names></name><name><surname>Mick</surname><given-names>E</given-names></name><name><surname>Monuteaux</surname><given-names>MC</given-names></name><name><surname>Smoller</surname><given-names>JW</given-names></name><name><surname>Faraone</surname><given-names>SV</given-names></name></person-group><article-title>Effect of candidate gene polymorphisms on the course of attention deficit hyperactivity disorder</article-title><source>Psychiatry Res</source><year>2009</year><volume>170</volume><issue>2&#8211;3</issue><fpage>199</fpage><lpage>203</lpage><?supplied-pmid 19906444?><pub-id pub-id-type="pmid">19906444</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grzywacz</surname><given-names>A</given-names></name><name><surname>Kucharska-Mazur</surname><given-names>J</given-names></name><name><surname>Samochowiec</surname><given-names>J</given-names></name></person-group><article-title>Association studies of dopamine D4 receptor gene exon 3 in patients with alcohol dependence</article-title><source>Psychiatr Pol</source><year>2008</year><volume>42</volume><issue>3</issue><fpage>453</fpage><lpage>461</lpage><?supplied-pmid 19899572?><pub-id pub-id-type="pmid">19899572</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kotler</surname><given-names>M</given-names></name><name><surname>Cohen</surname><given-names>H</given-names></name><name><surname>Segman</surname><given-names>R</given-names></name><name><surname>Gritsenko</surname><given-names>I</given-names></name><name><surname>Nemanov</surname><given-names>L</given-names></name><name><surname>Lerer</surname><given-names>B</given-names></name><name><surname>Kramer</surname><given-names>I</given-names></name><name><surname>Zer-Zion</surname><given-names>M</given-names></name><name><surname>Kletz</surname><given-names>I</given-names></name><name><surname>Ebstein</surname><given-names>RP</given-names></name></person-group><article-title>Excess dopamine D4 receptor (D4DR) exon III seven repeat allele in opioid-dependent subjects</article-title><source>Mol Psychiatry</source><year>1997</year><volume>2</volume><issue>3</issue><fpage>251</fpage><lpage>254</lpage><?supplied-pmid 9152990?><pub-id pub-id-type="pmid">9152990</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawarai</surname><given-names>T</given-names></name><name><surname>Kawakami</surname><given-names>H</given-names></name><name><surname>Yamamura</surname><given-names>Y</given-names></name><name><surname>Nakamura</surname><given-names>S</given-names></name></person-group><article-title>Structure and organization of the gene encoding human dopamine transporter</article-title><source>Gene</source><year>1997</year><volume>195</volume><fpage>11</fpage><lpage>18</lpage><?supplied-pmid 9300814?><pub-id pub-id-type="pmid">9300814</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moron</surname><given-names>JA</given-names></name><name><surname>Brockington</surname><given-names>A</given-names></name><name><surname>Wise</surname><given-names>RA</given-names></name><name><surname>Rocha</surname><given-names>BA</given-names></name><name><surname>Hope</surname><given-names>BT</given-names></name></person-group><article-title>Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines</article-title><source>J Neurosci Off J Soc Neurosci</source><year>2002</year><volume>22</volume><issue>2</issue><fpage>389</fpage><lpage>395</lpage></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vandenbergh</surname><given-names>DJ</given-names></name><name><surname>Persico</surname><given-names>AM</given-names></name><name><surname>Hawkins</surname><given-names>AL</given-names></name><name><surname>Griffin</surname><given-names>CA</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Jabs</surname><given-names>EW</given-names></name><name><surname>Uhl</surname><given-names>GR</given-names></name></person-group><article-title>Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR</article-title><source>Genomics</source><year>1992</year><volume>14</volume><issue>4</issue><fpage>1104</fpage><lpage>1106</lpage><?supplied-pmid 1478653?><pub-id pub-id-type="pmid">1478653</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torres</surname><given-names>GE</given-names></name><name><surname>Gainetdinov</surname><given-names>RR</given-names></name><name><surname>Caron</surname><given-names>MG</given-names></name></person-group><article-title>Plasma membrane monoamine transporters: structure, regulation and function</article-title><source>Nat Rev Neurosci</source><year>2003</year><volume>4</volume><issue>1</issue><fpage>13</fpage><lpage>25</lpage><?supplied-pmid 12511858?><pub-id pub-id-type="pmid">12511858</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sonders</surname><given-names>MS</given-names></name><name><surname>Zhu</surname><given-names>SJ</given-names></name><name><surname>Zahniser</surname><given-names>NR</given-names></name><name><surname>Kavanaugh</surname><given-names>MP</given-names></name><name><surname>Amara</surname><given-names>SG</given-names></name></person-group><article-title>Multiple ionic conductances of the human dopamine transporter: the actions of dopamine and psychostimulants</article-title><source>J Neurosci Off J Soc Neurosci</source><year>1997</year><volume>17</volume><issue>3</issue><fpage>960</fpage><lpage>974</lpage></element-citation></ref><ref id="CR91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wheeler</surname><given-names>DD</given-names></name><name><surname>Edwards</surname><given-names>AM</given-names></name><name><surname>Chapman</surname><given-names>BM</given-names></name><name><surname>Ondo</surname><given-names>JG</given-names></name></person-group><article-title>A model of the sodium dependence of dopamine uptake in rat striatal synaptosomes</article-title><source>Neurochem Res</source><year>1993</year><volume>18</volume><issue>8</issue><fpage>927</fpage><lpage>936</lpage><?supplied-pmid 8371835?><pub-id pub-id-type="pmid">8371835</pub-id></element-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ciliax</surname><given-names>BJ</given-names></name><name><surname>Drash</surname><given-names>GW</given-names></name><name><surname>Staley</surname><given-names>JK</given-names></name><name><surname>Haber</surname><given-names>S</given-names></name><name><surname>Mobley</surname><given-names>CJ</given-names></name><name><surname>Miller</surname><given-names>GW</given-names></name><name><surname>Mufson</surname><given-names>EJ</given-names></name><name><surname>Mash</surname><given-names>DC</given-names></name><name><surname>Levey</surname><given-names>AI</given-names></name></person-group><article-title>Immunocytochemical localization of the dopamine transporter in human brain</article-title><source>J Comp Neurol</source><year>1999</year><volume>409</volume><issue>1</issue><fpage>38</fpage><lpage>56</lpage><?supplied-pmid 10363710?><pub-id pub-id-type="pmid">10363710</pub-id></element-citation></ref><ref id="CR93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Yan</surname><given-names>SF</given-names></name><name><surname>Walker</surname><given-names>JR</given-names></name><name><surname>Zwingman</surname><given-names>TA</given-names></name><name><surname>Jiang</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name></person-group><article-title>Study of gene function based on spatial co-expression in a high-resolution mouse brain atlas</article-title><source>BMC Syst Biol</source><year>2007</year><volume>1</volume><fpage>19</fpage><?supplied-pmid 17437647?><pub-id pub-id-type="pmid">17437647</pub-id></element-citation></ref><ref id="CR94"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawarai</surname><given-names>T</given-names></name><name><surname>Kawakami</surname><given-names>H</given-names></name><name><surname>Yamamura</surname><given-names>Y</given-names></name><name><surname>Nakamura</surname><given-names>S</given-names></name></person-group><article-title>Structure and organization of the gene encoding human dopamine transporter</article-title><source>Gene</source><year>1997</year><volume>195</volume><issue>1</issue><fpage>11</fpage><lpage>18</lpage><?supplied-pmid 9300814?><pub-id pub-id-type="pmid">9300814</pub-id></element-citation></ref><ref id="CR95"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sano</surname><given-names>A</given-names></name><name><surname>Kondoh</surname><given-names>K</given-names></name><name><surname>Kakimoto</surname><given-names>Y</given-names></name><name><surname>Kondo</surname><given-names>I</given-names></name></person-group><article-title>A 40-nucleotide repeat polymorphism in the human dopamine transporter gene</article-title><source>Hum Genet</source><year>1993</year><volume>91</volume><issue>4</issue><fpage>405</fpage><lpage>406</lpage><?supplied-pmid 8500798?><pub-id pub-id-type="pmid">8500798</pub-id></element-citation></ref><ref id="CR96"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>GM</given-names></name><name><surname>Madras</surname><given-names>BK</given-names></name></person-group><article-title>Polymorphisms in the 3&#8242;-untranslated region of human and monkey dopamine transporter genes affect reporter gene expression</article-title><source>Mol Psychiatry</source><year>2002</year><volume>7</volume><issue>1</issue><fpage>44</fpage><lpage>55</lpage><?supplied-pmid 11803445?><pub-id pub-id-type="pmid">11803445</pub-id></element-citation></ref><ref id="CR97"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sacchetti</surname><given-names>P</given-names></name><name><surname>Mitchell</surname><given-names>TR</given-names></name><name><surname>Granneman</surname><given-names>JG</given-names></name><name><surname>Bannon</surname><given-names>MJ</given-names></name></person-group><article-title>Nurr1 enhances transcription of the human dopamine transporter gene through a novel mechanism</article-title><source>J Neurochem</source><year>2001</year><volume>76</volume><issue>5</issue><fpage>1565</fpage><lpage>1572</lpage><?supplied-pmid 11238740?><pub-id pub-id-type="pmid">11238740</pub-id></element-citation></ref><ref id="CR98"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gainetdinov</surname><given-names>RR</given-names></name><name><surname>Wetsel</surname><given-names>WC</given-names></name><name><surname>Jones</surname><given-names>SR</given-names></name><name><surname>Levin</surname><given-names>ED</given-names></name><name><surname>Jaber</surname><given-names>M</given-names></name><name><surname>Caron</surname><given-names>MG</given-names></name></person-group><article-title>Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity</article-title><source>Science (New York, NY)</source><year>1999</year><volume>283</volume><issue>5400</issue><fpage>397</fpage><lpage>401</lpage></element-citation></ref><ref id="CR99"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greenwood</surname><given-names>TA</given-names></name><name><surname>Alexander</surname><given-names>M</given-names></name><name><surname>Keck</surname><given-names>PE</given-names></name><name><surname>McElroy</surname><given-names>S</given-names></name><name><surname>Sadovnick</surname><given-names>AD</given-names></name><name><surname>Remick</surname><given-names>RA</given-names></name><name><surname>Kelsoe</surname><given-names>JR</given-names></name></person-group><article-title>Evidence for linkage disequilibrium between the dopamine transporter and bipolar disorder</article-title><source>Am J Med Genet</source><year>2001</year><volume>105</volume><issue>2</issue><fpage>145</fpage><lpage>151</lpage><?supplied-pmid 11304827?><pub-id pub-id-type="pmid">11304827</pub-id></element-citation></ref><ref id="CR100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>B</given-names></name><name><surname>Chan</surname><given-names>RC</given-names></name><name><surname>Jing</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Sham</surname><given-names>P</given-names></name><name><surname>Chen</surname><given-names>RY</given-names></name></person-group><article-title>A meta-analysis of association studies between the 10-repeat allele of a VNTR polymorphism in the 3&#8242;-UTR of dopamine transporter gene and attention deficit hyperactivity disorder</article-title><source>Am J Med Genet Part B Neuropsychiatr Genet Off publ Int Soc Psychiatr Genet</source><year>2007</year><volume>144B</volume><issue>4</issue><fpage>541</fpage><lpage>550</lpage></element-citation></ref><ref id="CR101"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sander</surname><given-names>T</given-names></name><name><surname>Harms</surname><given-names>H</given-names></name><name><surname>Podschus</surname><given-names>J</given-names></name><name><surname>Finckh</surname><given-names>U</given-names></name><name><surname>Nickel</surname><given-names>B</given-names></name><name><surname>Rolfs</surname><given-names>A</given-names></name><name><surname>Rommelspacher</surname><given-names>H</given-names></name><name><surname>Schmidt</surname><given-names>LG</given-names></name></person-group><article-title>Allelic association of a dopamine transporter gene polymorphism in alcohol dependence with withdrawal seizures or delirium</article-title><source>Biol Psychiatry</source><year>1997</year><volume>41</volume><issue>3</issue><fpage>299</fpage><lpage>304</lpage><?supplied-pmid 9024952?><pub-id pub-id-type="pmid">9024952</pub-id></element-citation></ref><ref id="CR102"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ueno</surname><given-names>S</given-names></name><name><surname>Nakamura</surname><given-names>M</given-names></name><name><surname>Mikami</surname><given-names>M</given-names></name><name><surname>Kondoh</surname><given-names>K</given-names></name><name><surname>Ishiguro</surname><given-names>H</given-names></name><name><surname>Arinami</surname><given-names>T</given-names></name><name><surname>Komiyama</surname><given-names>T</given-names></name><name><surname>Mitsushio</surname><given-names>H</given-names></name><name><surname>Sano</surname><given-names>A</given-names></name><name><surname>Tanabe</surname><given-names>H</given-names></name></person-group><article-title>Identification of a novel polymorphism of the human dopamine transporter (DAT1) gene and the significant association with alcoholism</article-title><source>Mol Psychiatry</source><year>1999</year><volume>4</volume><issue>6</issue><fpage>552</fpage><lpage>557</lpage><?supplied-pmid 10578237?><pub-id pub-id-type="pmid">10578237</pub-id></element-citation></ref><ref id="CR103"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ueno</surname><given-names>S</given-names></name></person-group><article-title>Genetic polymorphisms of serotonin and dopamine transporters in mental disorders</article-title><source>J Med Invest</source><year>2003</year><volume>50</volume><issue>1&#8211;2</issue><fpage>25</fpage><lpage>31</lpage><?supplied-pmid 12630565?><pub-id pub-id-type="pmid">12630565</pub-id></element-citation></ref><ref id="CR104"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beaver</surname><given-names>KM</given-names></name><name><surname>Wright</surname><given-names>JP</given-names></name><name><surname>DeLisi</surname><given-names>M</given-names></name></person-group><article-title>Delinquent peer group formation: evidence of a gene x environment correlation</article-title><source>J Genet Psychol</source><year>2008</year><volume>169</volume><issue>3</issue><fpage>227</fpage><lpage>244</lpage><?supplied-pmid 18788325?><pub-id pub-id-type="pmid">18788325</pub-id></element-citation></ref><ref id="CR105"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laasonen-Balk</surname><given-names>T</given-names></name><name><surname>Kuikka</surname><given-names>J</given-names></name><name><surname>Viinamaki</surname><given-names>H</given-names></name><name><surname>Husso-Saastamoinen</surname><given-names>M</given-names></name><name><surname>Lehtonen</surname><given-names>J</given-names></name><name><surname>Tiihonen</surname><given-names>J</given-names></name></person-group><article-title>Striatal dopamine transporter density in major depression</article-title><source>Psychopharmacology</source><year>1999</year><volume>144</volume><issue>3</issue><fpage>282</fpage><lpage>285</lpage><?supplied-pmid 10435396?><pub-id pub-id-type="pmid">10435396</pub-id></element-citation></ref><ref id="CR106"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bannon</surname><given-names>MJ</given-names></name><name><surname>Poosch</surname><given-names>MS</given-names></name><name><surname>Xia</surname><given-names>Y</given-names></name><name><surname>Goebel</surname><given-names>DJ</given-names></name><name><surname>Cassin</surname><given-names>B</given-names></name><name><surname>Kapatos</surname><given-names>G</given-names></name></person-group><article-title>Dopamine transporter mRNA content in human substantia nigra decreases precipitously with age</article-title><source>Proc Natl Acad Sci U S A</source><year>1992</year><volume>89</volume><issue>15</issue><fpage>7095</fpage><lpage>7099</lpage><?supplied-pmid 1353885?><pub-id pub-id-type="pmid">1353885</pub-id></element-citation></ref><ref id="CR107"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kilty</surname><given-names>JE</given-names></name><name><surname>Lorang</surname><given-names>D</given-names></name><name><surname>Amara</surname><given-names>SG</given-names></name></person-group><article-title>Cloning and expression of a cocaine-sensitive rat dopamine transporter</article-title><source>Science (New York, NY)</source><year>1991</year><volume>254</volume><issue>5031</issue><fpage>578</fpage><lpage>579</lpage></element-citation></ref><ref id="CR108"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kahlig</surname><given-names>KM</given-names></name><name><surname>Javitch</surname><given-names>JA</given-names></name><name><surname>Galli</surname><given-names>A</given-names></name></person-group><article-title>Amphetamine regulation of dopamine transport</article-title><source>Combined Meas Transp Curr Transporter Imaging Support Endocytosis active Carrier J Biol Chem</source><year>2004</year><volume>279</volume><issue>10</issue><fpage>8966</fpage><lpage>8975</lpage></element-citation></ref><ref id="CR109"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>KE</given-names></name></person-group><article-title>The actions of amphetamine on neurotransmitters: a brief review</article-title><source>Biol Psychiatry</source><year>1977</year><volume>12</volume><issue>3</issue><fpage>451</fpage><lpage>462</lpage><?supplied-pmid 17437?><pub-id pub-id-type="pmid">17437</pub-id></element-citation></ref><ref id="CR110"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>LA</given-names></name><name><surname>Guptaroy</surname><given-names>B</given-names></name><name><surname>Lund</surname><given-names>D</given-names></name><name><surname>Shamban</surname><given-names>S</given-names></name><name><surname>Gnegy</surname><given-names>ME</given-names></name></person-group><article-title>Regulation of amphetamine-stimulated dopamine efflux by protein kinase C beta</article-title><source>J Biol Chem</source><year>2005</year><volume>280</volume><issue>12</issue><fpage>10914</fpage><lpage>10919</lpage><?supplied-pmid 15647254?><pub-id pub-id-type="pmid">15647254</pub-id></element-citation></ref><ref id="CR111"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kahlig</surname><given-names>KM</given-names></name><name><surname>Binda</surname><given-names>F</given-names></name><name><surname>Khoshbouei</surname><given-names>H</given-names></name><name><surname>Blakely</surname><given-names>RD</given-names></name><name><surname>McMahon</surname><given-names>DG</given-names></name><name><surname>Javitch</surname><given-names>JA</given-names></name><name><surname>Galli</surname><given-names>A</given-names></name></person-group><article-title>Amphetamine induces dopamine efflux through a dopamine transporter channel</article-title><source>Proc Natl Acad Sci U S A</source><year>2005</year><volume>102</volume><issue>9</issue><fpage>3495</fpage><lpage>3500</lpage><?supplied-pmid 15728379?><pub-id pub-id-type="pmid">15728379</pub-id></element-citation></ref><ref id="CR112"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schultz</surname><given-names>W</given-names></name></person-group><article-title>Predictive reward signal of dopamine neurons</article-title><source>J Neurophysiol</source><year>1998</year><volume>80</volume><issue>1</issue><fpage>1</fpage><lpage>27</lpage><?supplied-pmid 9658025?><pub-id pub-id-type="pmid">9658025</pub-id></element-citation></ref><ref id="CR113"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vandenbergh</surname><given-names>DJ</given-names></name></person-group><article-title>Molecular cloning of neurotransmitter transporter genes: beyond coding region of cDNA</article-title><source>Methods Enzymol</source><year>1998</year><volume>296</volume><fpage>498</fpage><lpage>514</lpage><?supplied-pmid 9779470?><pub-id pub-id-type="pmid">9779470</pub-id></element-citation></ref><ref id="CR114"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michelhaugh</surname><given-names>SK</given-names></name><name><surname>Fiskerstrand</surname><given-names>C</given-names></name><name><surname>Lovejoy</surname><given-names>E</given-names></name><name><surname>Bannon</surname><given-names>MJ</given-names></name><name><surname>Quinn</surname><given-names>JP</given-names></name></person-group><article-title>The dopamine transporter gene (SLC6A3) variable number of tandem repeats domain enhances transcription in dopamine neurons</article-title><source>J Neurochem</source><year>2001</year><volume>79</volume><issue>5</issue><fpage>1033</fpage><lpage>1038</lpage><?supplied-pmid 11739616?><pub-id pub-id-type="pmid">11739616</pub-id></element-citation></ref><ref id="CR115"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guindalini</surname><given-names>C</given-names></name><name><surname>Howard</surname><given-names>M</given-names></name><name><surname>Haddley</surname><given-names>K</given-names></name><name><surname>Laranjeira</surname><given-names>R</given-names></name><name><surname>Collier</surname><given-names>D</given-names></name><name><surname>Ammar</surname><given-names>N</given-names></name><name><surname>Craig</surname><given-names>I</given-names></name><name><surname>O&#8217;Gara</surname><given-names>C</given-names></name><name><surname>Bubb</surname><given-names>VJ</given-names></name><name><surname>Greenwood</surname><given-names>T</given-names></name><name><surname>Kelsoe</surname><given-names>J</given-names></name><name><surname>Asherson</surname><given-names>P</given-names></name><name><surname>Murray</surname><given-names>RM</given-names></name><name><surname>Castelo</surname><given-names>A</given-names></name><name><surname>Quinn</surname><given-names>JP</given-names></name><name><surname>Vallada</surname><given-names>H</given-names></name><name><surname>Breen</surname><given-names>G</given-names></name></person-group><article-title>A dopamine transporter gene functional variant associated with cocaine abuse in a Brazilian sample</article-title><source>Proc Natl Acad Sci U S A</source><year>2006</year><volume>103</volume><issue>12</issue><fpage>4552</fpage><lpage>4557</lpage><?supplied-pmid 16537431?><pub-id pub-id-type="pmid">16537431</pub-id></element-citation></ref><ref id="CR116"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vandenbergh</surname><given-names>DJ</given-names></name><name><surname>Kozlowski</surname><given-names>LT</given-names></name><name><surname>Bennett</surname><given-names>CJ</given-names></name><name><surname>Grant</surname><given-names>MD</given-names></name><name><surname>Strasser</surname><given-names>AA</given-names></name><name><surname>O&#8217;Connor</surname><given-names>R</given-names></name><name><surname>Stauffer</surname><given-names>RL</given-names></name><name><surname>Vogler</surname><given-names>GP</given-names></name></person-group><article-title>DAT&#8217;s not all, but it may be more than we realize</article-title><source>Nicotine Tob Res Off J Soc Res Nicotine Tob</source><year>2002</year><volume>4</volume><issue>3</issue><fpage>251</fpage><lpage>252</lpage></element-citation></ref><ref id="CR117"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cook</surname><given-names>EH</given-names><suffix>Jr</suffix></name><name><surname>Stein</surname><given-names>MA</given-names></name><name><surname>Krasowski</surname><given-names>MD</given-names></name><name><surname>Cox</surname><given-names>NJ</given-names></name><name><surname>Olkon</surname><given-names>DM</given-names></name><name><surname>Kieffer</surname><given-names>JE</given-names></name><name><surname>Leventhal</surname><given-names>BL</given-names></name></person-group><article-title>Association of attention-deficit disorder and the dopamine transporter gene</article-title><source>Am J Hum Genet</source><year>1995</year><volume>56</volume><issue>4</issue><fpage>993</fpage><lpage>998</lpage><?supplied-pmid 7717410?><pub-id pub-id-type="pmid">7717410</pub-id></element-citation></ref><ref id="CR118"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>GJ</given-names></name><name><surname>Volkow</surname><given-names>ND</given-names></name><name><surname>Wigal</surname><given-names>T</given-names></name><name><surname>Kollins</surname><given-names>SH</given-names></name><name><surname>Newcorn</surname><given-names>JH</given-names></name><name><surname>Telang</surname><given-names>F</given-names></name><name><surname>Logan</surname><given-names>J</given-names></name><name><surname>Jayne</surname><given-names>M</given-names></name><name><surname>Wong</surname><given-names>CT</given-names></name><name><surname>Han</surname><given-names>H</given-names></name><name><surname>Fowler</surname><given-names>JS</given-names></name><name><surname>Zhu</surname><given-names>W</given-names></name><name><surname>Swanson</surname><given-names>JM</given-names></name></person-group><article-title>Long-term stimulant treatment affects brain dopamine transporter level in patients with attention deficit hyperactive disorder</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><issue>5</issue><fpage>e63023</fpage><?supplied-pmid 23696790?><pub-id pub-id-type="pmid">23696790</pub-id></element-citation></ref><ref id="CR119"><label>119.</label><mixed-citation publication-type="other">Watanabe M, Macmura K, Kanbara K, Tamayama T, Hayasaki H (2002) GABA and GABA receptors. In: Jeon KW (ed) Int Rev Cytol, vol 213. pp 1&#8211;47</mixed-citation></ref><ref id="CR120"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szabadics</surname><given-names>J</given-names></name><name><surname>Varga</surname><given-names>C</given-names></name><name><surname>Molnar</surname><given-names>G</given-names></name><name><surname>Olah</surname><given-names>S</given-names></name><name><surname>Barzo</surname><given-names>P</given-names></name><name><surname>Tamas</surname><given-names>G</given-names></name></person-group><article-title>Excitatory effect of GABAergic axo-axonic cells in cortical microcircuits</article-title><source>Science (New York, NY)</source><year>2006</year><volume>311</volume><issue>5758</issue><fpage>233</fpage><lpage>235</lpage></element-citation></ref><ref id="CR121"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Xu</surname><given-names>E</given-names></name></person-group><article-title>The role and the mechanism of gamma-aminobutyric acid during central nervous system development</article-title><source>Neurosci Bull</source><year>2008</year><volume>24</volume><issue>3</issue><fpage>195</fpage><lpage>200</lpage><?supplied-pmid 18500393?><pub-id pub-id-type="pmid">18500393</pub-id></element-citation></ref><ref id="CR122"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schousboe</surname><given-names>A</given-names></name><name><surname>Waagepetersen</surname><given-names>HS</given-names></name></person-group><article-title>GABA: homeostatic and pharmacological aspects</article-title><source>Prog Brain Res</source><year>2007</year><volume>160</volume><fpage>9</fpage><lpage>19</lpage><?supplied-pmid 17499106?><pub-id pub-id-type="pmid">17499106</pub-id></element-citation></ref><ref id="CR123"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petroff</surname><given-names>OA</given-names></name></person-group><article-title>GABA and glutamate in the human brain</article-title><source>Neuroscientist Rev J Bringing Neurobiol Neurol Psychiatry</source><year>2002</year><volume>8</volume><issue>6</issue><fpage>562</fpage><lpage>573</lpage></element-citation></ref><ref id="CR124"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bown</surname><given-names>AW</given-names></name><name><surname>Shelp</surname><given-names>BJ</given-names></name></person-group><article-title>The metabolism and functions of [gamma]-aminobutyric acid</article-title><source>Plant Physiol</source><year>1997</year><volume>115</volume><issue>1</issue><fpage>1</fpage><lpage>5</lpage><?supplied-pmid 12223787?><pub-id pub-id-type="pmid">12223787</pub-id></element-citation></ref><ref id="CR125"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foster</surname><given-names>AC</given-names></name><name><surname>Kemp</surname><given-names>JA</given-names></name></person-group><article-title>Glutamate- and GABA-based CNS therapeutics</article-title><source>Curr Opin Pharmacol</source><year>2006</year><volume>6</volume><issue>1</issue><fpage>7</fpage><lpage>17</lpage><?supplied-pmid 16377242?><pub-id pub-id-type="pmid">16377242</pub-id></element-citation></ref><ref id="CR126"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chapouthier</surname><given-names>G</given-names></name><name><surname>Venault</surname><given-names>P</given-names></name></person-group><article-title>A pharmacological link between epilepsy and anxiety?</article-title><source>Trends Pharmacol Sci</source><year>2001</year><volume>22</volume><issue>10</issue><fpage>491</fpage><lpage>493</lpage><?supplied-pmid 11583788?><pub-id pub-id-type="pmid">11583788</pub-id></element-citation></ref><ref id="CR127"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muller</surname><given-names>EE</given-names></name><name><surname>Locatelli</surname><given-names>V</given-names></name><name><surname>Cocchi</surname><given-names>D</given-names></name></person-group><article-title>Neuroendocrine control of growth hormone secretion</article-title><source>Physiol Rev</source><year>1999</year><volume>79</volume><issue>2</issue><fpage>511</fpage><lpage>607</lpage><?supplied-pmid 10221989?><pub-id pub-id-type="pmid">10221989</pub-id></element-citation></ref><ref id="CR128"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Powers</surname><given-names>ME</given-names></name><name><surname>Yarrow</surname><given-names>JF</given-names></name><name><surname>McCoy</surname><given-names>SC</given-names></name><name><surname>Borst</surname><given-names>SE</given-names></name></person-group><article-title>Growth hormone isoform responses to GABA ingestion at rest and after exercise</article-title><source>Med Sci Sports Exerc</source><year>2008</year><volume>40</volume><issue>1</issue><fpage>104</fpage><lpage>110</lpage><?supplied-pmid 18091016?><pub-id pub-id-type="pmid">18091016</pub-id></element-citation></ref><ref id="CR129"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>FJ</given-names></name></person-group><article-title>Synaptic regulation of mesocorticolimbic dopamine neurons</article-title><source>Annu Rev Neurosci</source><year>1996</year><volume>19</volume><fpage>405</fpage><lpage>436</lpage><?supplied-pmid 8833449?><pub-id pub-id-type="pmid">8833449</pub-id></element-citation></ref><ref id="CR130"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ikemoto</surname><given-names>S</given-names></name><name><surname>Kohl</surname><given-names>RR</given-names></name><name><surname>McBride</surname><given-names>WJ</given-names></name></person-group><article-title>GABA(A) receptor blockade in the anterior ventral tegmental area increases extracellular levels of dopamine in the nucleus accumbens of rats</article-title><source>J Neurochem</source><year>1997</year><volume>69</volume><issue>1</issue><fpage>137</fpage><lpage>143</lpage><?supplied-pmid 9202304?><pub-id pub-id-type="pmid">9202304</pub-id></element-citation></ref><ref id="CR131"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Theile</surname><given-names>JW</given-names></name><name><surname>Morikawa</surname><given-names>H</given-names></name><name><surname>Gonzales</surname><given-names>RA</given-names></name><name><surname>Morrisett</surname><given-names>RA</given-names></name></person-group><article-title>Ethanol enhances GABAergic transmission onto dopamine neurons in the ventral tegmental area of the rat</article-title><source>Alcohol Clin Exp Res</source><year>2008</year><volume>32</volume><issue>6</issue><fpage>1040</fpage><lpage>1048</lpage><?supplied-pmid 18422836?><pub-id pub-id-type="pmid">18422836</pub-id></element-citation></ref><ref id="CR132"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>SW</given-names></name><name><surname>North</surname><given-names>RA</given-names></name></person-group><article-title>Opioids excite dopamine neurons by hyperpolarization of local interneurons</article-title><source>J Neurosci Off J Soc Neurosci</source><year>1992</year><volume>12</volume><issue>2</issue><fpage>483</fpage><lpage>488</lpage></element-citation></ref><ref id="CR133"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Namkoong</surname><given-names>K</given-names></name><name><surname>Cheon</surname><given-names>KA</given-names></name><name><surname>Kim</surname><given-names>JW</given-names></name><name><surname>Jun</surname><given-names>JY</given-names></name><name><surname>Lee</surname><given-names>JY</given-names></name></person-group><article-title>Association study of dopamine D2, D4 receptor gene, GABAA receptor beta subunit gene, serotonin transporter gene polymorphism with children of alcoholics in Korea: a preliminary study</article-title><source>Alcohol (Fayetteville, NY)</source><year>2008</year><volume>42</volume><issue>2</issue><fpage>77</fpage><lpage>81</lpage></element-citation></ref><ref id="CR134"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noble</surname><given-names>EP</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Ritchie</surname><given-names>T</given-names></name><name><surname>Lawford</surname><given-names>BR</given-names></name><name><surname>Grosser</surname><given-names>SC</given-names></name><name><surname>Young</surname><given-names>RM</given-names></name><name><surname>Sparkes</surname><given-names>RS</given-names></name></person-group><article-title>D2 dopamine receptor and GABA(A) receptor beta3 subunit genes and alcoholism</article-title><source>Psychiatry Res</source><year>1998</year><volume>81</volume><issue>2</issue><fpage>133</fpage><lpage>147</lpage><?supplied-pmid 9858031?><pub-id pub-id-type="pmid">9858031</pub-id></element-citation></ref><ref id="CR135"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Konishi</surname><given-names>T</given-names></name><name><surname>Calvillo</surname><given-names>M</given-names></name><name><surname>Leng</surname><given-names>AS</given-names></name><name><surname>Lin</surname><given-names>KM</given-names></name><name><surname>Wan</surname><given-names>YJ</given-names></name></person-group><article-title>Polymorphisms of the dopamine D2 receptor, serotonin transporter, and GABA(A) receptor beta(3) subunit genes and alcoholism in Mexican-Americans</article-title><source>Alcohol (Fayetteville, NY)</source><year>2004</year><volume>32</volume><issue>1</issue><fpage>45</fpage><lpage>52</lpage></element-citation></ref><ref id="CR136"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edenberg</surname><given-names>HJ</given-names></name><name><surname>Dick</surname><given-names>DM</given-names></name><name><surname>Xuei</surname><given-names>X</given-names></name><name><surname>Tian</surname><given-names>H</given-names></name><name><surname>Almasy</surname><given-names>L</given-names></name><name><surname>Bauer</surname><given-names>LO</given-names></name><name><surname>Crowe</surname><given-names>RR</given-names></name><name><surname>Goate</surname><given-names>A</given-names></name><name><surname>Hesselbrock</surname><given-names>V</given-names></name><name><surname>Jones</surname><given-names>K</given-names></name><name><surname>Kwon</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>TK</given-names></name><name><surname>Nurnberger</surname><given-names>JI</given-names><suffix>Jr</suffix></name><name><surname>O&#8217;Connor</surname><given-names>SJ</given-names></name><name><surname>Reich</surname><given-names>T</given-names></name><name><surname>Rice</surname><given-names>J</given-names></name><name><surname>Schuckit</surname><given-names>MA</given-names></name><name><surname>Porjesz</surname><given-names>B</given-names></name><name><surname>Foroud</surname><given-names>T</given-names></name><name><surname>Begleiter</surname><given-names>H</given-names></name></person-group><article-title>Variations in GABRA2, encoding the alpha 2 subunit of the GABA(A) receptor, are associated with alcohol dependence and with brain oscillations</article-title><source>Am J Hum Genet</source><year>2004</year><volume>74</volume><issue>4</issue><fpage>705</fpage><lpage>714</lpage><?supplied-pmid 15024690?><pub-id pub-id-type="pmid">15024690</pub-id></element-citation></ref><ref id="CR137"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>DH</given-names></name><name><surname>Bolo</surname><given-names>N</given-names></name><name><surname>Daniels</surname><given-names>MA</given-names></name><name><surname>Lyoo</surname><given-names>IK</given-names></name><name><surname>Min</surname><given-names>KJ</given-names></name><name><surname>Kim</surname><given-names>CH</given-names></name><name><surname>Renshaw</surname><given-names>PF</given-names></name></person-group><article-title>Craving for alcohol and food during treatment for alcohol dependence: modulation by T allele of 1519T&gt;C GABAAalpha6</article-title><source>Alcohol Clin Exp Res</source><year>2008</year><volume>32</volume><issue>9</issue><fpage>1593</fpage><lpage>1599</lpage><?supplied-pmid 18616664?><pub-id pub-id-type="pmid">18616664</pub-id></element-citation></ref><ref id="CR138"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Enoch</surname><given-names>MA</given-names></name><name><surname>Baghal</surname><given-names>B</given-names></name><name><surname>Yuan</surname><given-names>Q</given-names></name><name><surname>Goldman</surname><given-names>D</given-names></name></person-group><article-title>A factor analysis of global GABAergic gene expression in human brain identifies specificity in response to chronic alcohol and cocaine exposure</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><issue>5</issue><fpage>e64014</fpage><?supplied-pmid 23717525?><pub-id pub-id-type="pmid">23717525</pub-id></element-citation></ref><ref id="CR139"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dhawan</surname><given-names>BN</given-names></name><name><surname>Cesselin</surname><given-names>F</given-names></name><name><surname>Raghubir</surname><given-names>R</given-names></name><name><surname>Reisine</surname><given-names>T</given-names></name><name><surname>Bradley</surname><given-names>PB</given-names></name><name><surname>Portoghese</surname><given-names>PS</given-names></name><name><surname>Hamon</surname><given-names>M</given-names></name></person-group><article-title>International union of pharmacology</article-title><source>XII Classification Opioid Recept Pharmacological Rev</source><year>1996</year><volume>48</volume><issue>4</issue><fpage>567</fpage><lpage>592</lpage></element-citation></ref><ref id="CR140"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janecka</surname><given-names>A</given-names></name><name><surname>Fichna</surname><given-names>J</given-names></name><name><surname>Janecki</surname><given-names>T</given-names></name></person-group><article-title>Opioid receptors and their ligands</article-title><source>Curr Top Med Chem</source><year>2004</year><volume>4</volume><issue>1</issue><fpage>1</fpage><lpage>17</lpage><?supplied-pmid 14754373?><pub-id pub-id-type="pmid">14754373</pub-id></element-citation></ref><ref id="CR141"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waldhoer</surname><given-names>M</given-names></name><name><surname>Bartlett</surname><given-names>SE</given-names></name><name><surname>Whistler</surname><given-names>JL</given-names></name></person-group><article-title>Opioid receptors</article-title><source>Annu Rev Biochem</source><year>2004</year><volume>73</volume><fpage>953</fpage><lpage>990</lpage><?supplied-pmid 15189164?><pub-id pub-id-type="pmid">15189164</pub-id></element-citation></ref><ref id="CR142"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldstein</surname><given-names>A</given-names></name><name><surname>Lowney</surname><given-names>LI</given-names></name><name><surname>Pal</surname><given-names>BK</given-names></name></person-group><article-title>Stereospecific and nonspecific interactions of the morphine congener levorphanol in subcellular fractions of mouse brain</article-title><source>Proc Natl Acad Sci U S A</source><year>1971</year><volume>68</volume><issue>8</issue><fpage>1742</fpage><lpage>1747</lpage><?supplied-pmid 5288759?><pub-id pub-id-type="pmid">5288759</pub-id></element-citation></ref><ref id="CR143"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pert</surname><given-names>CB</given-names></name><name><surname>Snyder</surname><given-names>SH</given-names></name></person-group><article-title>Opiate receptor: demonstration in nervous tissue</article-title><source>Science (New York, NY)</source><year>1973</year><volume>179</volume><issue>4077</issue><fpage>1011</fpage><lpage>1014</lpage></element-citation></ref><ref id="CR144"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Terenius</surname><given-names>L</given-names></name></person-group><article-title>Stereospecific interaction between narcotic analgesics and a synaptic plasm a membrane fraction of rat cerebral cortex</article-title><source>Acta Pharmacol Toxicol (Copenh)</source><year>1973</year><volume>32</volume><issue>3</issue><fpage>317</fpage><lpage>320</lpage><pub-id pub-id-type="pmid">4801733</pub-id></element-citation></ref><ref id="CR145"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simon</surname><given-names>EJ</given-names></name><name><surname>Hiller</surname><given-names>JM</given-names></name><name><surname>Edelman</surname><given-names>I</given-names></name></person-group><article-title>Stereospecific binding of the potent narcotic analgesic (3H) Etorphine to rat-brain homogenate</article-title><source>Proc Natl Acad Sci U S A</source><year>1973</year><volume>70</volume><issue>7</issue><fpage>1947</fpage><lpage>1949</lpage><?supplied-pmid 4516196?><pub-id pub-id-type="pmid">4516196</pub-id></element-citation></ref><ref id="CR146"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corbett</surname><given-names>AD</given-names></name><name><surname>Henderson</surname><given-names>G</given-names></name><name><surname>McKnight</surname><given-names>AT</given-names></name><name><surname>Paterson</surname><given-names>SJ</given-names></name></person-group><article-title>75&#160;years of opioid research: the exciting but vain quest for the Holy Grail</article-title><source>Br J Pharmacol</source><year>2006</year><volume>147</volume><issue>Suppl 1</issue><fpage>S153</fpage><lpage>S162</lpage><?supplied-pmid 16402099?><pub-id pub-id-type="pmid">16402099</pub-id></element-citation></ref><ref id="CR147"><label>147.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Girdlestone</surname><given-names>D</given-names></name><etal/></person-group><person-group person-group-type="editor"><name><surname>Cox</surname><given-names>BM</given-names></name><name><surname>Chavkin</surname><given-names>C</given-names></name><name><surname>Christie</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Opioid Receptors</article-title><source>The IUPHAR Compendium of Receptor Characterization and Classification</source><year>2003</year><edition>2</edition><publisher-loc>London</publisher-loc><publisher-name>IUPHAR Media</publisher-name><fpage>321</fpage><lpage>333</lpage></element-citation></ref><ref id="CR148"><label>148.</label><mixed-citation publication-type="other">Opioid Receptors (2008) IUPHAR Database; International Union of Pharmacology</mixed-citation></ref><ref id="CR149"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kapur</surname><given-names>S</given-names></name><name><surname>Sharad</surname><given-names>S</given-names></name><name><surname>Singh</surname><given-names>RA</given-names></name><name><surname>Gupta</surname><given-names>AK</given-names></name></person-group><article-title>A118g polymorphism in mu opioid receptor gene (oprm1): association with opiate addiction in subjects of Indian origin</article-title><source>J Integr Neurosci</source><year>2007</year><volume>6</volume><issue>4</issue><fpage>511</fpage><lpage>522</lpage><?supplied-pmid 18181266?><pub-id pub-id-type="pmid">18181266</pub-id></element-citation></ref><ref id="CR150"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mura</surname><given-names>E</given-names></name><name><surname>Govoni</surname><given-names>S</given-names></name><name><surname>Racchi</surname><given-names>M</given-names></name><name><surname>Carossa</surname><given-names>V</given-names></name><name><surname>Ranzani</surname><given-names>GN</given-names></name><name><surname>Allegri</surname><given-names>M</given-names></name><name><surname>van Schaik</surname><given-names>RH</given-names></name></person-group><article-title>Consequences of the 118A&gt;G polymorphism in the OPRM1 gene: translation from bench to bedside?</article-title><source>J Pain Res</source><year>2013</year><volume>6</volume><fpage>331</fpage><lpage>353</lpage><?supplied-pmid 23658496?><pub-id pub-id-type="pmid">23658496</pub-id></element-citation></ref><ref id="CR151"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Capraris</surname><given-names>A</given-names></name><name><surname>Cinnella</surname><given-names>G</given-names></name><name><surname>Marolla</surname><given-names>A</given-names></name><name><surname>Salatto</surname><given-names>P</given-names></name><name><surname>Da Lima</surname><given-names>S</given-names></name><name><surname>Vetuschi</surname><given-names>P</given-names></name><name><surname>Consoletti</surname><given-names>L</given-names></name><name><surname>Gesualdo</surname><given-names>L</given-names></name><name><surname>Dambrosio</surname><given-names>M</given-names></name></person-group><article-title>Micro opioid receptor A118G polymorphism and post-operative pain: opioids&#8217; effects on heterozygous patients</article-title><source>Int J Immunopathol Pharmacol</source><year>2011</year><volume>24</volume><issue>4</issue><fpage>993</fpage><lpage>1004</lpage><?supplied-pmid 22230405?><pub-id pub-id-type="pmid">22230405</pub-id></element-citation></ref><ref id="CR152"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>YC</given-names></name><name><surname>Wang</surname><given-names>WS</given-names></name></person-group><article-title>Human mu-opioid receptor gene A118G polymorphism predicts the efficacy of tramadol/acetaminophen combination tablets (ultracet) in oxaliplatin-induced painful neuropathy</article-title><source>Cancer</source><year>2012</year><volume>118</volume><issue>6</issue><fpage>1718</fpage><lpage>1725</lpage><?supplied-pmid 21837673?><pub-id pub-id-type="pmid">21837673</pub-id></element-citation></ref><ref id="CR153"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Setiawan</surname><given-names>E</given-names></name><name><surname>Pihl</surname><given-names>RO</given-names></name><name><surname>Benkelfat</surname><given-names>C</given-names></name><name><surname>Leyton</surname><given-names>M</given-names></name></person-group><article-title>Influence of the OPRM1 A118G polymorphism on alcohol-induced euphoria, risk for alcoholism and the clinical efficacy of naltrexone</article-title><source>Pharmacogenomics</source><year>2012</year><volume>13</volume><issue>10</issue><fpage>1161</fpage><lpage>1172</lpage><?supplied-pmid 22909206?><pub-id pub-id-type="pmid">22909206</pub-id></element-citation></ref><ref id="CR154"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kranzler</surname><given-names>HR</given-names></name><name><surname>Gelernter</surname><given-names>J</given-names></name><name><surname>O&#8217;Malley</surname><given-names>S</given-names></name><name><surname>Hernandez-Avila</surname><given-names>CA</given-names></name><name><surname>Kaufman</surname><given-names>D</given-names></name></person-group><article-title>Association of alcohol or other drug dependence with alleles of the mu opioid receptor gene (OPRM1)</article-title><source>Alcohol Clin Exp Res</source><year>1998</year><volume>22</volume><issue>6</issue><fpage>1359</fpage><lpage>1362</lpage><?supplied-pmid 9756053?><pub-id pub-id-type="pmid">9756053</pub-id></element-citation></ref><ref id="CR155"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teo</surname><given-names>YY</given-names></name></person-group><article-title>Common statistical issues in genome-wide association studies: a review on power, data quality control, genotype calling and population structure</article-title><source>Curr Opin Lipidol</source><year>2008</year><volume>19</volume><issue>2</issue><fpage>133</fpage><lpage>143</lpage><?supplied-pmid 18388693?><pub-id pub-id-type="pmid">18388693</pub-id></element-citation></ref><ref id="CR156"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Archer</surname><given-names>T</given-names></name><name><surname>Oscar-Berman</surname><given-names>M</given-names></name><name><surname>Blum</surname><given-names>K</given-names></name><name><surname>Gold</surname><given-names>M</given-names></name></person-group><article-title>Neurogenetics and epigenetics in impulsive behaviour: impact on reward circuitry</article-title><source>J Genet Syndr Gene Ther</source><year>2012</year><volume>3</volume><issue>3</issue><fpage>1000115</fpage><?supplied-pmid 23264884?><pub-id pub-id-type="pmid">23264884</pub-id></element-citation></ref><ref id="CR157"><label>157.</label><mixed-citation publication-type="other">Archer T, Oscar-Berman M, Blum K, Gold M (2013) Epigenetic Modulation of Mood Disorders. J Genet Syndr Gene Ther 4 (120). doi:10.4172/2157-7412.1000120</mixed-citation></ref><ref id="CR158"><label>158.</label><mixed-citation publication-type="other">Archer T, Oscar-Berman M, Blum K (2011) Epigenetics in developmental disorder: ADHD and Endophenotypes. J Genet Syndr Gene Ther 2 (104)</mixed-citation></ref><ref id="CR159"><label>159.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Dackis</surname><given-names>CA</given-names></name><name><surname>Gold</surname><given-names>MS</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Volkow</surname><given-names>ND</given-names></name><name><surname>Swann</surname><given-names>AC</given-names></name></person-group><article-title>Biological aspects of cocaine addiction</article-title><source>Cocaine in the brain</source><year>1988</year><publisher-loc>New Brunswick</publisher-loc><publisher-name>Rutgers University Press</publisher-name></element-citation></ref><ref id="CR160"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neill</surname><given-names>DB</given-names></name><name><surname>Peay</surname><given-names>LA</given-names></name><name><surname>Gold</surname><given-names>MS</given-names></name></person-group><article-title>Identification of a subregion within rat neostriatum for the dopaminergic modulation of lateral hypothalamic self-stimulation</article-title><source>Brain Res</source><year>1978</year><volume>153</volume><issue>3</issue><fpage>515</fpage><lpage>528</lpage><?supplied-pmid 698791?><pub-id pub-id-type="pmid">698791</pub-id></element-citation></ref><ref id="CR161"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>NS</given-names></name><name><surname>Gold</surname><given-names>MS</given-names></name></person-group><article-title>Dual diagnoses: psychiatric syndromes in alcoholism and drug addiction</article-title><source>Am Fam Physician</source><year>1991</year><volume>43</volume><issue>6</issue><fpage>2071</fpage><lpage>2076</lpage><?supplied-pmid 2042549?><pub-id pub-id-type="pmid">2042549</pub-id></element-citation></ref><ref id="CR162"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>NS</given-names></name><name><surname>Dackis</surname><given-names>CA</given-names></name><name><surname>Gold</surname><given-names>MS</given-names></name></person-group><article-title>The relationship of addiction, tolerance, and dependence to alcohol and drugs: a neurochemical approach</article-title><source>J Subst Abus Treat</source><year>1987</year><volume>4</volume><issue>3&#8211;4</issue><fpage>197</fpage><lpage>207</lpage></element-citation></ref><ref id="CR163"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>NS</given-names></name><name><surname>Gold</surname><given-names>MS</given-names></name></person-group><article-title>Management of withdrawal syndromes and relapse prevention in drug and alcohol dependence</article-title><source>Am Fam Physician</source><year>1998</year><volume>58</volume><issue>1</issue><fpage>139</fpage><lpage>146</lpage><?supplied-pmid 9672434?><pub-id pub-id-type="pmid">9672434</pub-id></element-citation></ref><ref id="CR164"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buck</surname><given-names>K</given-names></name><name><surname>Lischka</surname><given-names>T</given-names></name><name><surname>Dorow</surname><given-names>J</given-names></name><name><surname>Crabbe</surname><given-names>J</given-names></name></person-group><article-title>Mapping quantitative trait loci that regulate sensitivity and tolerance to quinpirole, a dopamine mimetic selective for D(2)/D(3) receptors</article-title><source>Am J Med Genet</source><year>2000</year><volume>96</volume><issue>5</issue><fpage>696</fpage><lpage>705</lpage><?supplied-pmid 11054779?><pub-id pub-id-type="pmid">11054779</pub-id></element-citation></ref><ref id="CR165"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phillips</surname><given-names>TJ</given-names></name><name><surname>Crabbe</surname><given-names>JC</given-names></name><name><surname>Metten</surname><given-names>P</given-names></name><name><surname>Belknap</surname><given-names>JK</given-names></name></person-group><article-title>Localization of genes affecting alcohol drinking in mice</article-title><source>Alcohol Clin Exp Res</source><year>1994</year><volume>18</volume><issue>4</issue><fpage>931</fpage><lpage>941</lpage><?supplied-pmid 7978106?><pub-id pub-id-type="pmid">7978106</pub-id></element-citation></ref><ref id="CR166"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crabbe</surname><given-names>JC</given-names></name><name><surname>Phillips</surname><given-names>TJ</given-names></name><name><surname>Harris</surname><given-names>RA</given-names></name><name><surname>Arends</surname><given-names>MA</given-names></name><name><surname>Koob</surname><given-names>GF</given-names></name></person-group><article-title>Alcohol-related genes: contributions from studies with genetically engineered mice</article-title><source>Addict Biol</source><year>2006</year><volume>11</volume><issue>3&#8211;4</issue><fpage>195</fpage><lpage>269</lpage><?supplied-pmid 16961758?><pub-id pub-id-type="pmid">16961758</pub-id></element-citation></ref><ref id="CR167"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feero</surname><given-names>WG</given-names></name></person-group><article-title>Clinical application of whole-genome sequencing: proceed with care</article-title><source>JAMA</source><year>2014</year><volume>311</volume><issue>10</issue><fpage>1017</fpage><lpage>1019</lpage><?supplied-pmid 24618961?><pub-id pub-id-type="pmid">24618961</pub-id></element-citation></ref><ref id="CR168"><label>168.</label><mixed-citation publication-type="other">Hall FS, Sora I, Uhl GR (2001) Ethanol consumption and reward are decreased in mu-opiate receptor knockout mice. Psychopharmacology (Berl) 154(1):43&#8211;49</mixed-citation></ref><ref id="CR169"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reynolds</surname><given-names>GP</given-names></name><name><surname>McGowan</surname><given-names>OO</given-names></name><name><surname>Dalton</surname><given-names>CF</given-names></name></person-group><article-title>Pharmacogenomics in psychiatry: the relevance of receptor and transporter polymorphisms</article-title><source>Br J Clin Pharmacol</source><year>2013</year></element-citation></ref><ref id="CR170"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>BZ</given-names></name><name><surname>Kranzler</surname><given-names>HR</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Farrer</surname><given-names>LA</given-names></name><name><surname>Boerwinkle</surname><given-names>E</given-names></name><name><surname>Potash</surname><given-names>JB</given-names></name><name><surname>Gelernter</surname><given-names>J</given-names></name></person-group><article-title>Integrating GWASs and human protein interaction networks identifies a gene subnetwork underlying alcohol dependence</article-title><source>Am J Hum Genet</source><year>2013</year><volume>93</volume><issue>6</issue><fpage>1027</fpage><lpage>1034</lpage><?supplied-pmid 24268660?><pub-id pub-id-type="pmid">24268660</pub-id></element-citation></ref><ref id="CR171"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uhl</surname><given-names>GR</given-names></name><name><surname>Drgonova</surname><given-names>J</given-names></name><name><surname>Hall</surname><given-names>FS</given-names></name></person-group><article-title>Curious cases: altered dose-response relationships in addiction genetics</article-title><source>Pharmacol Ther</source><year>2014</year><volume>141</volume><issue>3</issue><fpage>335</fpage><lpage>346</lpage><?supplied-pmid 24189489?><pub-id pub-id-type="pmid">24189489</pub-id></element-citation></ref><ref id="CR172"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ehlers</surname><given-names>CL</given-names></name><name><surname>Gizer</surname><given-names>IR</given-names></name></person-group><article-title>Evidence for a genetic component for substance dependence in Native Americans</article-title><source>Am J Psychiatry</source><year>2013</year><volume>170</volume><issue>2</issue><fpage>154</fpage><lpage>164</lpage><?supplied-pmid 23377636?><pub-id pub-id-type="pmid">23377636</pub-id></element-citation></ref><ref id="CR173"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Z</given-names></name><name><surname>Guo</surname><given-names>AY</given-names></name><name><surname>van den Oord</surname><given-names>EJ</given-names></name><name><surname>Aliev</surname><given-names>F</given-names></name><name><surname>Jia</surname><given-names>P</given-names></name><name><surname>Edenberg</surname><given-names>HJ</given-names></name><name><surname>Riley</surname><given-names>BP</given-names></name><name><surname>Dick</surname><given-names>DM</given-names></name><name><surname>Bettinger</surname><given-names>JC</given-names></name><name><surname>Davies</surname><given-names>AG</given-names></name><name><surname>Grotewiel</surname><given-names>MS</given-names></name><name><surname>Schuckit</surname><given-names>MA</given-names></name><name><surname>Agrawal</surname><given-names>A</given-names></name><name><surname>Kramer</surname><given-names>J</given-names></name><name><surname>Nurnberger</surname><given-names>JI</given-names><suffix>Jr</suffix></name><name><surname>Kendler</surname><given-names>KS</given-names></name><name><surname>Webb</surname><given-names>BT</given-names></name><name><surname>Miles</surname><given-names>MF</given-names></name></person-group><article-title>Multi-species data integration and gene ranking enrich significant results in an alcoholism genome-wide association study</article-title><source>BMC Genomics</source><year>2012</year><volume>13</volume><issue>Suppl 8</issue><fpage>S16</fpage><?supplied-pmid 23282140?><pub-id pub-id-type="pmid">23282140</pub-id></element-citation></ref><ref id="CR174"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agrawal</surname><given-names>A</given-names></name><name><surname>Wetherill</surname><given-names>L</given-names></name><name><surname>Bucholz</surname><given-names>KK</given-names></name><name><surname>Kramer</surname><given-names>J</given-names></name><name><surname>Kuperman</surname><given-names>S</given-names></name><name><surname>Lynskey</surname><given-names>MT</given-names></name><name><surname>Nurnberger</surname><given-names>JI</given-names><suffix>Jr</suffix></name><name><surname>Schuckit</surname><given-names>M</given-names></name><name><surname>Tischfield</surname><given-names>JA</given-names></name><name><surname>Edenberg</surname><given-names>HJ</given-names></name><name><surname>Foroud</surname><given-names>T</given-names></name><name><surname>Bierut</surname><given-names>LJ</given-names></name></person-group><article-title>Genetic influences on craving for alcohol</article-title><source>Addict Behav</source><year>2013</year><volume>38</volume><issue>2</issue><fpage>1501</fpage><lpage>1508</lpage><?supplied-pmid 22481050?><pub-id pub-id-type="pmid">22481050</pub-id></element-citation></ref><ref id="CR175"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>CY</given-names></name><name><surname>Zhou</surname><given-names>WZ</given-names></name><name><surname>Zhang</surname><given-names>PW</given-names></name><name><surname>Johnson</surname><given-names>C</given-names></name><name><surname>Wei</surname><given-names>L</given-names></name><name><surname>Uhl</surname><given-names>GR</given-names></name></person-group><article-title>Meta-analysis and genome-wide interpretation of genetic susceptibility to drug addiction</article-title><source>BMC Genomics</source><year>2011</year><volume>12</volume><fpage>508</fpage><?supplied-pmid 21999673?><pub-id pub-id-type="pmid">21999673</pub-id></element-citation></ref><ref id="CR176"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>CY</given-names></name><name><surname>Mao</surname><given-names>X</given-names></name><name><surname>Wei</surname><given-names>L</given-names></name></person-group><article-title>Genes and (common) pathways underlying drug addiction</article-title><source>PLoS Comput Biol</source><year>2008</year><volume>4</volume><issue>1</issue><fpage>e2</fpage><?supplied-pmid 18179280?><pub-id pub-id-type="pmid">18179280</pub-id></element-citation></ref><ref id="CR177"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Derringer</surname><given-names>J</given-names></name><name><surname>Krueger</surname><given-names>RF</given-names></name><name><surname>Dick</surname><given-names>DM</given-names></name><name><surname>Aliev</surname><given-names>F</given-names></name><name><surname>Grucza</surname><given-names>RA</given-names></name><name><surname>Saccone</surname><given-names>S</given-names></name><name><surname>Agrawal</surname><given-names>A</given-names></name><name><surname>Edenberg</surname><given-names>HJ</given-names></name><name><surname>Goate</surname><given-names>AM</given-names></name><name><surname>Hesselbrock</surname><given-names>VM</given-names></name><name><surname>Kramer</surname><given-names>JR</given-names></name><name><surname>Lin</surname><given-names>P</given-names></name><name><surname>Neuman</surname><given-names>RJ</given-names></name><name><surname>Nurnberger</surname><given-names>JI</given-names><suffix>Jr</suffix></name><name><surname>Rice</surname><given-names>JP</given-names></name><name><surname>Tischfield</surname><given-names>JA</given-names></name><collab>GENEVA consortium</collab><name><surname>Bierut</surname><given-names>LJ</given-names></name></person-group><article-title>The aggregate effect of dopamine genes on dependence symptoms among cocaine users: cross-validation of a candidate system scoring approach</article-title><source>Behav Genet</source><year>2012</year><volume>42</volume><issue>4</issue><fpage>626</fpage><lpage>635</lpage><?supplied-pmid 22358648?><pub-id pub-id-type="pmid">22358648</pub-id></element-citation></ref><ref id="CR178"><label>178.</label><mixed-citation publication-type="other">Feltus FA (2014) Systems genetics: A paradigm to improve discovery of candidate genes and mechanisms underlying complex traits. Plant Sci 223C:45&#8211;48. doi:10.1016/j.plantsci.2014.03.003</mixed-citation></ref><ref id="CR179"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jordi</surname><given-names>E</given-names></name><name><surname>Heiman</surname><given-names>M</given-names></name><name><surname>Marion-Poll</surname><given-names>L</given-names></name><name><surname>Guermonprez</surname><given-names>P</given-names></name><name><surname>Cheng</surname><given-names>SK</given-names></name><name><surname>Nairn</surname><given-names>AC</given-names></name><name><surname>Greengard</surname><given-names>P</given-names></name><name><surname>Girault</surname><given-names>JA</given-names></name></person-group><article-title>Differential effects of cocaine on histone posttranslational modifications in identified populations of striatal neurons</article-title><source>Proc Natl Acad Sci U S A</source><year>2013</year><volume>110</volume><issue>23</issue><fpage>9511</fpage><lpage>9516</lpage><?supplied-pmid 23690581?><pub-id pub-id-type="pmid">23690581</pub-id></element-citation></ref><ref id="CR180"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Byrnes</surname><given-names>J</given-names></name><name><surname>Johnson</surname><given-names>NL</given-names></name><name><surname>Carini</surname><given-names>LM</given-names></name><name><surname>Byrnes</surname><given-names>EM</given-names></name></person-group><article-title>Multigenerational effects of adolescent morphine exposure on dopamine D2 receptor function</article-title><source>Psychopharmacology (Berl)</source><year>2013</year><volume>227</volume><issue>2</issue><fpage>263</fpage><lpage>272</lpage><pub-id pub-id-type="pmid">23314440</pub-id></element-citation></ref><ref id="CR181"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DiNieri</surname><given-names>JA</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Szutorisz</surname><given-names>H</given-names></name><name><surname>Spano</surname><given-names>SM</given-names></name><name><surname>Kaur</surname><given-names>J</given-names></name><name><surname>Casaccia</surname><given-names>P</given-names></name><name><surname>Dow-Edwards</surname><given-names>D</given-names></name><name><surname>Hurd</surname><given-names>YL</given-names></name></person-group><article-title>Maternal cannabis use alters ventral striatal dopamine D2 gene regulation in the offspring</article-title><source>Biol Psychiatry</source><year>2011</year><volume>70</volume><issue>8</issue><fpage>763</fpage><lpage>769</lpage><?supplied-pmid 21820648?><pub-id pub-id-type="pmid">21820648</pub-id></element-citation></ref><ref id="CR182"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belsky</surname><given-names>J</given-names></name><name><surname>Beaver</surname><given-names>KM</given-names></name></person-group><article-title>Cumulative-genetic plasticity, parenting and adolescent self-regulation</article-title><source>J Child Psychol Psychiatry</source><year>2011</year><volume>52</volume><issue>5</issue><fpage>619</fpage><lpage>626</lpage><?supplied-pmid 21039487?><pub-id pub-id-type="pmid">21039487</pub-id></element-citation></ref><ref id="CR183"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>JC</given-names></name><name><surname>Baker</surname><given-names>RE</given-names></name><name><surname>Chow</surname><given-names>W</given-names></name><name><surname>Sun</surname><given-names>CK</given-names></name><name><surname>Elsholtz</surname><given-names>HP</given-names></name></person-group><article-title>Epigenetic mechanisms in the dopamine D2 receptor-dependent inhibition of the prolactin gene</article-title><source>Mol Endocrinol</source><year>2005</year><volume>19</volume><issue>7</issue><fpage>1904</fpage><lpage>1917</lpage><?supplied-pmid 15731170?><pub-id pub-id-type="pmid">15731170</pub-id></element-citation></ref><ref id="CR184"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Schroeder</surname><given-names>FA</given-names></name><name><surname>Youngs</surname><given-names>RM</given-names></name><name><surname>Schmidt</surname><given-names>TW</given-names></name><name><surname>Ferris</surname><given-names>C</given-names></name><name><surname>Konradi</surname><given-names>C</given-names></name><name><surname>Akbarian</surname><given-names>S</given-names></name></person-group><article-title>Dopamine D2-like antagonists induce chromatin remodeling in striatal neurons through cyclic AMP-protein kinase A and NMDA receptorsignaling</article-title><source>J Neurochem</source><year>2004</year><volume>90</volume><issue>5</issue><fpage>1117</fpage><lpage>1131</lpage><?supplied-pmid 15312167?><pub-id pub-id-type="pmid">15312167</pub-id></element-citation></ref><ref id="CR185"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nestler</surname><given-names>EJ</given-names></name></person-group><article-title>Transcriptional mechanisms of drug addiction</article-title><source>Clin Psychopharmacol Neurosci</source><year>2012</year><volume>10</volume><issue>3</issue><fpage>136</fpage><lpage>143</lpage><?supplied-pmid 23430970?><pub-id pub-id-type="pmid">23430970</pub-id></element-citation></ref><ref id="CR186"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Downs</surname><given-names>B</given-names></name><name><surname>Oscar-Berman</surname><given-names>M</given-names></name><name><surname>Waite</surname><given-names>R</given-names></name><name><surname>Madigan</surname><given-names>M</given-names></name><name><surname>Giordano</surname><given-names>J</given-names></name><name><surname>Beley</surname><given-names>T</given-names></name><name><surname>Jones</surname><given-names>S</given-names></name><name><surname>Simpatico</surname><given-names>T</given-names></name><name><surname>Hauser</surname><given-names>M</given-names></name><name><surname>Borsten</surname><given-names>J</given-names></name><name><surname>Febo</surname><given-names>M</given-names></name><name><surname>Braverman</surname><given-names>E</given-names></name><name><surname>Lohmann</surname><given-names>R</given-names></name><name><surname>Dushaj</surname><given-names>K</given-names></name><name><surname>Helman</surname><given-names>M</given-names></name><name><surname>Barh</surname><given-names>D</given-names></name><name><surname>Schoenthaler</surname><given-names>S</given-names></name><name><surname>Han</surname><given-names>D</given-names></name><name><surname>Blum</surname><given-names>K</given-names></name></person-group><article-title>Have we hatched the addiction egg: reward deficiency syndrome solution system&#8482;</article-title><source>J Genet Syndr Gene Ther</source><year>2013</year><volume>4</volume><issue>136</issue><fpage>14318</fpage><?supplied-pmid 24077767?><pub-id pub-id-type="pmid">24077767</pub-id></element-citation></ref><ref id="CR187"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barr</surname><given-names>CL</given-names></name><name><surname>Kidd</surname><given-names>KK</given-names></name></person-group><article-title>Population frequencies of the A1 allele at the dopamine D2 receptor locus</article-title><source>Biol Psychiatry</source><year>1993</year><volume>34</volume><issue>4</issue><fpage>204</fpage><lpage>209</lpage><?supplied-pmid 8399816?><pub-id pub-id-type="pmid">8399816</pub-id></element-citation></ref><ref id="CR188"><label>188.</label><mixed-citation publication-type="other">Belcher AM, Volkow ND, Moeller FG, Ferr&#233; S (2014) Personality traits and vulnerability or resilience to substance use disorders. Trends Cogn Sci</mixed-citation></ref><ref id="CR189"><label>189.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dahlgren</surname><given-names>A</given-names></name><name><surname>Wargelius</surname><given-names>HL</given-names></name><name><surname>Berglund</surname><given-names>KJ</given-names></name><name><surname>Fahlke</surname><given-names>C</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name><name><surname>Oreland</surname><given-names>L</given-names></name><name><surname>Berggren</surname><given-names>U</given-names></name><name><surname>Balldin</surname><given-names>J</given-names></name></person-group><article-title>Do alcohol-dependent individuals with DRD2 A1 allele have an increased risk of relapse? a pilot study</article-title><source>Alcohol Alcohol</source><year>2011</year><volume>46</volume><issue>5</issue><fpage>509</fpage><lpage>513</lpage><?supplied-pmid 21613303?><pub-id pub-id-type="pmid">21613303</pub-id></element-citation></ref></ref-list></back></article>